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Abstract 
Solid organ transplantation is the gold standard treatment for a variety of conditions 
that result in organ failure. However, despite considerable advances in clinical 
transplantation in recent decades, the almost ubiquitous requirement of life-long 
immunosuppression of transplant recipients persists and is complicated by graft loss 
to rejection in the long term and multiple serious adverse effects that are frequently 
life limiting.  
Helminths currently infect more than one quarter of the world’s population and it is 
now well established that their success as parasites is the result of active 
immunomodulation of the host immune response.  Whilst this primarily secures on-
going survival of the parasites, in some cases helminth-induced immunomodulation 
can be beneficial to the infected host and is not associated with the adverse sequelae 
of pharmacological immunosuppression. An emerging body of evidence suggests 
that harmful immune responses to alloantigens can be suppressed by helminths, but 
little mechanistic data exists and the active immunomodulators involved have 
remained hitherto unidentified. 
The hypothesis behind this thesis is that the model intestinal nematode, 
Heligmosomoides polygyrus, produces immunomodulatory molecules that can 
suppress responses to allo- and auto-antigens in animal models of transplantation and 
autoimmunity, and that some of these molecules could potentially be exploited as 
novel therapeutic agents. 
Full-thickness skin grafting was performed between fully-allogeneic mouse strains 
(BALB/c to C57BL/6). Recipient mice infected with H. polygyrus immediately prior 
to transplantation showed significantly prolonged allograft survival. Likewise, 
protection from allograft rejection could be replicated in recipient mice in which H. 
polygyrus excretory-secretory products (HES) (isolated from culture of adult worms) 
were delivered by continuous infusion via surgically implanted osmotic minipumps. 
A number of potential mechanisms underlying allograft protection were identified 
 
  iv 
including induction of CD4+CD25+Foxp3+ regulatory T cells (Treg) and suppression 
of Th1 and Th17 effector CD4+ T cell phenotypes. 
H. polygyrus and HES were further shown to ameliorate disease in murine (pMOG) 
experimental autoimmune encephalomyelitis and colitis induced by T cell transfer. In 
addition to expansion of Treg, H. polygyrus-mediated protection against EAE was 
found to be almost completely lost in IL-4 receptor deficient mice, indicating a 
protective role of Th2 immune responses in this context. 
Finally, the mechanisms of action of the newly-identified TGF-β mimic, TGM, 
contained within HES were investigated. Despite bearing no sequence homology or 
structural resemblance to TGF-β, TGM was shown to act through the TGF-β receptor 
complex to induce Treg in human and mouse CD4+ T cells in vitro and to suppress 
murine allogeneic skin graft rejection in vivo. TGM may represent the origin of a 
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1. Introduction  1 
1 Introduction 
 
The necessity for life-long immunosuppression following organ transplantation is 
associated with multiple serious adverse consequences, such that the life expectancy 
of transplant recipients is frequently curtailed as a direct result of the medication 
prescribed for them. This is a predicament that has changed little over the last thirty 
years and the need for novel therapeutic options is clear. In this introduction, the 
current state of clinical organ transplantation will be explored, followed by an 
overview of helminth parasites’ immunomodulatory capabilities in relation to 
autoimmunity and transplantation, and conclude with an outline the remaining 
questions this thesis aims to answer. 
 
1.1 Solid Organ Transplantation 
 
1.1.1 The Role for Transplantation 
Organ transplantation is now widely accepted as the gold standard treatment for a 
vast array of diseases that culminate in organ failure1. In comparison to dialysis, 
kidney transplantation has been shown to be beneficial in terms of improved survival 
(mortality 68% lower than that of patients on the transplant waiting list2), quality of 
life and cost effectiveness. The comparative health and economic benefits of 
transplantation are seen in all groups of potential recipients, including those with 
advanced age or co-morbidity3. However, despite consistently excellent short-term 
outcomes of organ transplantation, results in the longer term have been 
disappointing, largely as a result of chronic allograft rejection and toxicity from 
currently-employed immunosuppressive agents (Figure 1-1)4. Results from a small 
number of trials aiming to minimise immunosuppression following kidney 
transplantation were also not encouraging and showed that most patients who did 
develop an episode of acute rejection on minimization protocols ultimately lost their 
grafts5,6. 
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Figure 1-1 Cumulative graft failure yearly attrition rates of first kidney transplant. Reproduced 
from Lamb et al7. 
 
1.1.2 Current Clinical Practice and Challenges 
Until the 1990s, transplantation from cadaveric donors was performed almost 
exclusively following brain death, known as ‘Donation after Brain Death (DBD)’8.  
The available pool of ‘ideal’ donors following brain death has inexorably decreased 
however, largely as a result of reductions in fatal road traffic trauma and 
improvements in blood pressure control (reducing the incidence of fatal cerebral 
haemorrhage)9. With the requirement for donated organs continuing to increase, 
necessity drove a number of strategies to increase the available pool of donor organs. 
Some of these strategies present additional immunological challenges, such as 
donation from HLA- or ABO-incompatible donors, donation after circulatory death 
(with the potential for allograft damage from longer periods of warm ischaemia) and 
acceptance of suboptimal ‘extended criteria donors’10,11. However, living donor 
donation has also increased (figure 1-2) and presents novel therapeutic opportunities 





Figure 4: Cumulative graft failure
yearly attrition rates of first kidney
transplants (A) Deceased SCD donor,
(B) living donor, (C) Nonblack deceased
SCD donor and (D) black deceased
SCD donor.
An interesting area in this data is the comparison between
black and nonblack recipients. In general the data highlights
the profound differences in outcomes between black and
nonblack patients, which have been described previously
(8). The small improvements in half-lives have been nearly
aral el between black and nonblack pati nts as shown in
Figure 2(B). It is interesting to note though that death-
censored half-lives have been somewhat more stagnant in
black patients compared to nonblack patients (Figure 3B)
with the caution again that the forecasts in nonblack recipi-
ents death-censored data might not be very solid because
the half-lives are so long. On the other hand looking at the
graft attrition data in black patients who clearly have the
highest graft attrition there seems to be a more percepti-
ble trend of improvement over the years as can be seen
in Figure 4(D). In fact even though the absolute increase in
half-life was only about 4 years, the half-life almost doubled
from 1989 (4 years) to 2005 (7.4 years).
We specifically analyzed attrition rates because half-lives
assess only the cumulative effect of graft loss overtime, but
there is a clear difference in the early rate of graft loss ver-
sus late and the underlying pathogenetic processes might
even be somewhat distinct. Clearly first-year attrition rates
are significantly higher for all subpopulations and have im-
proved significantly overtime. The subsequent graft attri-
tion rates are fairly constant. When comparing the 1–3,
3–5 and 5—10-year attrition rate there do not seem to
be dramatic differences with increasing time posttrans-
plant but overall the 5—10-year attrition rate is for the
most part somewhat higher. This seems to be most ev-
ident in living-donor transplants where the 1–3, 3–5 and 5–
10 year yearly attrition rates increase by about 1% for each
subsequent episode in both black and nonblack patients.
This phenomenon is neither evident in the death-censored
data nor in low-risk deceased-donor transplants namely
with both donor and recipient age below 45 years. This
means that the mild increase in attrition rates is probably
driven by death rather than graft loss. In fact when looking
at the death-censored attrition rates there is no increase in
the attrition with increasing time posttransplant.
When comparing attrition rates between populations the
most striking difference is between living- and deceased-
donor recipients. Most of this difference is based on the
well-known better short-term outcomes in living-donor
transplants. Long-term attrition rates are also lower in
living-donor transplants but only in nonblack patients. In
black patients there seems to be a higher long-term attri-
tion rate in living-donor transplants compared to nonblack
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Whilst the number of organs donated following brain death (DBD) has remained 
relatively static over the five years preceding 2013 (figure 1.2), both the age and 
body mass index of donors within this group has increased considerably12. In the 
context of kidney transplantation, organs from elderly donors have been associated 
with poorer graft and recipient survival rates13, but this still compares favourably to 
the mortality associated with remaining on maintenance dialysis14,15. 
Donation after circulatory death (DCD) engenders a number of technical, logistical 
and legal difficulties. Prolonged organ ischaemia is of foremost concern, particularly 
as the law in most countries requires a specified ‘no touch’ period between the 
diagnosis of death and commencement of the organ retrieval operation (e.g. five 
minutes)8. Increased utilisation of DCD donors in the U.K. has played fundamental 
role in increasing the number of transplant operations performed (figure 1.2), to the 
extent of marginally reducing the transplant recipient waiting list in 201112. 
 
 
Figure 1-2 Transplanted Organs in the United Kingdom according to donor type. Source: 
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Until recently in the United States, up to 30% of potentially suitable living donors 
were withdrawn from the transplantation process following detection of circulating 
donor-specific ABO or HLA antibodies on initial screening16. At the same time, 
cultural unacceptability of transplantation from cadaveric donors in many Asian 
countries drove the development of aggressive approaches to overcoming 
immunological barriers to living donor donation. Successful ABO-incompatible 
donation programmes started in Japan with a protocol including pre-transplant 
splenectomy17, but have been refined over time with consecutively less invasive 
protocols showing similarly impressive outcomes in the short term (from the limited 
follow up data available)18,19. One major drawback of ABO-incompatible 
transplantation is cost: additional interventions including pre-transplant 
plasmapheresis, anti-CD20 conditioning and frequent antibody titer monitoring 
results in the transplant procedure costing up to 72% more than the ABO-compatible 
equivalent20. As a result, whilst the number of ‘incompatible’ transplants has 
increased considerably in recent years (figure 1-3), further expansion will likely be 
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1.1.3 Fundamentals of Allograft Rejection 
 
1.1.3.1 Innate Immunity 
The physical process of surgically explanting an organ and then subjecting it to a 
period of ischaemia prior to reperfusion in another patient inevitably leads to a 
degree of organ damage, resulting in the stimulation of an innate immune response21. 
The innate response occurs irrespective of the degree of allogeneic mismatch and, by 
inviting an alloantigen-specific adaptive immune response (and subsequently 
collaborating with it), innate immunity plays a fundamental role in determining graft 
outcome22. Ischaemia-reperfusion injury (IRI) arises when reperfusion of hypoxic 
tissue generates oxygen free radicals, resulting in cell damage and an inflammatory 
response that causes tissue injury in excess of that produced by ischaemia alone23. 

















































Figure 1-3 Source: NHSBT. HLAi: Human Leukocyte Antigen incompatible; ABOi: ABO 
incompatible. 
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the comparatively favourable outcomes of living donor transplantation24 and the 
positive results demonstrated by ex-vivo perfusion of explanted allografts compared 
to cold preservation25. 
Innate immune cells express pattern recognition receptors that enable them to 
recognise tissue injury through detection of characteristic endogenous protein 
signatures of damaged cells, known as damage-associated molecular patterns 
(DAMPs)26. Toll-like receptors (TLRs) are a ubiquitous group of highly conserved 
transmembrane pattern recognition receptors that recognise DAMPs from damaged 
cells and are upregulated during IRI27. DAMPs are expressed in pathological 
conditions such as hypoxia or oxidative stress (e.g. following donor brain death) and 
consist of a varied group of molecules including heat shock proteins, adenosine 
triphosphate (ATP), purines and the DNA-binding protein, high mobility group box 1 
(HMGB1)28. Ligation of TLRs by DAMPs (except TLR3) initiates an intracellular 
signalling cascade through the adapter protein, myeloid differentiation factor 88 
(MyD88). This leads to the release of inflammatory cytokines (IL-1, IL-6 and TNF) 
and chemokines, initiating a series of events that includes production of acute phase 
proteins and increased vascular permeability, allowing donor APCs to migrate to 
recipient draining lymphoid tissue and recipient inflammatory leucocytes to be 
specifically recruited into the allograft26. Genetically deficient mouse strains that are 
protected from injury in murine models of IRI include MyD88-/- mice, nude mice 
(lacking T cells)29 and Stat4-/- mice (lacking Th1 cells)30; demonstrating the critical 
role of TLR signalling and subsequent generation of an adaptive Th1 response. 
The complement system consists of a highly conserved set of proteins that allows for 
rapid escalation of a non-specific innate immune response to cell damage or 
pathogens31. Complement cascades all converge to mediate enzymatic cleavage of 
the third complement component, C3, into C3a and C3b. This stimulates multiple 
further enzymatic cascades resulting in the formation of a lytic ‘membrane attack 
complex’ (MAC) and multiple other soluble complement proteins that act as 
opsonins, chemoattractants and activating ligands for innate immune cells such as 
macrophages and neutrophils32. Further to this, C3a and C5a promote Th1 
differentiation of naïve CD4+ T cells, thereby inducing an adaptive immune response 
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that will contribute to allograft rejection33. Activation of the complement system is 
seen predominantly in IRI and episodes of acute rejection, and is associated with 
poor allograft outcomes in the medium term27. Interestingly, complement activation 
appears to be very much dependent on localised production of C3. Transplantation of 
a C3-/- kidney into a WT recipient mouse results in significant protection from IRI 
compared to a WT donor organ34. This suggests that an unusual situation arises 
whereby a transplanted allograft can become complicit in its own destruction and 
therefore intervention targeted at the donor organ may be a viable therapeutic 
prospect35. 
 
1.1.3.2 Alloantigen recognition by T cells 
The critical role of T cells in mediating allograft rejection is long-established: mice 
lacking T cells are unable to reject fully-allogeneic grafts36 and pharmacological T 
cell depletion is an effective therapeutic option for terminating episodes of acute 
rejection in the clinical setting37. Initiation of the adaptive immune response occurs 
mainly via two distinct pathways: direct recognition by T cells of allogeneic MHC 
molecules on the surface of transplanted donor cells (direct pathway)38 and via 
recognition of donor antigens that have been processed and presented on the MHC 
molecules of the transplant recipient’s APCs (indirect pathway)39. A third 
mechanism, semi-direct allorecognition, has also been described, whereby intact 
donor MHC-peptide complexes are presented on the surface of recipient dendritic 
cells40, a situation arising as a result of cell-cell contact41, or the transfer of intact 
MHC-peptide complexes via exosomes arising from the donor cells42. The existence 
of a semi-direct pathway presents a resolving solution as to how a single recipient 
APC can stimulate both CD8+ T cells (via ‘semi-direct’ recognition of an intact 
donor MHC-peptide complex) and CD4+ T cells (via ‘indirect’ recognition of 
processed donor peptides, presented on recipient MHC complexes)43,44. 
Classically, the direct pathway of allorecognition has been deemed responsible for 
acute rejection, whilst the indirect pathway of antigen presentation is responsible for 
chronic rejection. This is intuitively plausible: ‘passenger’ donor APCs in the 
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transplanted allograft are immediately available for allorecognition, but will 
disappear over time, whereas the indirect pathway requires some time for processing 
of allogeneic peptides, but may continue for the life of the graft. More recently, this 
strict dichotomy has been questioned and the indirect pathway has been shown to 
play a role in acute rejection as well45. 
In addition to recognition of allogeneic peptides, T cell activation requires a second 
signal in the form of co-stimulation. An extensive array of co-stimulatory molecules 
exists46, of which the most well-described is CD28. CD28 is constitutively expressed 
by T cells and ligated by CD80 and CD86 on the surface of APCs. Expression of 
CD80 is upregulated rapidly during an innate immune response, whist CD86 appears 
later with sustained APC activation. Ligation of CD28 leads to IL-2 production, T 
cell proliferation and a lower threshold for T cell activation47. Cytotoxic T 
lymphocyte antigen-4 (CTLA-4 / CD152) is a co-inhibitory molecule that also binds 
to CD80 and CD86, but with greater affinity and, in contrast to CD28, inhibits T cell 
activation through transendocytosis; a process that allows CTLA-4-expressing cells 
to engage, remove and subsequently degrade CD80 and CD86 from target cells48,49. 
More recently, additional co-inhibitory molecules have been discovered, including 
programmed cell death protein 1 (PD-1 / CD279). PD-1 is widely expressed on 
activated immune cells (including T cells, B cells and macrophages50); it recognises 
the ligands PDL-1 and PDL-2 on the surface of interacting cells and plays an 
important role in the maintenance of self-tolerance (PD-1-/- mice show increased 
susceptibility to systemic autoimmunity)51. Ligation of PD-1 dampens T cell 
activation, proliferation and production of inflammatory cytokines52. In 
transplantation, PD-1 signalling appears to play an important role both in directly 
suppressing alloreactive T cell responses53 and in promoting differentiation of naïve 
CD4+ T cells into Treg54. 
 
1.1.3.3 B Cells 
The capability of B cells to mediate graft destruction is most dramatically illustrated 
by clinical episodes of hyperacute rejection, where an allograft is transplanted into a 
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recipient with pre-formed antibodies, resulting in rapid activation of complement and 
clotting cascades, widespread thrombosis and graft infarction, often within minutes 
of reperfusion. This extremely rare scenario has historically arisen following 
transplantation of ABO-incompatible55 or HLA-incompatible allografts56. 
B cells play multiple roles in the alloimmune response. First, they can act as APCs, 
presenting alloantigens and co-stimulation to T cells in either a pro-inflammatory or 
regulatory fashion57. In presenting alloantigens to T cells, cell clusters are formed, 
where activated T cells can produce cytokines to act in a paracrine fashion and 
influence adjacent B cell activation, differentiation and antibody production35. In this 
way, immature B cells develop into memory B cells or plasma cells, producing 
alloantigen-specific antibodies58. Antibody deposition within the allograft leads to 
activation of the classical complement cascade, which can effect graft destruction 
directly, through formation of the MAC and indirectly through recruitment of 
neutrophils and macrophages59.  
The risk of antibody-mediated rejection is clearly increased by sensitising events 
such as previous transplants, blood transfusions or pregnancies; but previous 
infections can also play a role. Memory B cells (and T cells) generate an amplified 
and more rapid response upon re-exposure to their cognate antigen. Over time and 
the course of repeated infections, an ever-expanding repertoire of memory B cells 
accumulates and, as a result of antigen cross-reactivity, this can underlie an increased 
risk of heterologous antibodies showing affinity for donor antigens in the elderly 
transplant recipient60.  
 
1.1.3.4 Th1 CD4+ T Cells 
Sub-classification of CD4+ helper T cells according to their transcription factor and 
cytokine profile began with the Th1/Th2 paradigm in 198661. Since then, it has 
become clear that numerous subtypes exist, into which naïve CD4+ T cells can 
differentiate, and that these types are generally mutually exclusive. The mature 
phenotype of an activated CD4+ T cell is determined by a number of factors 
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including antigen concentration, co-stimulation and the surrounding cytokine 
environment62,63.  
Th1 lymphocytes develop upon exposure to antigen in the presence of IL-2 and IL-
12; they are identified by the transcription factor ‘T box expressed in T cells’ (Tbet, 
Tbx21) and production of IFN-γ and are functionally involved in the effector T cell 
response during intracellular pathogen infection, organ-specific autoimmunity and 
allograft rejection64. Numerous mechanisms of Th1-mediated allograft rejection have 
been described. First, Th1 lymphocytes produce IL-2 and can therefore promote the 
proliferation of CD8+ cytotoxic T cells. As CD8+ T cells produce IFN-γ (which 
promotes Th1 differentiation), a reciprocal positive feedback arrangement can be 
established, thereby amplifying allogeneic effector T cells and rapidly contributing to 
rejection64. Secondly, release of Th1 cytokines (including IL-1, IFN-γ and TNF) 
augments cytotoxicity by recruiting macrophages to release additional non-specific 
mediators such as reactive oxygen species and nitric oxide. Thirdly, Th1 
lymphocytes are capable of directly killing target cells through expression of Fas 
ligand (FasL) which, when recognised by Fas receptors (CD95) on the surface of 
target cells, induces apoptosis65. Finally, Th1 cytokines also activate B cells to 
produce alloantigen-specific antibodies, augmenting the rejection process, as 
previously discussed. In addition to animal models suggesting a Th1-mediated 
process of rejection, T cells isolated from rejecting kidneys in human transplant 
recipients show elevated expression of Tbet and FasL compared to isolates from 
allografts not undergoing rejection66. Upon ex-vivo restimulation, CD4+ T cells from 
rejecting organs also secrete IFN-γ (and not IL-4 or IL-5)67. 
 
1.1.3.5 Th2 CD4+ T Cells 
As one of the primary roles of Th1 lymphocytes is to mount a powerful immune 
response against rapidly proliferating pathogens, the risk of collateral damage (harm 
to self tissues or structures) is an acceptable evolutionary tradeoff. By contrast, Th2 
responses are often induced by helminth infections; organisms that do not complete 
their life cycle (and therefore proliferate) inside their hosts, but do penetrate through 
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tissues and mucosal barriers with the potential for considerable harm. In this 
circumstance, therefore, a different imperative exists: control of parasite numbers is 
not an immediate priority, but repair of injury and prevention of further collateral 
damage very much is68. Accordingly, Th2 immune responses are predominantly 
involved in promoting wound repair and limiting other inflammatory responses 
(discussed in more detail later). 
Th2 lymphocytes are characterised by the transcription factor GATA-3 and a 
cytokine profile dominated by IL-4, IL-5 and IL-13. Th2 cytokines inhibit Th1 
responses and it has therefore long been suggested that a Th2 response may be 
capable of inhibiting or preventing allograft rejection69. Indeed, administration of 
exogenous IL-4 has previously been shown to prolong cardiac allograft survival in 
rats by 43% and was suggested as a possible therapeutic strategy70. However, other 
studies suggest that Th2 responses are capable of mediating rejection of murine 
islet70 and cardiac allografts, possibly as a result of IL-5-driven eosinophil 
recruitment70. Subsequently, Illigens et al71 demonstrated that a Th2 response 
abrogated CD8+ T cell allograft infiltration, markedly delaying rejection of single 
class I MHC-mismatched skin grafts, but did also induce de novo chronic rejection in 
cardiac transplants of the same allogeneic combination. Additionally, one clinical 
study of 102 kidney transplant recipients has shown a significant correlation between 
genetic polymorphisms associated with low IL-4 production and protection from 
chronic allograft rejection72. In total, the available evidence therefore suggests that 
(1) Th2 responses may protect allografts from acute rejection by suppressing Th1 
and, particularly, CD8+ effector mechanisms; (2) acute rejection may still occur 
indirectly, as a result of Th2-mediated eosinophil recruitment and (3) in the longer 
term, Th2 activity may contribute to chronic allograft damage secondary to fibrosis. 
 
1.1.3.6 Th17 CD4+ T Cells 
Since 2005, the Th1/Th2 paradigm has been expanded to encompass numerous CD4+ 
effector T cell subtypes including Th17 cells73, identified by the transcription factor 
RORγt and secretion of cytokines including IL-17, IL-21 and IL-22. The discovery 
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of Th17 lymphocytes resolved a number of anomalous experimental findings. 
Foremost amongst these, Miura et al showed that fully-allogenic cardiac allografts 
were subject to accelerated rejection in IFN-γ-/- recipient mice compared to WT 
recipients74. In these experiments, the pathological processes leading to rejection also 
appeared to be different: WT recipients showed a characteristic mononuclear cellular 
infiltration of the allograft comprised mainly of CD8+ T cells, whilst IFN-γ-/- 
recipient allografts had very few infiltrating lymphocytes, but did show an intense 
neutrophil infiltration with extensive surrounding parenchymal necrosis of the graft. 
Depletion of neutrophils in these animals successfully prevented accelerated 
rejection, indicating a causative role74. Subsequently, Yuan et al demonstrated 
accelerated rejection of cardiac allografts in Tbet-/- mice (that are unable to mount a 
Th1 response) and were able to prevent this accelerated rejection by neutralisation of 
IL-1775.  
Naïve CD4+ T cells exposed in vitro to antigen in the presence of TGF-β alone tend 
to develop into regulatory T cells (Treg; discussed in detail later), but with the 
addition of IL-6, they can be induced to differentiate into the Th17 effector 
phenotype76. An array of additional mediators is also capable of augmenting or 
facilitating Th17 differentiation, many of which are released as a result of IRI, 
including IL-2377, prostaglandin E278, HMGB179 and TLR ligands80,81. A causative 
role for Th17 lymphocytes in mediating rejection has now been shown in multiple 
transplant models including murine skin82, heart83,84, trachea85 and lung86. Clinically, 
elevated serum levels of IL-17 have been observed during episodes of acute rejection 
following liver transplantation87 and the presence of Th17 cells within renal 
allografts has also been associated with accelerated rejection88. 
Th17 lymphocytes not only compete with Treg for the TGF-β necessary for their 
respective differentiation, but they also produce IL-21, which directly suppresses the 
transcription factor Foxp3 that is necessary for Treg development89. This, and 
possibly a number of other mechanisms, likely underlie the relative resistance of 
Th17 cells to Treg-mediated suppression90. The action of TGF-β on T cells is 
antagonised by IFN-γ and IL-4, therefore both of these cytokines can suppress Th17 
differentiation and potentially afford allografts some protection from rejection as a 
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result76. Interestingly, experiments with a murine kidney transplant model have 
shown prolonged allograft survival in IL-17-/- recipients, although in this setting, 
protection was associated with reduced, rather than elevated, IFN-γ production. This 
effect could be recapitulated in WT animals with antibody-mediated neutralisation of 
IL-17 and suggests that IL-17 can also facilitate Th1-mediated rejection (in contrast 
to the reciprocal situation, where Th1 responses likely suppress Th17 through 
production of IFN-γ)91. 
In summary, Th17 lymphocytes appear to have an unequivocally detrimental effect 
on transplanted allografts; Th1 lymphocytes are most often harmful, but the IFN-γ 
they produce can sometimes be beneficial in suppressing Th17 differentiation; Th2 
lymphocytes are often beneficial in respect of producing IL-4 that suppresses both 
Th1 and Th17 differentiation, but they are also capable of mediating acute rejection 
indirectly and probably contribute to graft dysfunction in the long term as a result of 
fibrosis. 
 
1.1.3.7 CD8+ T cells 
CD8+ cytotoxic T cell activation requires a number of steps: following recognition of 
MHC class I complexes on allogeneic cells, co-stimulation is required from either a 
highly-activated mature dendritic cell or, more usually, with additional input from an 
activated CD4+ T cell. In this arrangement, activated CD4+ T cells express CD40 
ligand (CD40L), which is detected by CD40 on the surface of APCs and thereby 
licences the APC to provide additional costimulation to the bound CD8+ cell35. Upon 
activation, CD8+ T cells can mediate killing through release of cytotoxic molecules 
(perforin and granzyme B) and upregulation of Fas ligand92,93. Prevention of CD8+ T 
cell activation via blockade of CD40 considerably prolongs the survival of rat 
cardiac allografts94 and, clinically, kidney allograft rejection has been found to 
correlate with urine concentrations of perforin and granzyme B mRNA95. 
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1.1.4 Regulatory Cells and Mechanisms 
Many of the component cell types that play a key role in rejecting an allograft (e.g. 
macrophages, DCs, B cells and T cells) are also capable of developing a regulatory 
phenotype and suppressing rejection96. In the absence of exogenous 
immunosuppressive agents, the balance between tolerance and rejection is 
determined by the comparative frequency and potency of effector vs. regulatory cells 
and the status of this equilibrium therefore fundamentally determines graft outcome 
in the long term. 
 
1.1.4.1 Macrophages 
Recipient macrophages infiltrate into allografts in the early post-transplantation 
period and are a component of the innate immune response to allograft damage. 
Classically, this can result in initiation and amplification of the alloimmune response 
as described above. However, macrophages can adopt an ‘alternatively activated’ 
phenotype which inhibits the release of inflammatory cytokines. Alternatively 
activated macrophages (AAM) are induced by the Th2 cytokines IL-4 and IL-13, and 
are closely associated with helminth infections and promotion of wound healing 
responses68. Additionally, in response to IL-10, macrophages appear to effectively 
skew the adaptive immune response away from a Th17 phenotype and can thereby 
ameliorate pathology such as colitis97. In the context of transplantation, AAM (and 
possibly type 2 immune responses in general) can be beneficial in the early post-
transplantation period by inhibiting pro-inflammatory cytokines, but may contribute 
to chronic graft dysfunction in the longer term as a consequence of fibrosis. 
A further population of ‘regulatory macrophages’ (distinct from AAM) is 
characterised by production of IL-1098. The significance of immune regulation 
exerted by macrophages has been demonstrated experimentally in a murine model of 
allogeneic haematopoietic cell transplantation, where antibody-mediated depletion of 
macrophage populations results in aggravated graft vs. host disease (GvHD) and an 
increase in mortality99. Further, one clinical pilot study infused donor-derived 
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regulatory macrophages into two patients prior to kidney transplantation from a 
living donor100. No adverse effects were experienced and both patients were 
subsequently maintained on minimal immunosuppression therapy with no signs of 
rejection in three years of follow up. Further investigation of the potential therapeutic 
role for regulatory macrophages will be conducted as one arm of a major multicentre 
clinical trail (the ONE study, NCT02129881). 
 
1.1.4.2 Tolerogenic dendritic cells 
The term ‘dendritic cell’ describes a heterogeneous group of monocytic phagocytes 
with multiple subtypes and functions101. Maturation and development of DCs is 
largely influenced by their surrounding cytokine environment and two main subtypes 
exist: conventional (or myeloid) DCs and plasmacytoid DCs (pDCs)102. Immature 
DCs exhibit relatively low expression of MHC and co-stimulatory molecules and can 
therefore present alloantigens in a ‘tolerogenic’ fashion; infusion of immature DCs in 
experimental murine models has been shown to be effective in inducing tolerance of 
allogeneic vascularised cardiac grafts103 and full thickness skin grafts104. 
Plasmacytoid DCs (pDCs) can also be effective in promoting allograft tolerance 
through generation of Treg, suggesting that maturity of DCs does not necessarily 
mandate development of a pro-inflammatory phenotype105.  
The prospect of therapeutic infusion of DCs in a clinical setting clearly presents a 
risk of enhancing alloantigen presentation and augmenting the adaptive immune 
response (particularly within the inflammatory cytokine milieu inside a rejecting 
allograft). It has been suggested that co-treatment with pharmacological agents to 
inhibit co-stimulation might be an effective strategy to negate this risk96. 
 
1.1.4.3 Regulatory T cells 
CD4+ regulatory T cells (Treg) are widely regarded as the single most important cell 
type in mediating peripheral tolerance106 and are comprised of two main subtypes. 
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The predominant form of regulatory T cells is identified by the transcription factor 
Foxp3 (described herein as ‘Treg’) and is further classified according to two origins: 
thymic Treg (tTreg) constitutively express Foxp3 and have the predominant role of 
maintaining tolerance to self antigens, whilst peripheral Treg (pTreg) develop in the 
periphery from naïve CD4+ cells that are exposed to antigens under tolerogenic 
conditions (for example by immature DCs with low levels of co-stimulation). A 
second group of CD4+ regulatory T cells that do not express Foxp3 has also been 
identified and named as Type I regulatory cells (Tr1)107. Tr1 cells are generated in 
the periphery upon antigen stimulation in the presence of IL-10 and utilise many of 
the same regulatory mechanisms as Treg108, but the two may have spatially and 
temporally distinct roles in achieving allograft tolerance in the in vivo setting109. 
Treg are crucial for physiological immune homeostasis and their absence leads to 
severe autoimmunity, which is universally fatal in ‘scurfy’ mice that lack Foxp3 
expression110 and manifests as a life-limiting multisystem disorder in humans – the 
immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome 
(IPEX)111,112. In transplantation, Hall et al first identified Treg in rats that had 
become tolerant of allogeneic cardiac grafts; they found that these cells showed 
alloantigen-specific unresponsiveness in vitro and then demonstrated that they could 
induce tolerance in rats with newly transplanted allografts113. Since then, Treg have 
been shown to mediate tolerance in a vast array of experimental murine allograft 
models including islet cells114, heart115, skin116 and haematopoietic stem cell 
transplantation (HSCT)117. 
Investigation of some of the small number of patients who have become tolerant of 
liver allografts following withdrawal of immunosuppression has also revealed larger 
populations of Treg in peripheral blood compared to patients who went on to reject 
their grafts118. However, Treg do also have the potential to cause harm by permitting 
neoplastic cells to evade anti-tumour immunity119 and preventing sterile immunity in 
certain viral infections106; the long term effects of artificially manipulating Treg 
populations in vivo are therefore unknown. 
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Treg appear to mediate suppression via four synergistic mechanisms: release of 
inhibitory cytokines, direct cytolysis, metabolic disruption and modulation of DC 
maturation and function106; each of these mechanisms has been shown to be effective 
and the relative importance of one over the others remains incompletely resolved. 
Treg actively secrete IL-10, TGF-β and IL-35. Of these, IL-10 secretion is common 
to multiple regulatory cell types and is an essential (non-redundant) mediator of 
immunoregulation in a wide variety of inflammatory conditions120. The IL-10 
receptor is most highly expressed on macrophages and DCs, but T cells, B cells and 
many others are also targets. Ligation of the IL-10 receptor leads to activation of 
signal transducer and activator of transcription 3 (STAT3), which blocks 
inflammatory signalling (especially signalling from Toll-like receptor stimulation)120. 
Anti-inflammatory actions of IL-10 include suppression of inflammatory cytokines, 
chemokines and nitric oxide release from macrophages121, suppression of both Th1 
and Th2 responses, and stimulation of CD4+ cells to produce more IL-10 in a 
positive feedback manner122. TGF-β plays a critical role in the generation and 
maintenance of iTreg and is discussed further in Section 1.5. Finally, IL-35 is also 
constitutively expressed by Treg and is an important mediator of suppression. IL-35 
can suppress T cell proliferation directly, but its overall effects more likely result 
from influencing T cell differentiation including suppression of Th1/Th17 
phenotypes, whilst enhancing the suppressive capacity of Treg and stimulating their 
proliferation and production of IL-10 and TGF-β123. 
Treg are able to directly induce apoptosis in target effector cells with cell-cell contact 
through production of the serine protease, granzyme A (GZMA)124. This method of 
suppression appears to be essential for effective regulatory function in specific 
circumstances including haematopoietic stem cell transplantation (HSCT). 
Transcriptional analysis from Treg of human patients undergoing HSCT has shown 
significantly elevated expression of granzyme A in immune tolerant patients 
compared to those experiencing GvHD125 and the relevance of this relationship has 
been recently confirmed experimentally: whilst GZMA-/- Treg are highly suppressive 
in vitro, they are unable to prevent GvHD (unlike WT Treg) in a murine model of 
HSCT124. 
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Extracellular adenosine is a physiological negative regulator of numerous immune 
cell types (including T cells, B cells, macrophages and dendritic cells) and its 
concentration can increase from metabolic changes in states of hypoxic stress, or as a 
result of active processes employed by Treg126. Cell surface expression of ‘ecto-
enzymes’ CD39 and CD73 is an effective mechanism for increasing the local 
extracellular concentration of adenosine: CD39 dephosphorylates ATP to AMP and 
CD73 further dephosphorylates AMP to adenosine. Treg express high levels of both 
CD39 and CD73, and adoptive transfer experiments with CD73-/- Treg have 
demonstrated that its expression is necessary for suppression of effector cells in 
murine models including HSCT127 and ischaemia-reperfusion injury128. At the same 
time, adenosine can act in an autocrine positive feedback fashion to augment the 
suppressive ability of Treg. Exposing Treg to an adenosine receptor agonist in 
culture promotes their expression of cell surface inhibitory molecules including 
CTLA-4129 and PD-1130 and enhances their ability to ameliorate ischaemia-
reperfusion injury. 
As mentioned above, DCs play a key role in determining the balance between 
inflammation and tolerance. Whilst tolerogenic DCs are able to promote Treg 
induction and expansion, Treg are also able to indirectly mediate tolerance by 
manipulating the phenotype of local DCs. Treg expression of CTLA-4 contributes to 
this by decreasing DC expression of CD80/CD86 costimulatory molecules, thereby 
reducing their ability to drive T cell activation131. Lymphocyte activation gene 3 
(LAG3/CD223) is a type I membrane glycoprotein found on the surface of Tr1 cells; 
binding of LAG3 to MHC II molecules on the surface of DCs directly inhibits DC 
maturation and expression of co-stimulatory molecules132. Expression of LAG3 
therefore provides a contact-dependent mechanism of inducing tolerogenic DCs, in 
addition to secretion of IL-10. 
In most instances of allogeneic transplantation, a relatively small number of 
functioning nTreg and iTreg are present, but their regulatory influence is 
overwhelmed by the comparatively very high number of circulating effector T cells 
with specificity for allogeneic MHC molecules. In light of the multiple effective 
regulatory mechanisms at their disposal, expansion of Treg populations is an 
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attractive therapeutic prospect; current strategies under investigation are discussed 
further in Section 1.1.6.  
 
1.1.4.4 Myeloid-derived suppressor cells 
Myeloid-derived suppressor cells (MDSCs) are a notoriously heterogeneous group 
consisting of immature myeloid cells and myeloid progenitor cells that are known to 
expand during inflammation and can potently suppress T cell proliferation133. In the 
context of transplantation, MDSCs have been shown to ameliorate allograft rejection 
through several mechanisms96,134. First, MDSCs can directly suppress proliferation of 
B cells, T cells and NK cells. Secondly, they promote or maintain regulatory 
phenotypes of other immune cells including Treg, regulatory macrophages and 
immature DCs. And thirdly, they also secrete soluble mediators to suppress 
inflammation, including IL-10 and haem oxygenase-1135, an enzyme that has been 
shown to ameliorate cell damage from ischaemia-reperfusion injury136.  However, 
due to the diversity of settings and stimuli that elicit MDSCs, and the marked 
heterogeneity of their origin and phenotypic markers, a clear role in allograft 
tolerance has yet to emerge. 
 
1.1.4.5 Mesenchymal stem cells 
Mesenchymal stem cells (MSCs) are multipotent stem cells that contribute to 
haematopoiesis in bone marrow, but also migrate into transplanted allografts 
following the release of inflammatory cytokines arising from the innate immune 
response. MSCs are capable of suppressing T cell proliferation through mechanisms 
similar to that of myeloid-derived suppressor cells (expansion of Treg, maintenance 
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1.1.5 Current Immunosuppression Regimens and Sequelae 
The degree of immunosuppression required to prevent rejection differs according to 
the particular organ being transplanted. Skin, small bowel and lung allografts are 
particularly prone to rejection, whilst pancreas, heart, kidney and liver are 
progressively less vulnerable138. Specific immunosuppression regimens therefore 
differ accordingly, but share the same set of commonly used pharmacological agents 
as summarised below. 
 
1.1.5.1 Corticosteroids 
Exogenous corticosteroids have been used clinically to combat inflammation from 
autoimmunity since 1948139 and remain the first line treatment for episodes of acute 
rejection in most centres today140. Corticosteroids act via a number of mechanisms to 
suppress inflammation, including inhibition of gene transcription leading to a 
reduction in prostaglandin synthesis and extra-genomic actions such as activation of 
endothelial nitric oxide synthase141. Whilst the immunosuppression achieved is 
effective in preventing allograft rejection, multiple serious adverse effects 
considerably limit clinical use. These include: diabetes, hypertension, dyslipidaemia, 
infection, poor wound healing, osteoporosis and accelerated cardiovascular disease. 
As a result, steroid therapy is usually reserved for use upon induction of 
immunosuppressive therapy (and rapidly tapered off), or for treatment of episodes of 
acute rejection, so that the cumulative dose is minimised wherever possible142. 
 
1.1.5.2 Purine Inhibitors 
Mycophenolate mofetil (MMF) and azathioprine act via different mechanisms to 
inhibit purine (and therefore DNA) synthesis necessary for lymphocyte activation. 
Azathioprine formed the mainstay of immunosuppressive therapy (in combination 
with corticosteroids) in the early days of transplantation, but has now been largely 
superseded by MMF, which is more potent and specific. MMF blocks purine 
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synthesis by inhibition of inosine monophosphate dehydrogenase and specificity for 
B and T cells is achieved because they almost uniquely lack the ability to 
alternatively generate purine from nucleotide breakdown products (the purine 
salvage pathway)143. MMF does not achieve sufficient immunosuppression as a sole 
agent to prevent rejection; it is teratogenic and associated with adverse effects 
including leucopoenia, abdominal pain, diarrhoea, diabetes and dyslipidaemia. 
 
1.1.5.3 Calcineurin Inhibitors 
Calcineurin is a protein phosphatase involved in a number of cellular processes, 
predominantly enabling nuclear factor of activated T cells (NFAT) to translocate to 
the nucleus and upregulate expression of IL-2, leading to T cell proliferation144. 
Drugs that inhibit calcineurin include cyclosporine and, more recently, tacrolimus. 
Cyclosporine alone is capable of preventing acute rejection and has formed the basis 
of most immunosuppression regimens (in combination with corticosteroids) over the 
last 30 years. However, renal impairment secondary to interstitial fibrosis is a major 
complication of calcineurin inhibitors - severe renal failure affects up to 20% of non-
kidney transplant recipients at 5 years145. Cyclosporine is also associated with 
additional specific adverse effects including hypertension, hirsuitism and gum 
hypertrophy. Tacrolimus is a macrolide with greater bioavailability and 
immunosuppressive potency than cyclosporine. It is also associated with fewer 
adverse effects overall, but does frequently cause neurological symptoms (tremor, 
headache, insomnia), dyslipidaemia and diabetes146. 
 
1.1.5.4 mTOR inhibitors 
Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that mediates T 
cell proliferation in response to IL-2 and several other cytokines. Sirolimus 
(rapamycin) inhibits mTOR-mediated signal transduction and the CD28-induced co-
stimulatory pathway. Sirolimus is less nephrotoxic than calcineurin inhibitors, 
promotes induction of Treg and, in contrast to most immunosuppressive agents, has 
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some anti-cancer properties. Adverse effects include bone marrow suppression, 
dyslipidaemia, thrombocytopenia and severely impaired wound healing, which 
presents a particular problem in the context of recent major surgery142.  
 
1.1.5.5 Depleting antibodies 
Antithymocyte globulin (ATG) is a polyclonal antibody raised against whole human 
T cells that acts on a number of fronts – preferential depletion of CD8+ and 
CD4+Foxp3- effector T cells compared to CD4+Foxp3+ Treg147, induction of B cell 
apoptosis and modulation of DC function148. ATG is a highly-effective 
immunosuppressant but its use is complicated by multiple severe adverse effects: in 
the short term these include ‘cytokine storm’ (manifesting as fever, hypotension and 
pulmonary oedema); in the longer term,  lymphopoenia can persist for more than 12 
months and therefore lymphoma and opportunistic infections are more common than 
with other immunosuppressant agents140. As a result, use of ATG is generally 
restricted to patients at high risk of rejection and for instances of acute rejection 
resistant to steroid therapy. 
Alemtuzumab is a humanised monoclonal antibody to CD52, which is abundantly 
expressed on the surface of T cells and B cells. Alemtuzumab is used for similar 
indications to ATG and is associated with fewer adverse events, but does carry a 
particular risk of de novo autoimmune conditions141. 
 
1.1.5.6 Non-depleting antibodies and novel agents 
Basiliximab is a monoclonal antibody to CD25, the α chain of the IL-2 receptor, 
which is expressed on activated T cells. This degree of specificity seems to result in 
basiliximab exhibiting fewer adverse effects compared to alemtuzumab (anti-CD52), 
but with the risk of more frequent episodes of acute rejection149. As CD25 is also 
expressed on Treg, basiliximab may also inhibit the development of tolerance. 
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Belatacept is a fusion protein comprised of the extracellular component of CTLA-4 
combined with the Fc domain of IgG1. Acting as an exogenous source of CTLA-4, it 
regulates T cells by effectively inhibiting co-stimulation through CD80/86. 
Belatacept can be used for maintenance immunosuppression, with the advantage of 
not causing any nephrotoxicity. However, its use is associated with bone marrow 
suppression, dyslipidaemia and a particularly high risk of de novo cancers149. 
 
1.1.5.7 Generic adverse effects 
Patients suffering from end-stage kidney disease (ESKD) show a slightly higher 
incidence of a variety of cancers in addition to those that are known to cause renal 
impairment (kidney, urinary tract, thyroid and myeloma)150. The increased risk of 
malignancy is seen both before and after commencing dialysis and may be partially 
attributable to uraemic immunosuppression151. Following transplantation, currently 
employed immunosuppression regimens contribute to a 100-fold increase in the 
relative risk of skin cancer and up to 5-fold increase in the relative risk of other 
cancers152,153. This pattern of malignancy is similar to, but greater than, the variety 
seen with immunocompromise arising through infection with Human 
Immunodeficiency Virus (HIV)154 and includes multiple neoplasms with a known 
viral aetiology such as non-Hodgkin lymphoma, Kaposi’s sarcoma and non-
melanomatous skin cancers150. Cancer risk with immunosuppression appears to be 
cumulative and therefore presents a particular challenge to the paediatric transplant 
recipient population155. 
As outlined above, significant cardiovascular risk factors (hypertension, diabetes, 
dyslipidaemia) are frequent complications of multiple immunosuppressive agents. As 
a result, cardiovascular mortality now accounts for the fact that the life expectancy of 
transplant recipients still falls short of the general population141. The repertoire of 
immunosuppressive agents described here has remained largely unchanged in recent 
years; novel therapeutic strategies are urgently required. 
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1.1.6 Emerging Therapies Under Investigation in 
Transplantation 
Allograft tolerance, defined as durable antigen-specific unresponsiveness in an 
immunocompetent host156, presents the ‘Holy Grail’ scenario of achieving the 
benefits of organ transplantation without the need for immunosuppression and all of 
the harmful sequelae it encompasses. 
Despite successful achievement of allograft tolerance in murine experimental models 
more than 60 years ago157, translation to routine clinical practice has remained 
elusive. Recent developments in the understanding of regulatory cell populations 
have however allowed some ground for optimism96. In particular, a recent trial of 
combining kidney transplantation with a simultaneous bone marrow transplant from 
single HLA-mismatched donors has allowed for successful withdrawal of all 
immunosuppression in four of five patients158. With this technique, patients 
developed transient mixed chimerism and lasting specific alloantigen 
unresponsiveness as a result. Using the same technique, Scandling et al. have 
independently demonstrated similarly impressive outcomes with HLA-matched 
kidney transplantation: from a cohort of 16 patients, 8 have achieved rejection-free 
avoidance of immunosuppressive medication for more than 1 year, and a further 4 
patients are in the process of withdrawal from medication159. Although many would 
consider simultaneous bone marrow transplantation to present an unacceptable level 
of complexity and risk in the pursuit of solid-organ allograft tolerance160, these 
important studies have shown that it is possible to achieve durable intragraft 
regulatory cell populations and successful allograft tolerance in a clinical setting as a 
result. 
Less invasive approaches to the achievement of clinical tolerance have focussed on 
the potential role for cellular therapy. The ONE Study (currently in progress) is a 
multicentre clinical trial investigating multiple cellular therapies in parallel: Treg, 
tolerogenic dendritic cells and regulatory macrophages161. Of these, Treg therapeutic 
strategies have received by far the most attention. 
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The ability of adoptively transferred Treg to mediate indefinite tolerance of murine 
allografts has now been demonstrated in multiple transplant models including 
pancreatic islet162, skin163 and heart164. Expectations of successful translation of Treg 
therapy into the clinical setting have been high and preliminary clinical trials have 
now been completed in graft-versus-host disease165 and hematopoietic stem cell 
transplantation166 with modest but encouraging results.  
However, a number of obstacles and concerns persist. First, Good Manufacturing 
Practice (GMP)-compliant ex vivo expansion of Tregs for subsequent reinfusion is a 
highly specialized process at a cost of approximately £30,000 ($45,000) per 
patient167. Even if this level of funding could be justified, the infrastructure and 
highly qualified personnel required are likely to limit translation into routine clinical 
practice. 
Secondly, due to the lack of a unique human regulatory T cell surface marker, 
accurate identification of Treg populations remains imperfect. The optimal approach 
is with fluorescence-activated cell sorting (FACS), with selection of, for example, 
CD4+CD25+CD127lo cells166. However, GMP-compliant FACS isolation of Treg for 
clinical therapeutic use is available at very few centres throughout the world and 
therefore current preliminary clinical trials are utilising magnetic cell sorting 
techniques, consequently resulting in Treg populations of a lower purity168,169. 
Currently employed regimens include depletion of CD8+ cells, followed by 
enrichment of CD25+ cells and subsequent expansion via stimulation with anti-CD3 
and anti-CD28 monoconal antibody-coated beads and the addition of IL-2 with 
rapamycin to selectively inhibit proliferation of non-Treg cells169. Whilst this 
technique limits alloreactive effector T cells to a very small percentage, it is likely 
that the few remaining are highly activated, and the long-term impact of their 
infusion into a transplant recipient is unpredictable169. 
Thirdly, concern remains over the question of whether isolated Treg maintain their 
regulatory phenotype following re-infusion, particularly in the context of an 
inflammatory environment.  Alloantigen-specific iTreg offer the potential advantages 
of high functional suppressive ability and a specificity of action that might lower the 
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risk of side effects such as early viral reactivation (observed in trial of Treg therapy 
in haematopoietic stem cell transplantation170) and the potential risk of neoplasia 
with non-specific Treg therapy. However, whilst ex vivo expansion of alloantigen-
specific iTreg driven by allogeneic dendritic cells may have advantages of specificity 
and potency, loss of Foxp3 expression (and therefore regulatory phenotype) has been 
reported171. This poses a risk of infusing a population of cells that effectively revert 
to allograft-specific effector T cells, and the ability or otherwise to treat this scenario 
with conventional immunosuppression is unknown172. Therapeutic infusion of nTreg 
and iTreg comprise two separate arms of the ONE Study that is currently underway 
(NCT02129881). 
Finally, in the long-term it is unknown whether Treg-mediated immunosuppression 
might present risks of infection or neoplasia comparable to those of current non-
specific immunosuppression regimens. To date, four clinical trials of Treg therapy 
have been published: three investigating prevention or treatment of graft vs host 
disease (GvHD)165,173,174 and one for treatment of type I diabetes175. Early follow-up 
has provided some degree of reassurance, with no adverse events reported other than 
a slightly increased incidence of viral reactivation in the context of GvHD170. 
However the longest follow-up period that has been reported is only 12 months175 
and, particularly regarding a potential long-term risk of malignancy, it may be very 
difficult to determine a follow-up period wherein this question can be answered 
definitively. In short, Treg cellular therapy is an attractive potential therapeutic 
strategy that has advanced rapidly in recent years, but many questions and logistical 
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1.2 Autoimmunity and the Hygiene Hypothesis 
 
1.2.1 Autoimmunity 
Autoimmune disease encompasses a diverse group of conditions characterised by 
abnormal immune reactivity in association with auto-reactive B and T cells that 
results in damage to host tissue. Disease ranges from the organ-specific (e.g. 
autoimmune thyroiditis and type I diabetes) to more general multi-system disorders 
(e.g. systemic lupus erythematosus). In a minority of patients, a specific aetiology or 
precipitant is determinable, such as a genetic lack of regulatory T cell activity in 
IPEX syndrome leading to multi-system autoimmunity111, or preceding Streptococcal 
infection leading to rheumatic fever176. In most cases, aetiology is thought to be 
multifactorial, with contributing risk factors of genetic susceptibilities and 
environmental exposures accumulating over time to manifest as clinical disease in 
adulthood177,178.  
Multiple sclerosis is an inflammatory disorder of the central nervous system that 
results in focal areas of axonal demyelination and currently represents the leading 
cause of neurological disability in young adults worldwide179,180. Whilst the precise 
aetiology of the disease is unknown, multiple factors combine to justify its 
classification as an autoimmune condition, including characteristically activated T 
cells in focal lesions of the central nervous system181, the presence of oligoclonal IgG 
in cerebrospinal fluid182 and differing susceptibility to the disease between distinct 
HLA alleles183.  
The prevalence of autoimmune diseases in general has been increasing in developed 
countries179,184, to such an extent that 3% of the general population of the United 
States is now affected185. Indeed, the rapidity of rising incidence is outwith a 
timescale that could be explained by genetic evolution and therefore strongly points 
towards a causative environmental change. A number of aetiological hypotheses 
have been proposed including changes in UV light exposure186, vitamin D levels187, 
geographical latitude188, month of birth189, novel inciting infections190, environmental 
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toxins191 and a relatively sudden change in sanitation and exposure to infection (the 
‘hygiene hypothesis’) 192. 
 
1.2.2 The Hygiene Hypothesis 
The hygiene hypothesis has developed into a number of forms over time. It began in 
1968 with the observation of a low incidence of rheumatoid arthritis in an area of 
West Africa where helminth infections were endemic193. Subsequently (and more 
conspicuously), Strachan proposed a causal link between household size in childhood 
and the incidence of hay fever in later life, suggesting that children from large 
families were exposed to a greater range of pathogens, which ‘educated’ the immune 
system and prevented inappropriate overactivity in later life192,194. Continuing this 
theme is the ‘Old Friends Hypothesis195’, that certain Palaeolithic commensal 
bacteria and helminth parasites have co-evolved with humans for thousands of years 
until their sudden widespread eradication in developed countries with improvements 
in sanitation and the advent of effective anti-helminthic therapy in the 1930s, a time 
that closely corresponds with the onset of an epidemic of allergic and autoimmune 
conditions in the same geographical regions. Rook and others proposed that the 
sudden removal of helminth-derived immunoregulation tipped the balance towards 
overactive immunity manifesting as atopy and autoimmunity196. 
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Figure 1-4  Evolution of Immune Responsiveness with Parasite Immunomodulation. Adapted 
from Allen & Maizels (2011)197.  
 
The ‘Old Friends’ hypothesis presents a clearly logical rationale: in the face of an 
evolutionary imperative, helminths have developed powerful mechanisms to 
modulate and suppress the immune responses of their host; over time, the host has 
adapted to this immunosuppression with a more active level of baseline immunity 
and sudden removal of the helminths’ suppressive influence tips the equilibrium 
towards harmful overactive immunity197. A considerable body of evidence now 
exists in support of this premise. Helminths chronically infect more than one quarter 
of the world’s population198 and their geographical prevalence bears a strikingly 
inverse correlation to that of multiple sclerosis (MS)184,196. Further to this, Fleming & 
Cook determined a quantitatively inverse relationship between prevalence of MS and 
the helminth Trichuris trichiura, with the observation that MS prevalence falls 
steeply when a threshold of approximately 10% prevalence of Trichuris trichiura 
infection is exceeded (Figure 1-4)199. The same dichotomous relationship has been 
found with other helminth species (Necator americanus and Ancylostoma 
Within the diverse spectrum of genetic 
polymorphisms of the human population, 
many non-coding alleles exert some 
influence on the general level of immune 
responsiveness. Evolution in the context 
of prevalent helminth infections (a) will 
compensate for the suppressive effect 
exerted by the parasites through positive 
selection of the most appropriate alleles; 
extremes of under- or over-responders 
are rare. Since the relatively sudden 
eradication of the helminth-derived 
suppressive effect in the modern-day 
environment (b) more pro-inflammatory 
genotypes that would have previously 
provided an appropriate level of immune 
responsiveness may now be prone to 
pathological over-activity in the form of 
allergic and autoimmune conditions.!
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Figure 1-5 - Dichotomous relationship between Trichuris trichiura and multiple sclerosis. 
Adapted from Fleming & Cook (2006)199 
 
In pursuing a causal relationship, van den Biggelaar et al performed skin allergen 
testing in 520 Gabonese schoolchildren and found a significantly lower prevalence of 
positive skin reactions amongst children with coincidental urinary schistosomiasis201. 
Peripheral blood T cells from infected children were found to produce significantly 
higher levels of IL-10 in response to parasite antigen stimulation, and serum IL-10 
was negatively associated with allergen reactivity. A follow-up study prospectively 
randomised 317 schoolchildren from the same region to receive pharmacological 
treatment to clear helminth infection (praziquantel and mebendazole)202. Repeated 
skin allergen testing at 3-monthly intervals revealed a significant increase in 
sensitivity to house dust mite following clearance of helminth infection in the 
treatment group, thus indicating a causal relationship for the first time. 
There is also some evidence to suggest that maternal helminth infection may afford 
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conducted a double-blind, placebo-controlled randomised controlled trial of 2,507 
pregnant women in Uganda to investigate the hypothesis that antihelminthic 
treatment in pregnancy might improve the efficacy of subsequent childhood 
immunisations203,204. After five years of follow-up, the study failed to show any 
effect on recall responses to Bacille Calmette Guérin (BCG) or tetanus 
immunisations. However, children born from mothers randomised to receive 
antihelminthic treatment (albendazole) experienced a significantly higher incidence 
of (physician-diagnosed) eczema205. This suggests that, in some cases at least, 
helminth infection may be not only safe in pregnancy, but beneficial in reducing 
atopic conditions in offspring as well. 
Evolutionary selection may influence the host as well as the parasite. Investigation of 
a population of wild Soay sheep on the island of St Kilda off the coast of Scotland 
revealed an inverse correlation of antibody responses to Teladorsagia circumcincta 
(a prevalent parasitic nematode) and reproductive fitness206. This relationship may 
underlie a selection bias of hosts that tolerate helminth infection. 
 
1.2.3 Observational Studies of Autoimmunity and Helminth 
Infection 
In Argentina, Correale and Farez initiated a small prospective double cohort study 
assessing the clinical disease course and radiological features of 24 patients with 
established MS – 12 patients with environmentally-acquired asymptomatic helminth 
infection and 12 matched, non-infected patients as a control cohort207. Over a period 
of 4.5 years, study subjects underwent a comprehensive neurological examination 
every three months, magnetic resonance imaging (MRI) brain scan every six months 
and further specific immunological investigations towards the end of the study 
period. The results are convincing: in 55.8 months, 3 episodes of clinical relapse 
were seen in the helminth-infected cohort, compared to 56 relapses in the uninfected 
control group (median annualised relapse rate of 0 vs. 1.10, p < 0.0001). 
Radiological findings support the clinical results – in the infected cohort, 6 out of 12 
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patients showed a change, with a total of 14 new or enlarging MRI lesions, compared 
with radiological changes in all patients of the non-infected cohort, with 164 new or 
enlarging MRI lesions in total. Mechanistically, peripheral blood analysis revealed a 
significantly greater percentage of CD4+Foxp3+ Treg in the helminth-infected cohort, 
in addition to elevated levels of the regulatory cytokines TGF-β and IL-10, and 
decreased expression of pro-inflammatory cytokines IFN-γ and IL-12.  
In 2011, Correale and Farez published an update on the original study above after 7.5 
years of follow-up208. After 63 months of monitoring, 4 out of the cohort of 12 
patients with helminth infection suddenly developed symptoms related to the 
infection, including abdominal pain and general malaise, and were therefore treated 
with anti-helminthic therapy. This intervention provided some additionally 
illuminating insights – whilst the 8 untreated patients with helminth infection 
continued to experience a very low clinical relapse rate (0.06 episodes per 
patient/year), those who had pharmacologically cleared the parasite infection saw a 
dramatic rise in their relapse rate of MS symptoms (1.1 episodes per patient/year, p = 
0.007), a level comparable to patients who had never experienced any helminth 
infection. Despite this study’s small sample size and lack of randomisation or 
blinding, the dramatic change in reported clinical disease course was very closely 
replicated by radiological evidence of additional new or enlarging lesions (figure 1-
5), a decrease in CD4+Foxp3+ Treg and a corresponding ‘switch’ in myelin basic 
protein (MBP)-specific cytokine profile (decreased IL-10 and TGF-β; increased IL-
12 and IFN-γ). 
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Figure 1-6 - Number of exacerbations (A) and changes in MRI parameters observed over time 
(B) in parasite infected MS patients, uninfected MS patients, and parasite infected MS patients 
under anti-parasite treatment. Arrows indicate onset of treatment with anti-parasite drugs. For 
all panels, data shown represents average values observed at each time point. Adapted (with 
permission) from Correale and Farez (2011)208 
 
1.2.4 Animal Studies of Autoimmunity and Helminth Infection 
The impact of helminths on autoimmunity has been investigated in animal models of 
several diseases including type I diabetes209, Graves’ hyperthyroidism210 and 
rheumatoid arthritis211, but multiple sclerosis has received the most attention and will 
form the basis of further review here. Several experimental animal models have been 
designed to replicate multiple sclerosis, including experimental autoimmune 
encephalomyelitis (EAE)212, viral-induced demyelination213 and the neurotoxic 
cuprizone model214. Whilst none of these are perfect surrogates of clinical MS, EAE 
is thought to capture many of its immunological features, and is the most frequently 
cited, featuring in almost 20% of all MS-related research publications215.  
The collective term EAE encompasses a number of models which broadly involve 
either immunisation with myelin antigens (active EAE), or adoptive transfer of 
myelin-specific effector T cells (passive EAE), such that demyelination (and a 
characteristic clinical phenotype) develops as a result of inflammation in the CNS. 
The pathogenesis of active EAE has two distinct phases: an induction phase 
A B
Number of exacerbations (A) and changes in MRI parameters observed over time in parasite infected MS patients, 
uninfected MS patients, and parasite infected MS patients under anti-parasite treatment. Arrows indicate onset of 
treatment with anti-parasite drugs. For all panels, data shown represents average values observed at each time point.
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(immunisation, presentation of myelin antigen by DCs, activation and expansion of 
myelin-specific T cells) and an effector phase (migration of myelin-specific T cells 
into the CNS, recognition of cognate antigen and T cell activation with secondary 
activation of microglia and macrophages, along with the onset of clinical disease).  
One particular difficulty that arises in attempting to extrapolate findings from EAE to 
MS is that the experimental model often produces a single episode of disease, in 
contrast to clinical MS, which is typically characterised by multiple episodes of 
relapse followed by remission with incomplete recovery. The natural history of 
disease is also clearly very different – modelling an uncertain spectrum of events 
over a prolonged period that eventually lead to MS with a very precise time point of 
immunisation in EAE. The possibility of prophylactic treatment therefore exists in 
EAE that does not for MS. 
To date, a total of 14 published studies have investigated the effect of treatment with 
helminths, helminth products or helminth-induced cell populations on the 
pathophysiology of EAE (outlined in table 1-1 below). All except one of these 
studies has shown a beneficial effect with helminth treatment. The exception 
(Chiuso-Minicucci et al.216), showed that Strongyloides venezuelensis had no impact 
on the disease course of EAE in Lewis rats. This may be an example of helminth-
specific variation in immunomodulatory capability. However, since Lewis rats are 
non-permissive of sustained S. venezuelensis infection216,217 the finding of an 
unchanged EAE course may represent inability of the parasite to establish rather than 
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Table 1-1 Studies of EAE and helminth therapy (adapted and updated from Tanasescu (2014)224 
and Hasseldam (2013)225). pMOG – Myelin Oligodendrocyte Glycoprotein peptide; SC – spinal 
cord; DA – Dark Agouti; PLP – proteolipid protein. 
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Table 1-1 (continued) Studies of EAE and helminth therapy (adapted and updated from 
Tanasescu (2014)224 and Hasseldam (2013)225). pMOG – Myelin Oligodendrocyte Glycoprotein 
peptide; SC – spinal cord; DA – Dark Agouti; PLP – proteolipid protein. 
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Although the EAE models, helminths and individual treatment conditions of the 
studies outlined above varied markedly, a number of summative conclusions can be 
drawn. First, effective helminth therapy generally involved treatment prior to 
induction of EAE, with the notable exception of Donskow-Łysoniewska et al, who 
showed a dramatic improvement in established disease 48 hours after infection with 
H. polygyrus218. This may be indicative of a crucial role for helminth-derived 
immunomodulation early in the disease process, such as antigen presentation and/or 
co-stimulation. Indeed, Sofronic-Milosavljevic et al showed that excretory-secretory 
(ES) products from Trichinella spiralis were able to suppress maturation of DCs and 
that adoptive transfer of these cells was able to ameliorate the severity of EAE in 
rats231. However, the necessity for pre-treatment in the EAE model is not necessarily 
indicative of a bar to clinical translation. A treatment that can prevent EAE from 
developing may be beneficial in a clinical setting by preventing future relapses of 
MS and, as a result, cumulative disability in the long term. 
Another recurring feature of helminth infection with EAE is of a change in the 
antigen-specific cytokine profile of splenocytes or inguinal lymph node cell 
populations upon restimulation, in the form of a reduction in IFN-γ and IL-17, and an 
increase in IL-4, IL-5 and IL-10. Interestingly, this switch to a ‘modified Th2’ 
cytokine response was also observed in mice that had received Trichinella spiralis 
ES-treated DCs231, suggesting that the change in cytokine profile is as a result of 
active mediators secreted by the helminth, rather than solely as a response to tissue 
damage arising from live infection. To evaluate the mechanistic significance of this 
finding, Sewell et al demonstrated that treatment with Schistosoma mansoni ova 
resulted in a reduced severity of disease in WT mice, but that this protection was 
completely lost in STAT6-/- animals (which are unable to mount a Th2 response)230.  
A number of further illuminating mechanistic insights were provided in a study of 
the role of Fasciola hepatica infection on EAE by Walsh et al222. F. hepatica is 
associated with a multicellular infiltration of the peritoneal cavity including DCs, 
macrophages, eosinophils and CD4+ T cells. Analysis of the DC population by flow 
cytometry revealed an immature (tolerogenic) phenotype with significantly lower 
expression of CD80, CD86, CD40 and MHC class II in comparison to uninfected 
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control mice. Additionally, both DCs and macrophages isolated from the peritoneal 
cavity of infected mice were found to express high levels of IL-10 and TGF-β. 
Subsequently, infection of WT and IL-10-/- mice with Fasciola hepatica revealed 
identical reductions in both EAE severity and MOG-specific	   IFN-γ and IL-17 
production by splenocytes, suggesting that IL-10 is not the mediator for suppressing 
pathology. However, when F.	  hepatica-­‐infected	  WT animals were treated with a TGF-
β neutralising antibody (vs. control IgG), protection from EAE afforded by the 
parasite was completely reversed, thus confirming a critical role for TGF-β in F. 
hepatica-mediated protection from EAE. 
Many helminth species are capable of inducing Foxp3+ Treg233-237 and Treg have 
separately been shown to potently suppress EAE238; notably, the one study detailed 
above that did not find any evidence of protection from EAE with helminth infection, 
also found no expansion of Treg in the infected group, which may account for the 
lack of protection216. Other regulatory cells have been shown to play a fundamental 
role as well: Wilson et al demonstrated that CD19+ B cells in the mesenteric lymph 
nodes of mice chronically-infected with H. polygyrus are able to effectively suppress 
EAE upon adoptive transfer into naïve recipients232. CD19+ B cells transferred from 
H. polygyrus-infected IL-10-/- were equally suppressive, providing further evidence 
that IL-10 is not the key mediator of suppression in this model. 
In summary, experimental studies with EAE strongly support the accumulating 
epidemiological and observational human studies suggestive of a role for helminths 
in ameliorating autoimmune disease. The precise pathophysiology of helminth-
mediated protection has yet to be fully elucidated, but some mechanistic insights 
have emerged:	   TGF-β, Th2 polarisation, tolerogenic DCs and B cells with a 
regulatory phenotype all appear to be non-redundant mechanisms of protection 
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1.2.5 Challenges Facing Therapeutic Helminth Infection 
The observational data summarised above presents a compelling case for progression 
to interventional clinical studies including randomised controlled trials and, 
accordingly, 17 clinical trials are now underway or completed239. However, the 
proposal of experimentally infecting patients with live helminths engenders a wide 
range of regulatory, logistical and scientific challenges, such that its unequivocal 
validation as a beneficial and viable therapy remains elusive240. 
Challenges include a heterogeneous response amongst the patient population to 
helminth infection that reflects the spectral nature of disease in humans. Individuals 
that mount a particularly weak response can develop very high worm burdens and 
suffer pathology as a result (e.g. local trauma, pain, anaemia)241, whilst those that 
mount an unusually overactive immune response may develop a low worm burden, 
but potentially also suffer pathological fibrosis as a form of ‘collateral damage’ from 
an overly exuberant Th2 response68.  
Whilst the vast majority of helminth infections may persist in an asymptomatic host 
without any overt pathology197, in a therapeutic context, inherent variability of worm 
burden presents a requirement for frequent monitoring of adverse effects and an 
inability to titrate dosage according to clinical disease severity (a standardised 
number of larvae could result in a wide range of adult worms in different patients).  
To the extent that varying response to helminth infection reflect long-standing 
genetic polymorphisms in the host immune system, it is plausible that the trade-off 
between the beneficial and detrimental effects of helminths may depend upon host 
genotype. However, at the present time no markers have been defined that would 
allow the patient cohorts to be stratified for clinical trials. 
Choice of helminth species is also difficult. In exploring the vast range of helminths 
that exist naturally, it is clear that many have a diverse range of complex 
immunomodulatory capabilities, and therefore likely not only that certain species 
will be better suited to ameliorating specific autoimmune conditions that others242, 
but also that the risk of unintentionally exacerbating disease may be inconsistent and 
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unpredictable243,244. The ideal ‘therapeutic helminth’ conforms to several 
criteria224,245: it should be easily administered and maintain chronic infection (to 
avoid repeated dosing); non-pathogenic and noncontagious; localise to the host 
intestine without migrating to other organs and not proliferate more aggressively in 
hosts receiving concomitant immunosuppressive therapy. No one helminth species 
fulfills every criterion, two helminths most closely matching have now been used 
therapeutically in clinical trials: Trichuris suis and Necator americanus. 
T. suis is a porcine whipworm that can colonise humans as a transient zoonotic 
infection246. It offers the advantages of a predictable life cycle (one egg releases one 
larva that matures into a single worm), infection confined to the host intestine and an 
inability to proliferate within the host247. However, as the infection is zoonotic, 
knowledge of the natural history of infection in humans is limited and therefore the 
possibility of systemic dissemination of parasites in a minority of cases cannot be 
completely excluded224. A further unknown is that the extent to which this species 
may be fine-tuned to modulating the porcine, rather than the human, immune system. 
Finally, infection persists for only up to 14 days, necessitating the expense of 
repeated dosing with Good Manufacturing Process (GMP)-compliant T. suis ova245.  
N. americanus currently infects more that 500 million people worldwide, and is 
thought to be one of the many helminths that was almost ubiquitous in humans until 
around the 1930s248. It therefore has the benefit of a known disease course and a 
direct theoretical connection to the ‘Old Friends’ hypothesis; replacing a long-
established and recently missed parasite’s regulatory influence. As a highly-prevalent 
helminth infection, N. americanus is generally well-tolerated and often 
asymptomatic.  However, infection with this parasite entails a life cycle that involves 
systemic distribution within the host: penetration of intact human skin followed by 
migration to the lungs, ascension of the bronchi and trachea, followed by swallowing 
and eventual establishment of chronic infection with maturation in the small 
intestine249. High worm burdens are associated with iron-deficiency anaemia 
secondary to intestinal blood loss250 and other, rarer, complications including 
anorexia, hypoalbuminaemia and reactive pneumonitis251. A number of pilot studies 
have reported no adverse events from infection with low doses of N. americanus 
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larvae252,253, but it is not yet known whether the resultant low-grade infections will be 
sufficient to achieve clinically-relevant immunomodulation. 
 
1.2.6 Clinical Trials of Therapeutic Helminth Infection in 
Autoimmunity 
A total of 25 clinical trials of therapeutic infection with T. suis or N. americanus are 
underway or have been completed (recently reviewed by Fleming and Weinstock239). 
Of the trials completed so far, emerging data are reassuring at least in terms of safety, 
with no reported serious adverse events to date239. Whilst all completed trials have so 
far used relatively small infective doses, and follow-up periods have been relatively 
short, some reassurance can also be garnered from the wealth of available long-term 
epidemiological and observational data from natural infections. This contrasts with 
the long-term complete unknown of, for example, infusion of Treg following ex-vivo 
expansion. 
Interestingly, early studies of therapeutic T. suis infection for inflammatory bowel 
disease (IBD) reported that infection was well-tolerated with no notable adverse 
effects254-256, but were contradicted by later studies of T. suis therapy for allergic 
rhinitis257 and MS258, in which 50% of participants reported gastrointestinal side 
effects such as abdominal pain and nausea. Side effects were reported as mild and 
therefore perhaps unnoticed by patients suffering from longstanding IBD. However, 
this finding does have relevance to the viability of therapeutic infection as a 
mainstream clinical option, particularly as the infective dosages used were smaller 
than that of most natural infections, upon which the previously described 
encouraging observational data is based. 
Results from the few interventional clinical studies that have been completed are less 
encouraging with regard to the efficacy of helminth infection as a therapeutic agent. 
Two double-blind RCTs investigating treatment of IBD have been reported on. 
Summers et al256 recruited 54 patients with active ulcerative colitis and randomised 
them to fortnightly treatment with 2,500 T. suis ova or placebo for 12 weeks, 
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followed by a median follow-up period of a further 12 weeks. No significant 
difference in the rate of clinical remission was observed between treatment groups, 
but investigators did report a marginally significant reduction in disease severity, as 
determined by reductions in the Ulcerative Colitis Disease Activity Index (comprised 
of scoring for frequency of diarrhoea, blood in stool, mucosal appearance, and 
overall assessment of clinical response) – a response rate of 43% for ova therapy vs. 
17% for placebo, p = 0.04, as determined by a 2-sided Fisher’s exact test). Sandborn 
et al conducted the second double-blind RCT in 2013259, randomising 36 patients 
with established Crohn’s disease to placebo or a variable dose of T. suis ova (400 – 
7,500) with 6 months of follow-up. The primary outcome was safety and tolerability; 
no dose-dependent adverse effects were reported, but nor was any clinical 
improvement seen. A subsequent review by the Cochrane Collaboration dismissed 
clinical improvement in Summers et al’s study256 as insignificant, based on 
comparison of the risk ratios for patients treated with ova compared to placebo (RR: 
2.6, 95% CI 0.97 to 6.95), and concluded that “there is insufficient evidence to allow 
any firm conclusions regarding the efficacy and safety of helminths used to treat 
patients with IBD. 260” 
Preliminary studies investigating the role of helminth therapy in combating MS 
benefit from the ability to objectively monitor disease activity by measuring new and 
enlarging inflammatory lesions of the brain and spinal cord with MRI scanning261. 
As MRI is a non-ionising imaging modality, serial scans can be performed for each 
study subject before, during and after a period of treatment, and can easily be 
assessed objectively by a radiologist blinded to the treatment conditions. The first 
clinical study, ‘Helminth-induced immunomodulation therapy’ (HINT 1) 258, was 
powered only to assess short-term safety concerns, with recruitment of 5 patients 
with newly diagnosed MS. Study subjects were given 2,500 T. suis ova for 3 months; 
no adverse events were reported and MRI findings were encouraging, but not 
statistically significant. A follow-up phase I study (HINT 2, NCT00645749) with 15 
patients undergoing 10 months of treatment with T. suis has since been conducted 
but not yet reported any results. Two further studies have also commenced, but 
similarly not yet reported any interim results. ‘Trichuris suis ova in relapsing-
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remitting multiple sclerosis and clinically isolated syndrome’ (TRIOMS)262 is 
anticipating recruitment of 50 subjects for randomisation of treatment with T. suis 
ova or placebo over 12 months, and ‘Worms for Immune Regulation in Multiple 
Sclerosis’ (WIRMS) is anticipating recruitment of 72 subjects for randomisation to 
treatment with N. americanus or placebo over 9 months (NCT01470521). 
The therapeutic potential of Necator americanus has so far been investigated with 
clinical trials of live infection in asthma263 and coeliac disease264. Both studies were 
limited by small number of subjects and difficulty in blinding subjects and 
investigators to treatment vs. placebo as a result of characteristic abdominal 
discomfort shortly after infection and pruritus at the site of cutaneous inoculation. As 
assessed by primary outcome measures, significant clinical improvement in asthma 
or coeliac disease has not been demonstrated with N. americanus infection. 
However, chronic low-grade infection was successfully established and, despite 
some initial discomfort, 23 out of 26 infected subjects declined anti-helminthic 
treatment at the end of the study periods. 
A number of possible explanations have been put forward as to why preliminary 
results from prospective randomised controlled trials have not lived up to 
expectations based on observational studies. First, and most plausibly, trial design: 
the small number of preliminary trials that have been performed to date have all been 
of limited power, particularly given the number of potentially crucial variables that 
exist (e.g. dosage, timing of infection, severity or stage of the target immunological 
condition) and, particularly in IBD, the often subjective outcome measures can result 
in a considerable placebo effect. Secondly, choice of therapeutic helminth: as 
discussed above, T. suis and N. americanus were (appropriately) chosen based on 
their safety characteristics, but it is possible that the least pathogenic helminths are 
also the least effective at subverting the host immune response. Whilst harmful 
helminths such as Schistosoma mansoni would be clearly unsuitable as live 
therapeutic agents, further investigation of the immunomodulatory mechanisms at 
their disposal may yield more effective novel pharmaceutical agents. Finally, Rook et 
al265 suggest that early childhood exposure to helminth infection may lead to 
important epigenetic changes that ‘pre-condition’ a regulatory response upon 
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subsequent exposure, explaining that the landmark observational studies in MS by 
Correale et al207,208 were performed in Argentina, where helminth infection is 
endemic265. This may be true and, if so, provides little room for optimism on future 
clinical translation. 
No clinical trials of helminth-derived immunomodulators have yet been performed, 
largely as a result of the considerable investment and negotiation of necessary 
regulatory hurdles required of the pharmaceutical industry266. As previously 
discussed, treatment with novel medications based on helminth-derived 
immunomodulatory products offer numerous advantages over therapeutic live 
infection; as further results emerge from clinical trials currently underway, the level 
of evidence required for the necessary pharmaceutical investment might be reached 
in the near future. 
 
1.3 Helminths and Organ Transplantation 
 
1.3.1 Background to helminth-mediated allograft protection 
The prospect of utilising helminths as a therapeutic option in transplantation is one 
that has received much less attention than in the field of autoimmunity. A number of 
barriers to investigation exist, not least that transplants are generally performed in 
high-resource countries with a low prevalence of helminth infection and patients 
receiving transplants are uniformly prescribed powerful immunosuppressant agents 
that would likely mask any beneficial effect of infection. Replication of the 
observational studies investigating helminths and autoimmunity is therefore all but 
impossible, however unique opportunities also exist: the pathophysiology of allograft 
rejection is very well described and, in contrast to most autoimmune conditions, the 
precise timing of onset of ‘disease’ is also known in advance. A total of 10 studies 
investigating helminth-derived allograft protection (Table 1.2) have been performed 
since 1972; these are summarised below with details for each parasite system given 
in the succeeding sections.    
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Rat	  heart	   2.04	   <0.05	  
Li	  et	  al.	  (2011)268 
Echinococcus	  
multilocularis 
Rat	  liver 1.57 <0.05	  
Liwski	  et	  al.	  (2000)269 
Nippostrongylus	  
brasiliensis 
Mouse	  heart 2.80 <0.03	  




Rat	  kidney 3.30 <0.001	  
Nippostrongylus	  
NES 
Rat	  kidney 2.22 <0.001	  




Human	  skin	   2.21	   0.001	  




Mouse	  skin 1.5* <0.001	  
Svet-­‐Moldavsky	  et	  
al.	  (1969)273 
Trichinella	  spiralis Mouse	  skin 2.13 Not	  stated	  
Faubert	  and	  Tanner.	  
(1975)274 
Trichinella	  spiralis Mouse	  skin 1.89 <0.001	  
Infected	  mouse	  
serum 
Mouse	  skin 1.67 Not	  stated	  
Chimyshkyan	  et	  al.	  
(1976)275 
Trichinella	  spiralis Mouse	  skin 2.48 <0.001	  








Mouse	  skin	   2.0	   Not	  stated	  
Trichinella	  spiralis	   Mouse	  skin 3.57 Not	  stated	  
Trichinella	  spiralis	  
extract	  
Mouse	  skin	   2.43	   Not	  stated	  
Table 1.2 Studies of helminth-mediated immunomodulation in transplantation. 
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1.3.2 Echinococcus tapeworms (cestodes) 
The metacestode Echinococcus multilocularis (Em) is endemic amongst foxes in 
many parts of Europe and China and humans can be affected as paratenic hosts.  
Infection usually results in severe disease with a clinical course resembling that of a 
malignant primary liver tumour (hepatocellularcarcinoma)277.  Radical surgical 
resection of liver lesions has been shown to be effective in improving survival and 
orthotopic liver transplantation is now largely accepted as appropriate treatment for 
advanced disease278.  Disease progression caused by the parasite has been found to 
advance rapidly in the presence of host immunosuppression either as a result of 
medication279 or Human Immunodeficiency Virus infection280.  This finding led to 
guidelines recommending reduced immunosuppression regimens following liver 
transplantation for Em281 and long-term follow up reported unexpectedly satisfactory 
tolerance of the allografts278.  Li et al have subsequently corroborated this finding in 
an experimental rat model of liver transplantation with Em infection268 (Table 1.2).  
In this study, survival following orthotopic liver transplantation was found to be 
significantly prolonged for Em-infected rats compared to naïve controls (15.5 ± 3.9 
days vs. 9.9 ± 2.3 days, p<0.05).  The Em-infected group was also found to have 
reduced CD4+, CD8+ and CD28+ T cell populations in peripheral blood, raised serum 
IL-10 levels and reduced histological liver allograft rejection scores, all of which 
reached statistical significance (p<0.05)268.  More recently, Hepiretihan et al have 
shown that Em infection exerts a similar protective effect against rejection of rat 
heart allografts (16.2 ± 3.2 days vs. 7.9 ± 1.9 days)267.  This was associated with a 
reduction in graft-infiltrating CD8+ lymphocytes and a shift towards a Th2 cytokine 
profile in the serum of peripheral blood.  In the clinical setting, eradication of Em 
infection usually proves impossible.  It therefore remains as yet unclear as to whether 
graft protection is afforded by an on-going influence of the parasite, or as the result 
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1.3.3 Nippostrongylus roundworms (nematodes) 
In 1996, Ledingham and colleagues demonstrated marked improvement in the 
survival of kidney allografts in rats infected with the gastrointestinal nematode, 
Nippostrongylus brasiliensis (Nb), or inoculated with its secretory products, 
compared to naïve controls (32 ± 10 days, 21 ± 4.6 days and 9.7 ± 1.2 days, 
respectively; p<0.001)270.  Representative histological examination five days after the 
transplant showed a dramatic reduction of graft cellular infiltration in the Nb-infected 
group and this finding was supported quantitatively with flow cytometric analysis of 
digested allograft single cell suspensions (84% and 81% reduction of CD8+ and 
CD4+ lymphocytes respectively).  Whilst the graft protection afforded by 
Nippostrongylus excretory-secretory products (NES) was less pronounced, the 
pharmacokinetic profile of the active mediator(s) in NES is unknown and this may 
therefore be a purely dose-dependent difference. 
The same group later showed similar graft protection in a mouse cardiac allograft 
model269.  Nb infection is known to induce a strong Th2 response in its host282, 
leading those authors to hypothesise that polarisation away from Th1-mediated 
allograft rejection may afford allograft protection.  Nb usually achieves only a 
limited infection in rodents - most mouse strains can clear the infection within ten 
days of inoculation with 3rd stage larvae282.  The finding that mouse heart allografts 
can survive for considerably longer than the period of infection269, presents the 
exciting therapeutic prospect that graft protection is afforded by T cell ‘phenotype 
switching’ at the time of alloantigen presentation rather than a mechanism dependent 
on persisting parasite infection.  ELISA analysis of mixed lymphocyte reactions 
supports this hypothesis in demonstrating a Th2 cytokine profile (IL-4 and IL-6) in 
alloreactive lymphocytes from Nb-infected mice compared to naïve controls269,283. 
 
1.3.4 Schistosome flukes (trematodes) 
Schistosoma are a genus of blood-borne trematode with a current prevalence of 
infection estimated at more than 200 million people worldwide284.  In light of the 
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very widespread prevalence of schistosomiasis and the diminishing supply of 
suitable cadaveric donor organs for transplantation, a number of human liver285,286 
and kidney287 transplants have been performed in patients with clinical 
schistosomiasis (donor and recipient, donor alone, and recipient alone).  No attempts 
at reducing immunosuppression or analysing differences in rejection rates have as yet 
been reported.  However, one remarkable study has looked at the differential 
rejection of full-thickness skin grafts in Egyptian patients with established 
schistosomiasis compared to healthy volunteers.  Aboul-Enein and colleagues271 
recruited 19 patients with advanced Schistosoma mansoni infection and 16 parasite-
free volunteer controls.  2.5cm-diameter full-thickness skin grafts were applied to the 
volar forearm.  Two grafts were performed for each patient: one ABO-matched 
allograft from a non-infected donor and one autograft control.  Grafts were assessed 
daily for signs for rejection and rejection was then confirmed histologically.  The 
control group rejected their allografts after a mean of 10.06 ± 3.21 days.  Of the 
Schistosoma-infected patients, in 16 cases rejection occurred after a mean of 22.25 ± 
6.46 days.  The remaining three infected patients showed no signs of rejection 60 
days after the grafting procedure.  Notably, the HLA status of donors and recipients 
was unknown in this study and therefore the three cases of long-term graft tolerance 
may well be the result of coincidental HLA matching.  In spite of this significant 
caveat, the difference in rejection times between the two groups was highly 
significant (p<0.001) and therefore unlikely to be the result of differences in HLA 
matching alone. 
Allograft protection with Schistosoma infection has previously been shown in a 
murine experimental model.  In 1977, Araujo et al found a highly significant 
difference in the rejection of fully-allogeneic skin grafts in Schistosoma mansoni-
infected vs naïve recipient mice272.   No difference was found after thirty days of 
infection, but for grafts performed after sixty days of infection, infected recipients 
tolerated their grafts for an average of 50% longer than naïve controls.  A strongly 
positive correlation between graft survival and the number of live parasites 
remaining in the recipient was also seen (r=0.096). 
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1.3.5 Trichinella spiralis 
Finally, murine experimental models of other helminth species have also 
demonstrated enhanced tolerance of skin allografts. Trichinella spiralis is a small 
nematode that encysts in mammalian muscle and can affect humans who consume 
infected meat.  Suppression of skin allograft rejection in mice infested with 
Trichinella was first described by Svet-Moldavsky et al in 1969273 and subsequently 
confirmed by Faubert274 (1975) and Chimyshkyan275 (1976).  In 1995, Alkarmi et al 
performed fully-allogeneic skin grafts (C57BL/6 to BALBc recipients and vice 
versa) on multiple groups of mice at varying time points following infection276.  
Graft protection was found to be critically dependent on the timing of skin 
transplantation in relation to initial infection and a maximum effect of 3.5-fold 
prolongation of graft survival was found when the transplants were performed 3 days 
after initial infection.  Repeated intraperitoneal injection of parasite secretions 
(culture supernatants) replicated the effect of active infection in a dose-dependent 
fashion with an observed maximum 2-fold prolongation in graft survival276. 
 
1.3.6 Heligmosomoides polygyrus 
Heligmosomoides polygyrus is a gastrointestinal nematode with powerful 
immunomodulatory capabilities, notably including induction of Foxp3+ Treg233,288. 
To date, no studies have investigated the potential role for H. polygyrus in preventing 
rejection of solid organ allografts. However, a recently published study by Li et al 
presents interesting inferable results from experimental murine haematopoietic stem 
cell transplantation (HSCT)289. 
HSCT is an often lifesaving procedure that can be used to treat a variety of 
haematological malignancies. Traditionally, treatment would begin with a period of 
chemotherapy or radiation to almost completely ablate the patient’s bone marrow 
prior to infusion of donor cells. This strategy carries considerable risk, particularly if 
problems with donor cell engraftment arise. As a result, many protocols are now 
modified with a less aggressive ablative strategy, relying on the healthy immune cells 
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of the donor population to kill residual neoplastic cells of the recipient (graft vs. 
tumour effect)290. However, if a degree of allogeneic mismatch exists between donor 
and recipient, there is a risk of the donor cell population recognising ‘self’ antigens 
of the recipients as allogeneic and attacking them. This results in ‘graft vs host 
disease’ (GvHD), which can be acute or chronic, involving multi-organ pathology 
(e.g. colitis, pneumonitis, dermatitis) and carry a considerable risk of mortality. 
Acute GvHD can be treated with aggressive immunosuppression in a similar way to 
acute rejection of solid organ transplants, but this encompasses all of the adverse 
effects previously discussed and, crucially, can significantly compromise the graft vs. 
tumour effect, resulting in relapse of the original malignancy and a higher risk of 
mortality291. 
Li et al performed fully-allogeneic (C57BL/6 to BALB/c) murine HSCT with 
recipient animals receiving either no treatment, or infection with 150 H. polygyrus 
3rd stage larvae by oral gavage 3 weeks in advance289. From 6 days after HSCT, the 
uninfected mice appeared visibly debilitated in contrast to the normal appearance of 
infected animals and went on to suffer a considerably higher mortality from GvHD 
(100% vs. 40%, p<0.0001 by Kaplan Meier log-rank analysis). Blinded histological 
scoring of lung and colon specimens at day six post HSCT (from a separate 
experiment) confirmed severe inflammation consistent with GVHD in the uninfected 
animals and normal mucosal appearances of those with H. polygyrus infection. 
Further analysis revealed significant expansion of Foxp3+ Treg with H. polygyrus 
infection and that H. polygyrus-mediated protection from disease was TGF-β-
dependent – HSCT with Type II TGF-β Receptor dominant negative donor cells 
obliterated the protective effect of infection. Finally, immunocompetence in 
controlling neoplastic cells was assessed by administering luciferase-expressing A20 
leukaemia/lymphoma cells. Control mice that received T cell-depleted HSCT died 
rapidly with an overwhelming tumour burden, whereas no tumour development was 
observed in both H. polygyrus-infected and uninfected mice, suggesting that H. 
polygyrus does not compromise the graft vs. tumour effect. 
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1.3.7 Mechanisms of allograft protection 
It is now clear that helminths act via multiple distinct and synergistic pathways to 
down-regulate host immunity.  Expansion of Treg populations in response to 
helminth infections such as Heligmosomoides polygyrus288 and Schistosoma 
mansoni236 is one well-recognised mechanism, but the same parasites can also 
engender immunosuppressive activity in B cell populations, as well as modified 
dendritic cell and macrophage populations292.  
In this context, it is possible that therapeutic extension of graft survival would also 
require more than one particular immunomodulatory pathway. With respect to Treg 
expansion, exogenous IL-2:anti-IL-2 antibody complex is a potent short-term 
stimulant of Treg populations which can effect long-term tolerance of allogeneic islet 
grafts in the absence of immunosuppression293.  However, multiple attempts to 
achieve similar tolerance of allogeneic skin grafts (BALB/c to C57BL/6) have 
failed294.  It is well known in the experimental and clinical setting that tolerance of 
skin allografts presents a particular challenge (compared to the solid organ 
transplants of heart, liver or kidney).  Important factors to overcome are likely to be 
the large proportion of resident dendritic cells in skin294 and more potent Toll-like 
receptor stimulation by colonising microbes295.  Failure of IL-2:anti-IL-2 complexes 
to achieve the same level of protection of fully allogeneic skin grafts against 
rejection294 that is seen in Schistosoma infection271 strongly suggests that Treg-
independent mechanisms also play a critical role in helminth-derived allograft 
protection. 
 
1.3.8 Translational feasibility 
Enhanced allograft tolerance with helminth infection has now been demonstrated in 
multiple species across multiple organ allograft models (mouse heart and skin; rat 
heart, liver and kidney).  These experimental data are consistent with historical 
results of skin grafting in established human schistosomiasis, and supported by more 
recent anecdotal suggestions of reduced immunosuppression requirement following 
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liver transplantation for human Echinococcus infection278.  Thus, the possibility can 
now be entertained of including specific live (non-pathogenic) helminth infection, or 
defined products from immunoregulatory helminths, in future transplantation 
protocols.  Ongoing trials of live helminth therapy in autoimmunity are keenly 
awaited as potential pathfinding studies for translation of this concept to the clinic. 
 
1.4 Secreted Immunomodulatory Products 
Identification and reproduction of individual helminth-secreted immunomodulatory 
molecules as potential novel therapeutic agents presents several advantages over live 
larval therapy. These include consistent pharmacokinetics, scope for 
pharmacological modification and optimisation (reducing immunogenicity of large 
molecules, for example), improved public acceptability and a lower cost barrier to 
large-scale production as a routine clinical therapy. The transcriptomes of several 
helminths have now been analysed in detail in the search for key immunomodulatory 
mediators, including: Heligmosomoides polygyrus296,297, Necator americanus245, 
Nippostrongylus brasiliensis298 and Trichuris suis245,299. However, proteomic 
analysis of (for example) H. polygyrus has revealed a daunting number of candidates 
(>300 ES molecules), many of which show no homology to any known protein296. 
Interestingly, individual helminth species appear to have evolved independently and 
therefore achieve immunomodulatory capabilities through numerous and often 
distinct mechanisms300. This reinforces the concept that each parasite is very 
specifically adapted to particular immunological mechanisms and, by extension, their 
secreted products are likely to be most suited as therapeutic candidates to some 
specific disease processes more than others. Similarly, products that have evolved to 
optimally modulate immunity in one host species may not be effective in another. 
Live infection with Schistosoma mansoni has been shown to ameliorate allograft 
rejection in both mice272 and humans271 (section 1.3.4), but infection is clearly 
associated with considerable morbidity301, such that therapeutic infection is not an 
attractive or feasible prospect. The effects of Schistosoma soluble egg antigen (SEA) 
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and its components have been studied widely, however, and may offer therapeutic 
opportunities that are translationally viable. In vivo, SEA has been shown to be 
effective in treating EAE229, murine T cell transfer-mediated colitis302 and type I 
diabetes in non-obese diabetic (NOD) mice236. 
SEA is known to act on DCs to induce strong Th2 responses in murine303 and human 
cells304, and this effect has subsequently been ascribed to the action of a glycoprotein 
component, Omega-1305,306. SEA is also capable of suppressing CD4+ T cell 
proliferation and inducing Foxp3 expression indirectly236. Whist DCs are necessary 
for SEA-driven Foxp3 induction, an increase in the expression of TGF-β latency 
associated peptide on the surface of CD4+ cells, suggests that SEA also induces 
enhanced secretion of TGF-β by activated T cells, further facilitating Foxp3+ Treg 
differentiation236. Omega-1 glycans within SEA bind to the mannose receptor of 
DCs, which enables internalisation and interference with mRNA and protein 
synthesis307. This probably accounts for the fact that Omega-1 has the ability to 
indirectly induce Foxp3+ Treg with high levels of CTLA-4 expression (through 
alteration of DCs), but does not affect T cell proliferation or T cell TGF-β secretion. 
The specificity of Omega-1 also suggests that multiple components of SEA promote 
Treg differentiation through distinct mechanisms308. Finally, Omega-1 is 
unfortunately both immunogenic and hepatotoxic309, so would require some 
modification to become therapeutically viable. 
Another component of SEA that has been identified is the Lewisx trisaccharide. 
Lacto-N-fucopentaose III (LNFPIII), is a glycan with very low cytotoxicity that 
contains Lewisx and is also found in human breast milk310. LNFPIII has multiple 
immunomodulatory capabilities including DC-derived Th2 differentiation311, 
alternative activation of macrophages312 and stimulation of IL-10 production from 
DCs and macrophages312. Dhutta et al have shown that LNFPIII induces high levels 
of programmed cell death ligand 1 (PD-L1) expression on the surface of 
macrophages, DCs and T cells, which indirectly promotes Treg differentiation313. 
With two transplant models (vascularised adult heterotopic cardiac allografts and 
non-vascularised neonatal cardiac allografts), these authors showed that LNFPIII was 
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able to significantly prolong allograft survival and that this protective effect was 
dependent on PD-L1:PD-1 signalling.  
LNFPIII has also been shown to ameliorate EAE, but potentially by different means. 
With an active (pMOG35-55) EAE model in C57BL/6 mice, Zhu et al administered 
LNFPIII conjugates or control dextran twice per week by IP injection and observed a 
significant reduction in disease severity as assessed by clinical scoring and the 
presence of inflammatory foci in the CNS upon histological analysis at day 20 post 
immunisation228. Immunohistochemistry revealed a reduction in CNS-infiltrating 
CD4+, F4/80+ and CD11c+ cells in LNFPIII-treated animals; Foxp3 expression was 
not reported. At day 9 post immunisation, CD11b+Ly6ChiLy6G- monocytes were 
isolated from the spleen and LNFPIII treatment was found to result in significantly 
elevated expression of nitric oxide synthase 2 (Nos2) mRNA. When the same 
monocyte populations were then cultured ex vivo with MOG-specific transgenic 
CD4+ (2D2) cells and MOG-pulsed APCs, T cell proliferation was suppressed by 
monocytes from LNFPIII-treated animals and unaffected by the dextran-treated 
controls. This suppression was completely reversed by L-NIL (a Nos2 inhibitor), 
confirming that the observed suppressive activity of monocytes was mediated by 
nitric oxide. 
Of all helminth secreted products, H. polygyrus ES (HES) is perhaps the most 
extensively characterised and has been found to contain numerous 
immunomodulatory components with distinct mechanisms of action288. However, in 
relation to allograft tolerance, perhaps the most significant finding is the ability of 
HES to induce Foxp3+ Treg differentiation independently of DCs (in common with 
the secreted products of Teladorsagia circumcincta). Grainger et al first showed that 
HES is able to induce Foxp3 expression in isolated CD4+Foxp3(GFP)- T cells in 
vitro with stimulation from Concanavalin A or plate-bound CD3/CD28233. HES also 
suppressed proliferation of CD4+Foxp3(GFP)- T cells and promoted IL-17 
expression from naïve CD4+ cells when co-cultured with IL-6. This led to further 
investigation with a TGF-β reporter cell line (TGF-β-/- fibroblasts transfected with a 
TGF-β-responsive alkaline phosphatase reporter, described in detail in Figure 5-1), 
which confirmed TGF-β activity within HES that could be completely ablated with a 
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type I TGF-β receptor kinase inhibitor, but was unaffected by a pan-vertebrate anti-
TGF-β blocking antibody. Thus, HES contains a TGF-β mimic that induces Foxp3 
through ligation of the TGF-β receptor complex, but is sufficiently structurally 
dissimilar to mammalian TGF-β as to be unaffected by a neutralising antibody. This 
work marked the beginning of a search for the TGF-β mimic within HES and its 
mechanism of action, some results of which are presented in chapter 5. 
Identification of key immunomodulators and therapeutic candidates within ES 
products engenders numerous challenges including specificity of action and the 
possibility of combinations of molecules being required for effective replication of 
the immunoregulation achieved by live infection224,314. However, in comparison to 
the coincidental discovery of immunosuppressive properties with currently used 
medications315, ES products provide a rich source of candidate immunomodulators 
with the benefit of millennia of evolutionary refinement and a favourable profile of 
adverse effects in the billions of people that have been exposed to them over long 
periods worldwide. 
 
1.5 TGF-β Signalling 
The TGF-β superfamily of cytokines is comprised of more than 30 distinct molecules 
including three isoforms of TGF-β, Bone Morphogenic Proteins (BMPs), activins, 
inhibins, nodal and growth differentiation factors316. This group of ligands can 
initiate pleiotropic effects in a vast array of biological processes including 
embryogenesis, immunity, angiogenesis and wound healing317. In light of the 
multiplicity of consequences that can result from TGF-β signalling, it is perhaps 
unsurprising that a complex signalling arrangement with several layers of regulation 
exists318.  
Regulation of TGF-β signalling takes place predominantly in three distinct regions: 
the extracellular space, the cell membrane and the intracellular region. TGF-β is 
synthesised as a component of a larger, inactive molecule that incorporates a 
‘latency-associated peptide’ (LAP). Prior to secretion from a cell, the LAP-TGF-β 
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complex binds to a further protein, latent TGF-β binding protein (LTBP). Because 
TGF-β is secreted in this way, as a component of a biologically inactive compound, 
processes that liberate the active TGF-β molecule can be as important to 
immunomodulation as its transcription and synthesis319. In the extracellular space, 
the active TGF-β molecule is also prone to sequestration by ‘ligand trap’ proteins 
(including LAP), such that active TGF-β cannot persist for long and cleavage 
mechanisms are afforded greater significance320. 
Cleavage of the active TGF-β molecule can only happen under specific conditions, 
such as low pH, proteolysis, or the binding of certain membrane-bound proteins321. 
In vivo, cell surface receptors including many integrins have the ability to bind LAP-
TGF-β and release active TGF-β322. This mechanism is of considerable importance – 
αv integrin null mice develop similar embryological aberrations to TGF-β-/- 
animals323. Indeed, functioning integrin-TGF-β interaction may be a key determinant 
of some tolerogenic cell phenotypes – the ability of DCs from αvβ8-/- mice to induce 
Treg is considerably impaired and these mice consequently develop spontaneous 
colitis in normal environmental conditions324. 
Activated TGF-β signals as a homodimer via the union of two type I TGF-β 
receptors (TβRI, also known as ALK5) and two type II TGF-β receptors (TβRII). In 
humans, 5 variants of the type I receptor and 7 variants of the type II receptor have 
been identified, in contrast to 29 potential ligands325. The affinity of each ligand for 
individual receptors varies, but most ligands are also able to bind multiple 
heteromeric combinations of type I and type II receptors, resulting in different 
downstream effects325. Upon binding of the TGF-β ligand, the constitutively active 
type II receptor is brought into close proximity of the type I receptor, thereby 
enabling phosphorylation of the TβRI intracellular ‘GS’ domain and initiating the 
Smad signalling cascade326 (Figure 1-6). Smads are intracellular proteins that 
mediate signalling from TGF-β receptors to the nucleus; 8 Smad proteins have been 
identified in vertebrates and they are sub-categorised according to their function: 
receptor-activated Smads (R-Smads), common Smads (Co-Smads) and inhibitory 
Smads (i-Smads)326. When TGF-β binds and activates the TGF-β receptor complex, 
the intracellular GS domain of TβRI phosphorylates Smad2 and Smad3 (R-Smads), 
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which then form a complex with Smad4 (Co-Smad) and enter the nucleus to initiate 
gene transcription116. This process can be regulated intracellularly by Smad7, an 
inhibitory Smad that can bind TβRI, prevent further signal transduction and then 
stimulate proteolytic degradation of the receptor326. At the level of the cell 
membrane, another regulatory mechanism comes into play in the form of ‘decoy’ 
receptors such as BAMBI (BMP and activin membrane-bound inhibitor), a 
transmembrane protein that is structurally very similar to TβRI, but lacks an 
intracellular GS domain327. BAMBI can therefore form a dimer with TβRII and bind 
TGF-β without initiating any Smad signalling and thereby reduce the number of 
TβRIIs available to bind other TGF-β molecules. 
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Figure 1-7  TGF-β Signalling and Regulation. (A) Active TGF-β is prevented from binding to 
receptors due to incorporation with ‘ligand trap proteins’ such as latency-associated peptide 
(LAP). (B) Binding of TGF-β to the Type II TGF-β receptor leads to phosphorylation of the 
Type I TGF-β receptor intracellular domain and activation of the Smad signalling pathway, in 
addition to Smad-independent signalling including MAPK pathways. (C) Decoy receptors such 
as BAMBI bind TGF-β but prevent downstream signalling. (D) Smad7, an inhibitory Smad, 
binds to the phosphorylated Type I TGF-β receptor and prevents downstream signalling. 
 
The Smad cascade is the ‘canonical’ signalling pathway for TGF-β and is essential 
for TGF-β-driven immunoregulation and Treg/Th cellular differentiation328. 
However, TGF-β is also able to activate a number of Smad-independent signalling 
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phosphorylation is an important event in the process of epithelial to mesenchymal 
transition (EMT), which is necessary in embryological development, but can 
contribute to pathological fibrosis329. EMT also promotes the ability of tumour cells 
to metastasize and therefore small molecule inhibitors are under investigation in this 
context330, but could prove to be useful for the prevention of TGF-β-related fibrosis 
in transplantation as well. 
In vitro stimulation of naïve CD4+ T cells in the presence of TGF-β reliably leads to 
the induction of Foxp3+ Treg that can suppress effector T cell activation and 
proliferation331, and prolong allograft survival upon adoptive transfer into recipient 
animals332. The level of Foxp3 expression by Treg correlates with functional 
suppressive capacity333; stability of Foxp3 expression is essential for maintenance of 
a regulatory phenotype334. TGF-β-dependent induction of Treg also occurs in vivo 
and techniques that exploit this mechanism to induce tolerance (such as low dose 
antigen therapy335) appear to generate Treg with more stable expression of Foxp3 
than those generated in vitro336. This suggests that additional (unknown) stabilising 
factors or conditions are present in the in vivo setting and might provide 
encouragement for in vivo Treg induction techniques over ex vivo expansion and 
reinfusion of isogeneic cells. Additionally, TGF-β is capable of inducing tolerance 
through Foxp3-independent mechanisms, such as upregulation of CD73337, an 
ectoenzyme that acts to increase the local extracellular concentration of adenosine (as 
discussed in section 1.1.4.3). 
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Figure 1-8  TGF-β and Cellular Differentiation (adapted from Hegner et al338).  
 
As previously discussed, TGF-β does have the potential to play janiform roles in the 
context of transplantation. Whilst TGF-β-induced immunoregulation is clearly 
beneficial to an allograft, detrimental effects can also arise through generation of 
Th17 effector cells and/or interstitial fibrosis as a result of increased myofibroblast 
differentiation338 (Figure 1-7). IL-1β, IL-6 and TLR ligands can all promote Th17 
differentiation338,339 (Figure 1-8), in addition to the frequently used 
immunosuppressant agents, ciclosporin and tacrolimus (through blockade of IL-2)340. 
This clearly cautions against the use of enhanced TGF-β activity as a therapeutic 
strategy. However, there is some evidence that Th17 cells can be generated in the 
absence of TGF-β341 and that without the influence of TGF-β, these Th17 cells are 
more pathogenic due to enhanced IL-23 receptor expression. Additionally, high 
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Combination therapy with synergistic ‘Treg permissive’ agents may allow some 
control over downstream cellular differentiation. Of these, rapamycin (sirolimus) can 
act synergistically with TGF-β to induce Foxp3 expression and Treg differentiation 
over Th17 effector cells343 and retinoic acid (RA) can effectively minimise the ability 
of inflammatory cytokines and co-stimulation to impair TGF-β-induced Foxp3 
expression344,345. Whilst the non-linear signalling and pleiotropic effects of TGF-β 
limit the therapeutic potential of the native molecule, it is now clear that helminths 
have evolved to exploit this pathway very effectively. Identification of how this is 
achieved could lead to novel therapeutic agents that are more efficacious and less 
harmful than currently available options in an area of considerable clinical need. 
 
1.6 Thesis objectives 
The aims of this thesis are: 
1. To establish if Heligmosomoides polygyrus infection suppresses allograft 
rejection and autoimmune disease. 
2. To investigate if secreted products from Heligmosomoides polygyrus replicates 
this suppressive effect. 
3. To investigate molecular and mechanistic pathways through which suppression 
might be achieved. 
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2 Materials and Methods 
 
2.1 General Reagents 
All reagents were acquired from Sigma unless otherwise stated. 
2.1.1 Complete RPMI 
RPMI medium containing HEPES (Gibco), supplemented with 2 mM L- glutamine, 
100 U/ml penicillin and 100 µg/ml streptomycin (Gibco), 10% heat-inactivated foetal 
calf serum (FCS) (Gibco), and 50 nM 2- mercaptoethanol (Gibco). 
2.1.2 ELISA carbonate buffer 
1 M solutions of Na2CO3 (Sigma) and Na2HCO3 (Sigma) were first formed in 
distilled water. 0.06 M carbonate buffer was then created with the addition of 45.3 ml 
(1 M) Na2CO3 and 18.2ml (1 M) Na2HCO3 to 936.5 ml of distilled water; followed 
by adjustment of the final solution to pH 9.6. 
2.1.3 FACS buffer 
PBS was supplemented with 0.5% heat-inactivated FCS (Gibco) and 0.05% sodium 
azide (Sigma). 
2.1.4 MACS buffer 
Hanks’ Balanced Salt Solution (HBSS, Gibco) supplemented with 2 % heat-
inactivated FCS and 2 mM EDTA. 
2.1.5 H. polygyrus media 
RPMI medium, containing HEPES (Gibco), was supplemented with 1% glucose, 
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2.2 Animals 
Inbred C57BL/6 (CD45.1 and CD45.2), BALB/c and CBA mice used for 
experiments were all aged 6-12 weeks old and bred in-house or purchased from 
Harlan Laboratories. Transgenic strains (OT-II, DO11.10, RAG1-/-, IL-4Rα-/-, Foxp3-
GFP) were all bred in house. Animals were housed in individually ventilated cages 
for the duration of experiments. All animal experiments were performed under a 
Project Licence granted by the UK Home Office and approved by the University of 
Edinburgh Veterinary Services. 
 
2.3 Heligmosomoides polygyrus Life Cycle 
 
2.3.1 Propagation and maintenance of H. polygyrus 
Day-to-day maintenance of the H. polygyrus life cycle was performed by Elaine 
Robertson and Yvonne Harcus. A more comprehensive protocol (and accompanying 
video) has been recently published by the Maizels lab346 and is included in appendix 
A. 
For experimental use, H. polygyrus L3 larvae can be safely stored at 4˚C for up to six 
months. To maintain the life cycle, CBAxC57BL/6 F1 mice were bred and 
maintained for their ability to withstand a high parasite burden in the absence of 
morbidity. L3 larvae were prepared by washing three times in dH2O, counting and 
resuspending at 2000 larvae / ml. Male F1 mice were then infected with 400 L3 
larvae in 200 µl dH2O by oral gavage. 14 days later mice were culled and intestines 
removed for adult harvest (see section 2.3.2), together with collection of faeces for 
larval culture.  Faecal samples were mixed with (washed) granulated charcoal 
(Merck) to achieve a damp paste that was then thinly applied to moist filter paper and 
placed in a petri dish inside a damp box (in the dark at 37˚C) for 12-14 days. Larvae 
were collected by washing the filter paper with dH2O and then stored at 4˚C; 
collection can take place from day 7 onwards, and was performed on at least two 
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occasions for each cycle.  Following a period of storage, larvae were washed again 
with dH2O three times prior to infection by oral gavage (200 L3 for inbred strains). 
 
2.3.2 Isolation of adult H. polygyrus worms 
F1 mice used to maintain the H. polygyrus life cycle were culled 14 days after 
infection. Post-mortem, the abdomen was prepared with 70% ethanol and the most 
proximal 20 cm of small intestine was excised (most adult worms are found in the 
duodenum). The small intestine was then placed in a (100 mm diameter) petri dish 
with HBSS (warmed to 37˚C) and opened longitudinally to reveal the intra-luminal 
worms.  The worms are best removed by gently scraping the small intestine between 
two glass slides; following removal of the worms, the gut wall was discarded. 
Adult worms were isolated from extraneous debris with a Baermann apparatus. 
Worms were placed into small muslin bags, which were stapled closed and fixed to a 
glass funnel as shown (figure 2-1). Once the muslin bags had been filled with worms 
from approximately 8 mice, the funnel was filled with HBSS and placed in a 37˚C 
incubator for 2 hours, with intermittent gentle agitation to dislodge any obstructing 
debris. 
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Figure 2-1  Setup of Baermann Apparatus for collection of adult H. polygyrus. 
 
 
After two hours, adult worms had slowly migrated to the bottom of the collection 
tube, which was then carefully detached, allowing the worms to be transferred to a 
50 ml Falcon tube and washed six times with 40 ml of HBSS. Moving to a laminar 
flow hood, the worms were then washed another six times in sterile HBSS 
supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin. Adult worms 
were counted in a volume of 20 µl, with a typical yield of 50% the number of L3 
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2.3.3 Culture and preparation of HES 
In preparation for culture of adult worms to produce HES, freshly isolated worms 
were incubated for 20 minutes in 10 ml of RPMI (Gibco) supplemented with 10 
µg/ml gentamycin and then washed a further six times with sterile HBSS 
(supplemented with 5 U/ml penicillin and 5 µg/ml streptomycin). The worms were 
then resuspended in H. polygyrus media (2.1.5) and transferred into vented T25 
flasks in aliquots of 15 ml containing approximately 1000 worms. The flasks were 
placed upright in an incubator at 37˚C (5% CO2) for 3 weeks. 
Once the worm culture was established as described above, culture media 
(containing HES) was removed and replenished with sterile H. polygrus media after 
24 hours and subsequently at intervals no longer than twice per week. Media 
collected after the first 24 hours of culture was set aside to minimise the risk of 
contamination with intestinal contents. Subsequent collections of the culture 
supernatant were pooled, filter sterilised through 0.2 µm low-protein binding filters 
and frozen at -20 ˚C for later concentration. At a later date, typically 500 ml of 
frozen HES-containing culture media (excluding the collection from the first 24 
hours of culture) was concentrated over a 3,000 MW cut-off filter under nitrogen 
pressure in an Amicon ultrafiltration device (Millipore). The amount of HES in each 
500 ml batch of culture media was quantified by Bradford assay (Life Technologies, 
performed as per manufacturer’s instructions), with a typical yield of 1.5 mg (figure 
2-2b). Finally, a chromogenic Limulus amebocyte Lysate (LAL) assay was 
performed (according to the manufacturer’s instructions) to test the level of LPS 
contamination. Of 41 batches, the median level of contamination was 86 U/mg of 
HES; batches with greater than 1000 U LPS per 1 mg of protein were considered 
unsuitable for future in vitro or in vivo experimental use (based on an extrapolation 
of the in vivo dose at which LPS begins to suppress allergic airway responses347). 
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Figure 2-2  (A) Data points shown represent worm burdens from 19 separate rounds of infection 
of C57BL/6xCBA mice with 400 L3 larvae.  (B) Yield of HES protein from 11 different batches 
derived from approximately 500 ml of culture supernatant. (C) Levels of LPS contamination in 
41 batches of HES measured by the Limulus amoebocyte lysate (LAL) assay. 
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Figure 2-3  Animated Schematic of H. polygyrus Life Cycle Summary of key life cycle stages 
from oral gavage of L3 larvae, through recovery of larvae and adult worms to isolation of HES. 
 
2.4 Full-thickness Skin Grafting 
 
2.4.1 General anaesthesia 
General anaesthesia was achieved with either an inhalational or injectable anaesthetic 
protocol. The body temperature of animals under anaesthesia was maintained with an 
insulated heat mat at 38°C. For inhalational anaesthesia, oxygen was continuously 
administered at 2 litres/minute with 4 % isoflurane (Abbott Laboratories Ltd) for 
induction and 2 % isoflurane for maintenance. Injectable anaesthesia (for a 25 gram 
mouse) involved 20 µg medetomidine (Domitor®, Vet Quinol Ltd) and 1.5 mg 
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ketamine (Vetalar®, Zoetis Ltd). A mixture was prepared of 0.5 ml medetomidine at 
1 mg/ml, 0.38 ml of ketamine at 100 mg/ml and 4.12 ml water, and each mouse 
received 200 µl injected intraperitoneally. Reversal of anaesthesia (for a 25 gram 
mouse) was achieved with 40 µg atipamezole (Antisedan®, Elanco Animal Health 
Ltd), for which  200 µl of atipamezole at 5mg /ml was mixed with 4.2 ml PBS; 250 
µl of this dilution was injected subcutaneously. 
For both anaesthetic protocols, buprenorphine (Vetergesic®, Reckitt Benckiser 
Healthcare Ltd) analgesia was administered on induction of anaesthesia and again 12 
hours later. A dose of 0.1 mg/kg was used, (2.5 µg for a 25 gram mouse) by diluting 
100 µl of buprenorphine at 0.5 mg/ml with 900 µl of PBS and injecting 50 µl 
subcutaneously. 
Upon adoption of the skin grafting method described below at the University of 
Edinburgh, inhalational (isoflurane) anaesthesia was used in accordance with local 
veterinary protocols and regulations.  Initially, wide variation in graft survival was 
seen within experimental groups. Since one donor mouse provides a graft for three 
recipient animals, it was hypothesised that the variation in survival was due to a wide 
range of graft ischaemia time for each recipient animal (with inhalational 
anaesthesia, the skin grafting procedure had to be performed from start to finish on 
each animal individually. This problem was resolved by changing to injectable 
anaesthesia, thereby allowing simultaneous anaesthesia for four recipient animals. 
Preparation of the skin and graft bed was then performed prior to culling the donor 
animal. Recipient graft beds were temporarily covered in saline-soaked gauze, until 
donor grafts could be placed almost simultaneously on all of the anaesthetised 
animals, eliminating variation in graft ischaemia time.   
 
2.4.2 Surgery 
Full-thickness skin transplantation was performed initially under the direction and 
supervision of Dr Andrew Bushell (Transplant Research Immunology Group, 
 
2. Materials and Methods  70 
University of Oxford), using a modified technique of that originally described by 
Billingham and Medawar348.  
Tail skin from donor mice was prepared (immediately post-mortem) by spraying 
with 70% ethanol, making a circumferential incision around the base of the tail and 
then extending the incision distally along the ventral midline.  The tail skin was then 
stripped, placed into cold PBS and fashioned into three 1x1 cm squares. 
Recipient animals were placed under general anaesthesia prior to shaving the right 
flank and preparing skin with chlorahexidine solution (Animal Care Ltd). The graft 
bed was prepared by dissecting skin from the right flank, taking care to preserve 
underlying subcutaneous adipose tissue (for microvascular blood supply to the graft).  
Optimally, the skin defect created was slightly larger than the size of the graft (1 mm 
at each edge), so that the graft remained taught and the risk of seroma formation was 
minimised. Following placement of the graft onto the graft bed, it was secured in 
place with methylated flexible collodion (William Ransom & Son Ltd), applied 
sparingly along the wound edges. Particular attention was paid to avoid excess 
collodion, which can present an inflammatory insult, to the detriment of the allograft. 
The grafts were covered with an iodine-impregnated non-adherent dressing 
(Inadine®, Johnson and Johnson Medical) and then secured in place with autoclave 
tape (Fisher Scientific), as shown in figure 2-4.  The animals were placed in an 
incubator at 30°C in the immediate post-operative period (for up to 2 hours).  Overall 
operative mortality was less than 2%.  
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Figure 2-4 Full-thickness skin grafting.  Following preparation of the recipient graft bed, the 
donor graft is placed in position (A), secured with flexible collodion around the wound edge (B), 
then covered with a non-adherent dressing (C) and finally secured with autoclave tape (D). 
 
Dressings were removed seven days after skin grafting under a brief general 
anaesthetic (inhalational isoflurane).  The grafts were assessed carefully at this point 
so that damaged grafts (usually from the animal’s attempt to remove dressings) could 
be prospectively excluded from analysis as technical failures.  Allografts were 
monitored on a daily basis following the removal of dressings and rejection was 
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2.5 Experimental Autoimmune Encephalomyelitis 
(EAE) Models 
 
2.5.1 Wild-type C57BL/6 Model Immunisation 
Active EAE induction was achieved according to a protocol described by O’Connor 
et al349. Female C57BL/6 mice were immunised with 100 µg pMOG35-55 and 
Complete Freund’s Adjuvant containing 50 µg heat-killed M. tuberculosis.  
Emulsification of the immunisation mixture was achieved with a sonicator and a 
final volume of 100 µl per mouse was administered – 50 µl by subcutaneous 
injection in each hind limb. 
 
2.5.2 Tg4 Transfer model immunisation 
Passive EAE induction was achieved according to the protocol described by 
McPherson et al350. One day following adoptive transfer of 106 Tg4 antigen-specific 
CD4+ cells, B10xB6 mice were immunised with 10 µg Ac1-9(4Y) peptide in emulsion 
with Complete Freund’s Adjuvant containing 30 µg heat-killed M. tuberculosis, via a 
subcutaneous injection of 50 µl into each hind limb.  
 
2.5.3 Pertussis Toxin 
Following immunisation with pMOG35-55 (C57BL/6) or Ac1-9(4Y) (B10xB6), 200 ng 
pertussis toxin (PTX) was administered by intraperitoneal injection in a volume of 
500 µl PBS on the same day and again 48 hours later (i.e. day 0 and day 2). 
 
2.5.4 Monitoring and Clinical Scoring 
Daily monitoring for features of clinical disease commenced on the sixth day 
following immunisation. The weight of all mice was recorded on day 0 and animals 
were culled if they were found to lose 30% or more of their original body weight. 
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Other humane end-points necessitating euthanasia included a clinical score of ‘5’ or 
additional descriptor ‘E’ on two consecutive days. 
 
Classical	  EAE	  Scoring	  
Clinical	  Features	   Score	   	   Additional	  Descriptors	   Annotation	  
Healthy	   0	   Pilo-­‐erection	   A	  
Flaccid	  tail	   1	   Reduced	  activity	   B	  
Impaired	  righting	  reflex	  
and/or	  impaired	  gait	  
2	   Hunched	  posture	   C	  
Substantially	  impaired	  
gait	  (not	  dragging	  limb)	  
2.5	   Lying	  on	  side	  (mobile)	   D	  
Partial	  hind	  limb	  paralysis	  
(dragging	  limb)	  
3	   Lying	  on	  side	  (immobile)	   E	  
Total	  hind	  limb	  paralysis	   4	   	  
Any	  sign	  of	  forelimb	  
paralysis	  
5	  
Moribund	  or	  found	  dead	   6	  
Table 2-1 Classical EAE Scoring 
 
2.5.5 Ex-vivo recall assay 
Post-mortem, the inguinal lymph nodes (adjacent to the site of immunisation) and 
spleen of experimental animals were excised and a single cell suspension was 
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prepared as described below (2.7.1). Following red blood cell lysis, cells were 
washed twice in cRPMI, counted on a haemocytometer and resuspended at a final 
concentration of 8 x106 cells/ml (spleen) or 6 x106 cell/ml (lymph node). For the 
pMOG EAE system, a ½log dilution series of peptide was established in a 96 well 
plate with a top concentration of 30 µM and 100 µl of cells was added to each well.  
A similar arrangement was prepared for the Tg4 system, but with a ½log dilution 
series commencing with 1 µM Ac1-9(4Y). Cells were incubated at 37 ˚C (5% CO2) for 
72 hours, whereupon supernatants were harvested for cytokine analysis by ELISA.  
 
2.6 T Cell Transfer Model of Colitis 
 
2.6.1 Induction of colitis 
Naïve effector CD4+ T cells were isolated from the spleen and peripheral lymph 
nodes of Foxp3-GFP reporter mice by positive magnet-assisted cell sorting (MACS, 
Section 2.8.3) selection for CD4+, followed by fluorescence-activated cell sorting 
(FACS, Section 2.9.4), gating: CD4+CD25-GFP-. Following isolation, 5x105 T cells 
were adoptively transferred into RAG1-/- recipients. Animals were monitored 
regularly throughout the experimental period, at the end of which colonic specimens 
were prepared for histological assessment. 
 
2.6.2 Pathology scoring 
Scoring of histology specimens was performed in a blinded fashion by Dr Mark 
Arends (consultant histopathologist). Specimens were accorded a combined 
histology severity score, comprising a score of 0-3 based on each of the following six 
parameters: crypt architecture, ulceration, crypt abscesses, goblet cell loss, mucosal 
inflammatory infiltration and submucosal inflammatory infiltration. 
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2.6.3 Disease Activity Index scoring 
Following adoptive transfer of naïve CD4+ T cells, RAG1-/- recipient mice were 
monitored regularly and accorded a Disease Activity Index score (Table 2-2) to aid 
objective comparison of the clinical progression of disease. 
 
Colitis	  Disease	  Activity	  Index	  
	  
(Cumulative	  score	  of	  four	  parameters,	  to	  a	  maximum	  of	  16)	  
Score	   Weight	  
Loss	  
General	  
Appearance	   Bleeding	   Stool	  Consistency	  
0	   None	  
(<	  1%)	   Normal	   None	   Normal	  
1	  











Loose	  /	  some	  blood	  
3	   10-­‐20%	   -­‐	   -­‐	   Diarrhoea	  adherent	  to	  the	  anus	  
4	  




Diarrhoea	  not	  adherent	  to	  the	  
anus	  
Table 2-2 Colitis Disease Activity Index 
 
2.7 Continuous Infusion via Osmotic Minipump 
Alzet® minipumps (supplied by Charles River UK) of 100 µl capacity were selected 
according to the duration of infusion required for individual experiments (model 
1007D – 7 days; model – 1002 – 14 days; model 1004 – 28 days). Minipumps were 
filled with the substance for infusion (HES, TGM or PBS control) and primed 
overnight by incubation in PBS at 37°C. 
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Under general anaesthesia (as per section 2.4.1), abdominal fur was removed by 
shaving and the skin was prepared with chlorahexidine solution (Animal Care Ltd). 
The peritoneal cavity was accessed through an upper midline incision and the 
minipump was placed in the right paracolic gutter. Closure was in two layers with 5-
0 undyed Vicryl® (Ethicon UK). 
 
2.8 Cell Isolation and Culture 
 
2.8.1 Preparation of single cell suspensions 
Freshly isolated spleen and lymph node specimens were macerated through 70 µm 
filters (BD) into solution with cRPMI.  Contaminating red blood cells were removed 
by resuspending the cells from one spleen in 2 ml of red blood cell lysis buffer and 
incubating at RT for 2 minutes. Cells were then washed with cRPMI and counted on 
a haemocytometer by trypan blue exclusion. 
 
2.8.2 Isolation of Human Lymphocytes 
Fresh peripheral blood was obtained by venepuncture of healthy volunteers under a 
protocol approved by the University of Edinburgh research ethics committee. Blood 
was collected into heparinised tubes (BD) and immediately diluted 1:1 with PBS. 
Ficoll-Paque (GE healthcare) was divided into 15 ml aliquots in separate 50 ml 
conical Falcon tubes (BD). 20 ml of diluted blood was then slowly added to each 
tube (aiming for two layers with minimal mixing of the two liquids). The tubes were 
then centrifuged at 400 × g for 40 minutes at RT with no brake.  
Following centrifugation, PBMCs were carefully aspirated with a Pasteur pipette at 
the plasma / ficoll interface and placed into a fresh 50 ml conical Falcon tube. The 
cells were washed three times by adding 40 ml of cRPMI and then centrifuging at 
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200 g for 10 minutes (RT). Finally, cells were counted on a haemocytometer in 
preparation for culture. 
 
2.8.3 CD4+ T Cell Enrichment by Magnetic Sorting 
Following preparation and counting of cells as described above, cells were 
resuspended in MACS buffer at a volume of 45 µl per 107 cells.  5 µl of microbeads 
(T3T4, Miltenyi Biotech) were then added per 107 cells and incubated at 4°C for 20 
minutes. At the end of the incubation period, cells were washed by centrifuging at 
200 g for 5 minutes and then resuspending in 10 ml of MACS buffer. Following two 
washes, cells were resuspended in MACS buffer at a volume of 500 µl per 108 cells. 
CD4+ cells were then isolated by performing a positive selection using an 
AutoMACS (Miltenyi Biotech) automated magnetic column according to the 
manufacturer’s instructions.  The positive fraction of cells was then resuspended in 
MACS buffer and counted. 
 
2.9 Flow Cytometric Analysis and Cell Sorting 
 
2.9.1 Cell viability and surface staining 
Between 4x105 and 2x106 cells were transferred into 5ml round-bottom polystyrene 
tubes (BD Falcon 352054) and washed twice with 1 ml of PBS (centrifuging samples 
200 g for 5 minutes between each wash). 
For viability staining, LIVE/DEAD® fixable blue (Life Technologies) was defrosted 
thoroughly and resuspended PBS at a dilution of 1:1000.  A volume of 200 µl of 
viability staining solution was added to each sample, incubated for 20 min at 4°C 
(protected from light) and then washed twice in 1 ml of FACS buffer. 
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To prevent non-specific antigen binding, cells were incubated with 50 µl of 
polyclonal IgG (diluted 1:50 in FACS buffer) for 10 minutes at 4°C and then washed 
twice in 1 ml of FACS buffer. 
FACS antibodies were diluted to an appropriate final concentration in FACS buffer 
(table 2-2), to a total volume of 50 µl diluted antibody per 5x106 cells.  Single stain 
controls were individually added to one drop of UltraComp eBeads (eBioscience 
#01-2222-42).  Samples were incubated for 20 min at 4°C, washed twice in 1 ml of 
FACS buffer and then resuspended in 200 µl FACS buffer for acquisition (if only 
surface staining is required). 
 
2.9.2 Transcription factor staining 
For analysis of transcription factors, cells were resuspended in 400 µl 
fixation/permeabilisation buffer (eBioscience) and incubated at 4°C for between 1 
and 18 hours.  Following incubation, cells were resuspended and washed twice in 1 
ml permeabilisation buffer (eBioscience).  50 µl of antibody or isotype control 
(diluted in permeabilisation buffer) was added to each sample. Cells were 
resuspended by gentle vortex and incubated at room temperature for 30 minutes.  
Finally, cells were washed in 2 ml of FACS buffer and resuspended in 200 µl FACS 
buffer for acquisition. 
 
2.9.3 Intracellular cytokine staining 
For assessment of intracellular cytokines, cells from the freshly-prepared single cell 
suspension above (2.8.1) were incubated at 37°C for four hours with PMA (50 
ng/ml), ionomycin (1 µg/ml) and Brefeldin A (10 µg/ml) in 200 µl cRPMI. At the 
end of the culture period, cells were stained for surface markers (as per 2.8.1) and 
then permeabilised by incubation with Cytofix/Cytoperm solution (BD) for 20 
minutes at 4°C. Following incubation, cells were washed twice in Perm/Wash buffer 
(BD) and then incubated for 20 minutes at 4°C with cytokine-specific antibodies 
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diluted to an appropriate concentration in Perm/Wash buffer. Finally, cells were 
washed in 2 ml of Perm/Wash buffer and resuspended in 200 µl FACS buffer for 
acquisition. 
Samples are acquired on a BD Biosciences LSR II or LSR Fortessa flow cytometer 
and analysed using FlowJo software (Tree Star). 
 
2.9.4 Fluorescence-activated Cell Sorting 
CD4+ cells (freshly isolated or from culture) were enriched by magnetic sorting 
(2.7.3) and then incubated with antibodies for surface markers as described above 
(2.8.1), but with the omission of a viability stain.  Following staining, cells were 
resuspended in MACS buffer at a concentration of 5x108 cells per ml. Sorting was 
performed on a BD FACSAria with a gating strategy of: lymphocytes (size exclusion 
by forward and side scatter), single cells and then stained populations, e.g. 
CD4+CD25-Foxp3-CD62Lhi. Cells were sorted into 2 ml of FCS (Gibco) and a 
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Flow	  Cytometry	  Antibodies	  
Antigen	   Fluorochrome	   Clone	   Manufacturer	  
CD3	   FITC	   17A2	   Biolegend	  
CD4	   AF700	   RM4-­‐5	   Biolegend	  
CD4	   BV650	   RM4-­‐5	   Biolegend	  





M290	   BD	  Pharmingen	  
CTLA-­‐4	  
(CD152)	   PE	  
UC10-­‐4F10-­‐
11	   BD	  
PD-­‐1	  
(CD379)	   PE	   RMPI-­‐30	   eBioscience	  
CD25	   APC	   PC61-­‐5	   eBioscience	  
TCR-­‐ß	   AF700	   H57-­‐597	   Biolegend	  
CD39	   PE-­‐Cy7	   Duha59	   Biolegend	  
CD44	   PE-­‐Cy7	   IM7	   Biolegend	  
Foxp3	   ef450	   FJK-­‐16s	   eBioscience	  
CD45.2	   ef450	   104	   Biolegend	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2.10 Proliferation Assays 
Cellular proliferation was assessed by generational tracing with CellTrace violet 
(Life Technologies) or by measurement of thymidine incorporation. 
For assessment with CellTrace, MACS purified CD4+ or CD8+ responder cells were 
washed twice and resuspended in PBS at a concentration of 106 cells per ml. Cell 
Trace was then added to a final concentration of 5 µM and the suspension was 
agitated thoroughly to ensure uniformity of cell labeling. Labeling cells were 
incubated for 20 minutes at 37°C, washed once in complete RPMI, then resuspended 
in 5 ml of complete RPMI and incubated for a further 30 minutes at 37°C to allow 
the CellTrace to fully incorporate. At the end of the incubation period, cells were 
washed twice with RPMI and resuspended at a concentration of 106 cell per ml; 105 
cells were then added to each well of a 96 well plate together with stimulation from 
CD3/CD28 Dynabeads® (Life Technologies, variable concentrations) and varied 
treatment conditions (e.g. HES). 
For assessment of proliferation by thymidine incorporation, whole splenocyte 
populations or MACS purified responder cells were washed twice and resuspended 
in complete RPMI at a concentration of 5 x 105 cells per ml. 104 responder cells were 
then added to each well of a 96 well plate. APCs (the unlabelled cells from a CD4+ 
MACS sort) were irradiated (30 Gy), then immediately washed twice in RPMI and 
added to culture in the 96 well plate at 1 x 105 cells per well. Stimulation was added 
to designated wells with soluble CD3 (eBioscience) at a concentration of 2 µg/ml. 
Finally, varied treatment conditions were added to designated wells. Cells were 
cultured for 4 days at 37°C and 0.3 µCi [3H] thymidine was added for the final 16 
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2.11 TGF-β Bioassay 
A TGF-β bioassay (MFB-F11) was developed by Tesseur et al by stably transfecting 
embryonic fibroblasts from Tgfb1-/- mice with a TGF-β-responsive reporter plasmid 
containing a secreted alkaline phosphatase reporter gene (SBE-SEAP)351. Thus, 
TGF-βR signaling is proportional to released alkaline phosphatase, which can be 
measured using an appropriate reagent (e.g. p-nitrophenyl phosphate). 
MFB-F11 cells were grown from frozen stocks in 30 ml DMEM with 10 % FCS, 100 
U/ml penicillin, 100 µg/ml streptomycin, 2mM L-glutamine and supplemented with 
15 µg/ml Hygromycin B (Invitrogen), for 3 days. Confluent cells were detached from 
the flask with trypsin, and resuspended in DMEM with 2.5 % FCS, 100 U/ml 
penicillin, 100 µg/ml streptomycin and 2mM L-glutamine at a concentration of 4x105 
cells/ml. In 100 µl, 4x104 cells were added to each well of a 96-well round-bottomed 
plate. Serial dilutions of test substances (HES, TGM, recombinant human TGF-β1) 
were then added to each well in a volume of 50 µl and incubated for 24 hours at 
37°C. Subsequently, 20 µl of supernatant was aspirated from each well, added to an 
ELISA plate (NUNC) with 50 µl of reconstituted Sigma FastTM p-nitrophenyl 
phosphate substrate and incubated at RT in the dark for up to 4 hours. Plates were 
read on at 405 nm on an Emax precision microplate reader (Molecular Devices). 
 
2.12 Foxp3+ Treg Induction Assay 
A single cell suspension was prepared from the spleen and peripheral lymph nodes of 
Foxp3-GFP transgenic mice. CD4+CD25-GFP-CD62Lhi cells were then isolated by 
MACS followed by FACS sorting (sections 2.7.3 and 2.8.4). Sorted cells were 
washed twice in complete RPMI and then resuspended in complete RPMI at a 
concentration of 5 x 105 cells per ml. CD3/CD28-coated 24 well plates (Costar) were 
prepared by adding 250 µl per well of CD3 and CD28 (eBioscience), both at 2 µg/ml 
in PBS, incubating for 2 hours at 37°C and then washing 3 times in PBS. 5 x 105 
cells were then added to each well in 1 ml of complete RPMI. Each well was made 
up to final volume of 2 ml complete RPMI, containing variable concentrations of 
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treatment conditions (eg. TGF-β) and IL-2 (produced in-house) at a final 
concentration of 100 U/ml. Cells were removed after 96 hours for flow cytometric 
analysis. 
 
2.13 Treg Suppression Assays 
Cells from the Treg induction assay described above were washed in MACS buffer 
and the CD4+CD25+GFP+ Treg population was isolated by FACS sorting. Responder 
cells (CD4+CD25-GFP-CD62Lhi) and nTreg (CD4+CD25+GFP+) were also isolated 
from a fresh Foxp3-GFP transgenic mouse single cell suspension (as in section 2.11). 
104 responder cells were added to each well of a 96 well round-bottomed plate 
together with 105 irradiated APCs, 2 µg/ml soluble CD3 stimulation and a variable 
concentration of Treg. Proliferation was assessed after 72 hours by thymidine 
incorporation (as described in section 2.9). 
 
2.14 Macromolecular Crowding Assays 
Assays performed by Dr Hannah Woodcock (Chambers Laboratory, UCL) according 
to a protocol described by Chen et al352. WI-38 human lung fibroblasts were cultured 
under crowded conditions for 48 hours at 37°C in DMEM supplemented by 0.4% 
FCS and variable concentrations of TGM or TGF-β. At the end of the culture period, 
cells were fixed with methanol and stained for α-smooth muscle actin (AF594) or 
type I collagen (AF488) and counterstained with DAPI. Image analysis was 
performed with MetaMorph® Imaging System software (Molecular Devices). 
 
2.15 Histology and Scoring 
Skin graft specimens were fixed in 10% buffered formalin solution overnight and 
then stored in 100% ethanol. Specimens were embedded in paraffin and then cut in 4 
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µm transverse sections. Haematoxylin and eosin (H&E) staining was then performed 
under automated protocol with a Gemini varistainer (Thermo Scientific), according 
to the manufacturer’s instructions. 
Histological scoring of allograft rejection was performed in a blinded fashion by Dr 
Thomas Brenn (consultant histopathologist) according to the Zdichavsky score353 
(Figure 3-2, A). Images were captured using a Leica DFC290 compound microscope 
and Leica Application Suite software. 
 
2.16 Immunohistochemistry 
Skin graft specimens were fixed in methacarn (60% methanol, 30% chloroform, 10% 
glacial acetic acid) overnight and then stored in 100% ethanol. Samples were 
embedded in paraffin and then cut in 4 µm transverse sections. Paraffin was then 
removed from sections by immersing slides in Histoclear (Brunel Microscopes Ltd) 
for 5 mins, and then hydrating through 100%, 95% and 70% ethanol successively.  
Antigen retrieval was achieved by incubating slides in citrate buffer (20 mM citric 
acid + 0.05% Tween 20 at pH6) at 95°C for 20 minutes. Following 2 washes (5 
minutes each) in PBS, slides were loaded into Sequenza racks (Fisher Scientific) and 
incubated with avidin blocking agent (Vector Laboratories) for 10 minutes at RT, 
followed by 2 wash steps in PBS (5 minutes each). Slides were incubated with biotin 
blocking agent (Vector Laboratories) for 10 minutes at RT, followed by 2 wash steps 
in PBS (5 minutes each). Next, slides were incubated for 10 minutes with serum-free 
protein blocking agent (DAKO) for 10 minutes at RT, followed by 2 wash steps in 
PBS (5 minutes each). Primary antibodies (anti-Foxp3 clone FJK-16s, eBioscience – 
1:50 dilution and anti-CD3 cloneFJK-16s, eBioscience – 1:100 dilution) were then 
added in a total volume of 125 µl (with DAKO Real antibody diluent) for each slide 
and incubated overnight at 4°C. 
Following 2 wash steps in PBS, secondary antibodies (goat anti-rabbit AF488, 
Invitrogen – 1:200 dilution and biotinylated goat anti-rat – 1:100 dilution) were 
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added in a total volume of 125 µl (with DAKO Real antibody diluent) for each slide 
and incubated for 1 hour at RT followed by 2 wash steps in PBS (5 minutes each). 
Slides were then incubated with 125 µl of Streptavidin AF594 (1:200 dilution in 
DAKO Real antibody diluent) overnight at 4°C and then washed twice in PBS before 
mounting with Permafluor aqueous mounting medium (Thermo Scientific). Slides 
were left to dry for 1 hour at RT, then stored at 4°C until image capture on a Leica 
SP5 C microscope. 
 
2.17 Ex-vivo Allogeneic Restimulation Assays 
For assessment of antigen-specific cytokine profiles, splenocytes were harvested 
from C57BL/6 mice 21 days after transplantation of a full-thickness BALB/c skin 
graft. Isolated splenocytes (106) were restimulated ex-vivo for 72 hours at 37°C in 
duplicate under multiple conditions including: soluble anti-CD3e stimulating 
antibody (eBioscience, 1 µg/ml), 106 irradiated BALB/c (donor strain alloantigen) 
splenocytes, 106 irradiated CBA (third party strain alloantigen) splenocytes, 106 
irradiated C57BL/6 (recipient strain syngeneic antigen) splenocytes, or complete 
RPMI media. 
 
2.18 Detection of Cytokines by ELISA 
For measurement of cytokine concentrations by enzyme-linked immunosorbent assay 
(ELISA), high-affinity 96-well plates (Immunoplate MaxiSorp, NUNC) were first 
coated by adding appropriate concentrations of monoclonal capture antibodies in 50 
µl of carbonate buffer to each well and incubating overnight at 4oC.  The incubating 
capture antibody was discarded after 16 hours and the plates were then blocked for 2 
hours at 37oC with 200 µl/well of TBS containing 0.05% Tween and 10% FCS. 
Plates were washed 5x in TBS with 0.05% Tween, then 40 µl of sample or standard 
was added to each well and incubated at 4°C overnight. In most instances, 
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supernatants were then transferred to a second set of plates to allow quantification of 
other cytokines. 
Following incubation, plates were washed five times in TBS containing 0.05% 
Tween.  Diluted biotinylated detection antibodies were added in a volume of 50 µl 
per well and incubated at 37oC for 1 hour.  Plates were then washed again 5x in TBS 
with 0.05% Tween and 50 µl of streptavidin-alkaline phosphatase (Sigma) was added 
to each well, followed by incubation at 37oC for a further 45 minutes. 
Finally, plates were washed three times with TBS with 0.05% Tween, and twice with 
distilled water, before adding 100 µl of p-nitrophenyl phosphate (pNPP) substrate to 
each well. Optical densities were measured using an Emax precision microplate 
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Cytokine	  ELISA	  Antibodies	  













IFN-­‐γ	   50	  ng/ml	   XMG1-­‐2	   0.5	  µg/ml	   R4-­‐6A2	   0.2	  µg/ml	  
IL-­‐4	   8	  ng/ml	   11B11	   0.5	  µg/ml	   BVD6-­‐24G2	   0.06	  µg/ml	  
IL-­‐5	   25	  ng/ml	   TRF-­‐K5	   0.125	  µg/ml	   TRF-­‐K4	   0.5	  µg/ml	  
IL-­‐10	   10	  ng/ml	   JES5-­‐16E3	   0.5	  µg/ml	   JES5-­‐2A5	   0.5	  µg/ml	  
IL-­‐13	   10	  ng/ml	   eBio-­‐	  	  	  13A	   4	  µg/ml	   eBio-­‐1316H	   0.5	  µg/ml	  
IL-­‐17	   20	  ng/ml	   eBio-­‐17CK15A5	   0.5	  µg/ml	   JES5-­‐2A5	   0.2	  µg/ml	  
Table 2-4 Cytokine ELISA Antibodies (all supplied by eBioscience) 
 
2.19 Detection of Cytokines by Cytokine Bead Array 
For all CBA dilutions and wash steps, filtered FACS buffer was used (0.5% BSA, 
0.05% sodium azide in PBS, passed through 0.22 µm syringe filter). 
Standards were defrosted from -80°C and prepared as a mixture according to all of 
the cytokines that were to be measured.  Each standard was diluted such that the top 
standard is at a concentration of 2,500 pg/ml in 200 µl of filtered FACS buffer.  
Doubling dilutions were then performed for 11 standards. 
Serum or culture supernatant samples were then added to a 96 well round-bottomed 
plate (50 µl of sample per well).  CBA beads (BD Biosciences) were vortexed 
thoroughly before adding 0.2 µl of each bead per well, in a volume of 50 µl filtered 
FACS buffer (1/250 dilution of each bead population in FACS buffer).  The plate 
was then shaken at 300 rpm for 1 minute, followed by incubation at room 
temperature for 1 hour. 
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Detection antibodies for each cytokine were then added to each of the samples and 
standards at the same concentration as the CBA beads (0.2 µl of each antibody per 
well, in 50 µl filtered FACS buffer). The plate was then shaken again at 300 rpm for 
1 minute and followed by incubation at room temperature for 1 hour. 
Finally, all samples and standards were washed twice with 200 µl of filtered FACS 
buffer and resuspended in 100 µl per well of filtered FACS buffer for aquisition.  
Samples were acquired on a BD FACSarray or BD Canto flow cytometer and 
analysed using FlowJo software (Tree Star). 
 
2.20 Protein Analysis by Western Blotting 
Following culture under various conditions, cells were resuspended in 1x cell lysis 
buffer (Cell Signaling Technology), incubated on ice for 15 minutes and then 
centrifuged at 200 g for 5 minutes at 4°C. Three parts of the supernatant was then 
added to one part 4x LDS Sample Buffer (Invitrogen) in the presence of 20 mM β-
mercaptoethanol and boiled for 10 minutes. Reduced samples and the SeeBlue Plus 2 
marker (Invitrogen) were then added to a NuPage 4-12% Bis-Tris pre-cast gel (Life 
Technologies) and run in 1x MOPS buffer (Invitrogen) at 140 V for 90 minutes. The 
gel was then transferred to a nitrocellulose membrane (Bio-Rad) in a semi-dry 
transfer system using transfer buffer (Invitrogen) supplemented with 10% methanol. 
The membrane was blocked in 10% (w/v) dried skimmed milk in TBS at 4°C for 2 
hours with continuous agitation. Following 4 washes (15 minutes each) in TBST, 
membranes were incubated with primary antibody (Smad2 or phospho-Smad2, Cell 
Signaling Technology) at a dilution of 1/1000 overnight at 4°C with continuous 
agitation. Following four further washes with TBST, membranes were incubated 
with secondary antibody (anti-rabbit IgG-HRP, Cayman Chemicals), diluted in 
TBST at a concentration of 1:1000, for 1 hour at room temperature. After 4 final 
washes in TBST, membranes were developed using a FluorChem SP gel imager 
(Alpha Innotech) and images were acquired on a FluorChem SP gel imager (Alpha 
Innotech). 
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2.21 Statistical Analysis 
All statistical analyses were performed using Prism 6.0 (Graphpad Software Inc.). 
For comparisons of two groups of parametric data, a two-tailed, unpaired t test was 
used. When three or more groups of parametric data were analysed, a one-way 
ANOVA was used with Dunnett’s multiple comparison test.  Graft survival was 
assessed by Kaplan-Meier analysis and statistical significance of difference in 
survival between experimental groups was determined by a log rank (Mantel-Cox) 
test. Comparison of groups of non-parametric data was with the Mann-Whitney U 
test or Kruskal-Wallis test unless otherwise stated. Generally, p values of <0.05 were 
considered to be significant; the following symbols were used to indicate 
significance levels: * denoting p<0.05, ** denoting p<0.01, *** denoting p<0.001 









Investigation of the ability of helminths to protect transplanted allografts from 
rejection first required selection of an appropriate model helminth species. Although 
H. polygyrus had not been investigated in this context before (in the limited number 
of published studies available, summarised in table 1-2), theoretically it offered a 
number of advantages over other candidate species. First, in contrast to many other 
helminths, H. polygyrus reliably establishes chronic infection in wild type C57BL/6 
mice354. This allows for a durable infection throughout the likely timeframe of 
allograft rejection and suggests superior capabilities for immunomodulation of the 
host immune response. Secondly, H. polygyrus and HES have been shown to 
powerfully induce Foxp3+ Treg233, an effect that could be fundamentally important in 
abrogating allograft rejection96. Lastly, significant progress in characterising the 
secreted immumodulators within HES has been made by the Maizels laboratory in 
recent years288,296 and therefore the opportunity for a reductionist approach to 
specific immunological mechanisms was available with this helminth over other 
species. While two earlier studies from Lee and colleagues reported enhanced 
experimental allograft survival following infection with Nippostrongylus 
brasiliensis269,270), more recent developments with H. polygyrus rendered it the more 
favourable species for this investigation (T. Lee, personal communication). 
Full-thickness skin grafting across allogeneic mouse strains is a reliable transplant 
model that has been used extensively in studies of immunological tolerance and 
rejection104,355,356. A primary limitation of this model is dependence on a 
microvascular blood supply, making grafts prone to ischaemia. Inflammation arising 
from an evolving alloimmune response can induce thrombosis that rapidly 
propagates and results in graft infarction and necrosis, such that rejection of the graft 
can occur in a relatively stochastic manner compared to an allograft with a 
macrovascular blood supply. However, skin grafts do generate a robust allogeneic 
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immune response for mechanistic analysis and can be performed in relatively high 
numbers with standard anaesthetic and surgical equipment. On adopting the skin 
grafting model, grafts were initially sutured onto the interscapular region of 
recipients (following the technique demonstrated by Mr Kourosh Saeb-Parsy, 
University of Cambridge). However, this approach required individual caging of 
recipient animals (to prevent graft damage from other animals, as no protective 
dressing could be applied in this position) and resulted in multiple allograft draining 
lymph node populations (bilateral occipital and cervical) with a significant degree of 
individual variability. The model was therefore adapted to use flexible collodion to 
fix skin grafts to the recipient flank (as described in section 2.4.2), followed by a 
dressing that remained in place for 7 days. This technique allowed for consistent 
allograft draining to the ipsilateral inguinal lymph node (for subsequent analysis by 
flow cytometry) and the ability to co-house graft recipients (necessary for later 
experiments involving more than 30 mice). All of the results described in this chapter 
are derived from experiments using the latter technique. 
Scoring of skin graft survival was conducted according to established protocols and 
corroborated by additional experiments with blinded histological scoring of 
haematoxylin and eosin-stained allograft sections performed by an independent 
consultant histopathologist. Histological assessment was performed at multiple time 
points and found to be optimal at 7 days after transplantation (sufficient for a robust 
allogeneic response to be underway, but not so advanced that extensive necrosis 
inhibits assessment). 
Finally, in vivo experiments with HES in the Maizels laboratory had hitherto been 
performed with administration by intraperitoneal injection or intranasal insufflation. 
Based on previously published studies, the timeframe for allograft rejection was 
predicted to be up to 3 weeks (for BALB/c to C57BL/6 skin grafts). In approaching 
experimental treatment with HES, a number of unknowns existed, including which 
component immunomodulators were relevant and their relative proportion, duration 
of action and bioavailability. Delivery by continuous infusion via an implantable 
osmotic minipump was therefore adopted, with a rate of infusion equivalent to that of 
130 adult H. polygyrus worms. 
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This chapter begins with a functional analysis of the impact of treatment with H. 
polygyrus and HES on allograft survival, followed by investigation of the 
mechanisms behind their alteration of the alloimmune response and finishing with 
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3.2 Results 
 
3.2.1 H. polygyrus and HES prolong survival of fully 
allogeneic skin grafts  
Full-thickness allogeneic skin grafts were performed from BALB/c tail skin onto the 
left flank of C57BL/6 recipient mice, as described in section 2.4.2. With 
simultaneous anaesthesia and preparation of three recipient mice for each donor, skin 
graft ischaemic time prior to transplantation was maintained at less than 5 minutes 
for each procedure. Dressings were removed 7 days after transplantation and grafts 
were then monitored on a daily basis until complete rejection, which was defined as 
more than 90% necrosis by surface area, or complete dehiscence (Figure 3-1, A). 
Mice that were infected with 200 stage 3 H. polygyrus larvae immediately prior to 
skin grafting (n = 28) showed significantly prolonged allograft survival with a 
median survival time of 14 days compared to 10 days for mice with identical 
allografts and no additional treatment (n = 26), p < 0.0001 as assessed by the Mantel-
Cox (log-rank) test. The hazard ratio (the risk of future rejection in a treatment group 
expressed as a ratio of the risk of rejection occurring in an untreated group) for H. 
polygyrus infection was 0.365 (95% CI: 0.103-0.368). Control syngeneic (C57BL/6 
to C57BL/6) skin grafts showed no signs at all of rejection at the termination of 
experiments on day 21 post transplantation (n = 6), thereby confirming that 
destruction of the allografts is as a result of the alloimmune response (Figure 3-1, B). 
It is possible that allograft protection afforded by H. polygyrus infection may be as a 
result of the physical presence of the parasite and the response to the intestinal 
trauma that it elicits (e.g. induction of a Th2 response and alteration of the gut 
microbiome). To assess this, further experiments were performed with an additional 
group of mice to which HES was administered via an osmotic minipump (Alzet® 
model 1004; n = 13) that was implanted into the peritoneal cavity immediately prior 
to skin grafting. The minipumps eluted 2.64 µg of HES per day for the duration of 
the experiment (0.11 µl per hour of HES at a concentration of 1 mg/ml). Treatment 
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with HES significantly prolonged allograft survival in a similar fashion to infection 
with live H. polygyrus larvae, with a median survival time of 14 days compared to 10 
days for untreated allograft recipients (p < 0.0001 as assessed by the Mantel-Cox 
test) and a hazard ratio of 0.323 (95% CI: 0.05 – 0.301) (Figure 3-1, C). 
 
3.2.2 H. polygyrus and HES ameliorate histological features 
of fully-allogeneic skin graft rejection 
To verify the observation of enhanced allograft survival following treatment with H. 
polygyrus infection or HES shown in Figure 3-1, further experiments were 
performed to allow for histological assessment of allografts 7 days after 
transplantation. Scoring was performed in a blinded fashion by Dr Thomas Brenn 
(consultant histopathologist) according to the Zdichavsky histology scale, which is 
based on the degree of vasculitis, folliculitis, dermal inflammation, and epidermal 
degeneration present353 (Figure 3-2, A-B). 
Full-thickness skin grafts were harvested 7 days after transplantation, fixed in 10% 
formalin for 18 hours and then embedded in paraffin for haematoxylin and eosin 
staining (Figure 3-2, B). Animals were divided into the following experimental 
groups (over two independent experiments): BALB/c to C57BL/6 allograft with no 
treatment (n = 14), BALB/c to C57BL/6 allograft with simultaneous implantation of 
an intraperitoneal osmotic minipump eluting 2.6 µg/day of HES (Alzet® model 
1004; n = 12) and BALB/c to C57BL/6 skin graft with simultaneous infection with 
200 H. polygyrus stage 3 larvae by oral gavage (n = 10), in addition to C57BL/6 to 
C57BL/6 syngeneic skin graft controls (n = 5). 
Despite the completely normal macroscopic appearance of syngeneic skin grafts up 
to 21 days after transplantation in the previous experiment, Figure 3-1, B-C), 
histological analysis at day 7 revealed the presence of sparse areas of inflammation 
that were sufficiently distinct from normal skin that 4 out of 5 grafts were assigned a 
grade 1 Zdichavsky score (mean = 0.8 ± 0.2; Figure 3-3, C). Allogeneic grafts with 
no additional treatment showed at day 7 severe, extensive areas of inflammatory 
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infiltration and necrosis (despite not having developed >90% macroscopic necrosis 
until a median of day 10 in the longer-term experiment), resulting in a mean 
Zdichavsky score of 3.57 ± 0.2; figure 3-3, C. Histological scores of allogeneic grafts 
onto recipients treated with HES or H. polygyrus infection were significantly lower 
than those that received no treatment (2.25 ± 0.37, p = 0.017 and 1.8 ± 0.36, p = 
0.0015, respectively as assessed by the Kruskal-Wallis test). 
 
3.2.3 H. polygyrus infection expands intra-allograft regulatory 
T cell populations 
To assess intra-allograft cell populations, BALB/c to C57BL/6 skin grafts were 
harvested 7 days after transplantation, as before in section 3.2.2, but fixed in 
methacarn rather than 10% formalin to allow optimal antigen preservation for 
immunohistochemical staining. Even with methacarn fixation, fluorescent staining of 
CD4 and CD8 epitopes was not possible. Frozen sections did facilitate CD4 and CD8 
staining, but the high proportion of connective tissue in skin led to unacceptably high 
background staining that did not allow for accurate quantification. A compromise of 
methacarn-fixed specimens with staining for CD3, Foxp3 and nucleic acids was 
therefore used (method described in section 2.14). Whilst this allowed for clear 
identification of co-localisation with low background fluorescence, limitations do 
exist: CD3+Foxp3+ cells have been designated as ‘Treg’ in light of the technical 
limitations outlined, but could represent either CD4+Foxp3+ or CD8+Foxp3+ cells and 
the relative proportion of CD4+ and CD8+ effector cells is not discernable. 
Nonetheless, immunohistochemical analysis of transplanted allogeneic skin grafts 
revealed a HS change (13.64 fold) in the mean number of CD3+Foxp3+ cells visible 
per high-powered field per graft (Figure 3.3, p = 0.0002). Whether these cells are in 
fact CD4+Foxp3+ or CD8+Foxp3+, both have a regulatory phenotype and both are 
likely to promote allograft survival.  
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3.2.4 HES expands Foxp3+ Treg populations in vivo and PD-1 
expression of Foxp3- effector CD4+ T cells 
To investigate the influence of HES on the alloimmune response, allogeneic 
(BALB/c to C57BL/6) full-thickness skin grafts were performed with recipient 
animals receiving either no additional treatment, or placement of a subcutaneous 
osmotic minipump eluting 2.6 µg/day of HES. Flow cytometric analysis of the 
allograft draining (inguinal) lymph node cellular composition revealed that treatment 
with HES resulted in a 42% increase in CD4+CD25+Foxp3+ Treg (as a percentage of 
all CD4+ cells; p = 0.009; Figure 3-4, A). Mean fluorescence intensity (MFI) of 
Foxp3 within the Treg population was also significantly increased with HES 
treatment (Figure 3-4, B). Analysis of Programmed cell death protein 1 (PD-1) 
showed increased expression induced by HES that was specific to the Foxp3- effector 
CD4+ population (Figure 3-4, C-E). CD4+Foxp3-PD-1+ cells as a proportion of total 
CD4+ increased by 62% following treatment with HES (p = 0.03; Figure 3-4, C), 
whilst expression of PD-1 within the CD4+Foxp3+ compartment was not 
significantly changed (p = 0.2; Figure 3-4, D). 
Following the use of subcutaneous implantation of minipumps in this experiment, the 
technique was modified to intraperitoneal placement for improved systemic 
absorption and reduced variability in the localised concentration of HES to which 
individual subcutaneous lymph node populations were exposed (a particularly 
important point for later experiments with animals immunised by bilateral hind limb 
injection). 
 
3.2.5 H. polygyrus and HES suppress peripheral blood serum 
inflammatory cytokines following allogeneic skin 
grafting 
To further investigate immunological effects of HES on the allogeneic response, 
serum cytokines were analysed. BALB/c full-thickness skin grafts were transplanted 
on to C57BL/6 recipient mice in the following experimental groups: no treatment (n 
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= 8), insertion of an intraperitoneal osmotic minipump eluting 2.5 µg/day of HES 
immediately prior to transplantation (n = 6), or infection with 200 H. polygyrus stage 
3 larvae immediately prior to transplantation (n = 7). C57BL/6 to C57BL/6 skin 
grafts were also performed as controls (n = 3). 
Seven days after transplantation, peripheral blood was collected from the brachial 
artery under terminal anaesthesia. Serum from each mouse was then analysed for 
multiple cytokine concentrations in parallel by cytokine bead array (as described in 
section 2.16). Treatment with HES significantly suppressed serum concentrations of 
multiple pro-inflammatory cytokines, notably including characteristic cytokines from 
Th1, Th2 and Th17 effector CD4+ T cell phenotypes (Figure 3-5). Most notably, 
serum IL-1α, which showed the strongest upregulation following allograft 
transplantation, was profoundly suppressed, as were levels of a number of other 
cytokines such as IL-6, IL-17 and IL-21 that had not been greatly increased in 
allograft recipients. The mean concentrations of all inflammatory cytokines 
measured from allografts treated with H. polygyrus infection were thus lower than 
those of untreated allograft recipients. The exception to the trend was with (the Th2 
cytokine) IL-5, in which HES did not effect any significant change and H. polygyrus 
infection led to a significantly raised concentration. The concentrations, fold changes 
and p values (determined by one-way ANOVA with Dunnett’s multiple comparison 
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Cytokine	   Allograft	  only	  	  
	  
Concentration	  -­‐	  pg/ml	  
+HES	  
	  
Concentration	  -­‐	  pg/ml	  
(fold	  change	  
compared	  to	  no	  
treatment;	  p	  value)	  
+H.	  polygyrus	  
	  
Concentration	  -­‐	  pg/ml	  
	  (fold	  change	  
compared	  to	  no	  
treatment;	  p	  value)	  
IL-­‐1α	   38.17	   17.14	  
(0.5;	  p	  =	  0.004)	  
27.18	  
(0.7;	  p	  =	  0.192)	  
TNF	   33.94	   28.68	  
(0.9;	  p	  =	  0.004)	  
32.15	  
(0.9;	  p	  =	  0.58)	  
IL-­‐17	   18.35	   16.36	  
(0.9;	  p	  =	  0.004)	  
16.94	  
(0.9;	  p	  =	  0.1128)	  
IL-­‐6	   62.32	   46.86	  
(0.8;	  p	  =	  0.042)	  
59.3	  
(0.9;	  p	  =	  0.328)	  
IL-­‐21	   96.64	   87.89	  
(0.9;	  p	  =	  0.039)	  
90.46	  
(0.9;	  p	  =	  0.151)	  
IFNγ	   129.3	   113.5	  
(0.9;	  p	  =	  0.102)	  
128.3	  
(1.0;	  p	  =	  0.935)	  
IL-­‐4	   37.23	   35.54	  
(0.9;	  p	  =	  0.015)	  
35.88	  
(1.0;	  p	  =	  0.084)	  
IL-­‐5	   30.53	   31.51	  
(1.0;	  p	  =	  0.528)	  
37.29	  
(1.2;	  p	  =	  0.014)	  
Table 3-1 Serum cytokines 7 days after BALB/c to C57BL/6 full-thickness skin grafts (n=8 per 
group) 
 
3.2.6 H. polygyrus-infected allogeneic skin graft recipients 
develop a shift from a Th1 and Th17 allogeneic 
response to Th2 upon restimulation 
To evaluate alloantigen-specific cytokine responses, as distinct from the systemic 
cytokine milieu in peripheral blood serum, splenocytes were harvested from 
uninfected and H. polygyrus-infected allograft recipients 21 days after 
transplantation and restimulated with irradiated donor allogeneic cells for 72 hours at 
37°C (Figure 3-4, A; method described in section 2.17).   
Analysis of culture supernatants by ELISA revealed significantly reduced IFNγ and 
IL-17 production from splenocytes of H. polygyrus-infected allograft recipients 
compared to those from untreated allograft recipients. This effect was most 
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pronounced at higher concentrations of stimulating allogeneic cells; with 106 
BALB/c stimulating cells, the mean IFNγ concentration arising from H. polygyrus-
infected allograft recipients was 2.41-fold lower than that from non-infected allograft 
recipients (p = 0.0004; Figure 3-14, B). The trend for IL-17 was the same, with 106 
BALB/c stimulating cells inducing a 4.21-fold reduction in IL-17 from H. polygyrus 
infected allograft recipients compared to uninfected controls (p < 0.0001; Figure 3-4, 
C). 
The relationship between H. polygyrus infection and cytokine production upon 
allogeneic restimulation was completely reversed with respect to IL-4: 106 BALB/c 
stimulating cells induced a 4.3-fold higher response from H. polygyrus infected 
allograft recipients compared to uninfected controls (p < 0.0006; Figure 3-4, D). This 
suggests that instead of H. polygyrus infection merely inducing a parasite-specific 
Th2 response in parallel to a separate anti-allograft response, concomitant infection 
actually alters the cytokine profile of the alloantigen-specific response itself. 
 
3.2.7 H. polygyrus-induced Th2 shift is donor alloantigen-
specific 
Further to the finding of a shift towards a Th2 response upon restimulation of 
splenocytes from H. polygyrus-infected allograft recipients with donor alloantigens, 
additional experiments were performed to compare this response to that against third-
party alloantigens. 
Full-thickness skin grafting was performed from BALB/c donors onto C57BL/6 
recipients as before with either no treatment (n = 5) or simultaneous infection with 
200 H. polygyrus stage 3 larvae by oral gavage (n = 6). Splenocytes were harvested 
from recipient animals 21 days after transplantation and restimulated ex vivo with 
syngeneic, donor allogeneic (BALB/c) or third party allogeneic (CBA) cells in 
parallel for 72 hours at 37°C, alongside anti-CD3 polyclonal stimuli (Figure 3-5, A). 
The concentrations of IFNγ, IL-4 and IL-10 in culture supernatants were then 
measured by ELISA. 
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Restimulation with irradiated BALB/c (donor strain) splenocytes revealed the same 
cytokine profile as previous experiments (as shown in Figure 3-4): the mean IFNγ 
concentration arising from splenocytes of H. polygyrus-infected allograft recipients 
was 53% lower than that of untreated allograft recipients (p = 0.007; Figure 3-5, B), 
whilst the mean IL-4 production from H. polygyrus-infected allograft recipients was 
reciprocally increased (2.0-fold change, p = 0.018; Figure 3-5, C) 
Following restimulation with irradiated CBA (third party allogeneic) cells, responses 
were generally much lower than with donor cells. However, a measurable IFNγ 
response was induced in splenocytes from allograft recipients, which was 56% lower 
in spleen cells from those treated with H. polygyrus infection (p = 0.003; Figure 3-5, 
B). In contrast to stimulation with donor strain BALB/c cells, no significant 
difference in IL-4 production was observed (0.16 ± 0.005 ng/ml vs. 0.17 ± 0.004 
ng/ml, p = 0.91; figure 3-5, C). Thus, it appears that the ‘Th2 switch’ previously 
observed upon allogeneic restimulation of splenocytes from H. polygyrus-infected 
skin graft recipients is alloantigen-specific for the skin graft donor strain. 
Polyclonal stimulation with soluble CD3 revealed a 65.21% reduction in IFNγ 
production from H. polygyrus-infected allograft recipient cells compared to untreated 
allograft recipients (p = 0.0001; Figure 3-5, B) and a corresponding 4.1-fold increase 
in IL-4 production was also seen (p = 0.012; Figure 3-5, C).  
In respect of IL-10, only restimulation with CD3 revealed a significant difference 
between H. polygyrus-infected allograft recipient cells compared to untreated 
allograft recipients, with a substantial increase observed (0.63 ± 0.13 ng/ml vs. 0.16 
± 0.04 ng/ml, p = 0.009; Figure 3-5, D). 
Control conditions of culture with 106 irradiated syngeneic C57BL/6 splenocytes or 
an equal volume of complete RPMI media revealed no significant difference in 
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3.2.8 HES-mediated allograft protection is not Th2-dependent 
 
Induction of a Th2 cytokine profile in alloreactive lymphocytes has previously been 
suggested as a possible mechanism behind Nippostrongylus brasiliensis-mediated 
protection of allogeneic mouse cardiac allografts269. Following the finding that 
allogeneic skin grafting with concomitant H. polygyrus infection induces a Th2 
response that is specific to donor alloantigens (section 3.2.7), a further experiment 
was performed with parallel wild type and IL-4 receptor deficient (IL-4Rα-/-) donor 
and recipient mice.  
Full-thickness wild type BALB/c skin grafts were transplanted on to wild type 
C57BL/6 recipients with no treatment (n = 6), insertion of an intraperitoneal osmotic 
minipump eluting 2.5 µg/day of HES (n = 7), or infection with 200 H. polygyrus 
stage 3 larvae (n = 8). In parallel, skin grafts from BALB/c IL-4Rα-/- donors were 
transplanted onto C57BL/6 IL-4Rα-/- recipients with either no treatment (n = 5) or 
insertion of an intraperitoneal osmotic minipump eluting 2.5 µg/day of HES (n = 4). 
An experimental group of IL-4Rα-/- mice receiving infection with H. polygyrus was 
not included due to a severely limited availability of these transgenic strains; 
treatment with HES was chosen over H. polygyrus infection because of concern that 
the greatly increased susceptibility of IL-4R-deficient mice to infection might make 
comparison of effects with the wild-type more difficult to interpret 
Kaplan-Meier analysis of the time for transplanted skin grafts to completely reject 
(>90% necrosis by surface area or complete dehiscence) revealed a 40% increase in 
the median survival of allografts onto wild-type recipients treated with HES (hazard 
ratio = 0.247, p = 0.0003) and H. polygyrus infection (hazard ratio = 0.304; p = 
0.002) (Figure 3-8, A). Similarly, median survival of BALB/c IL-4Rα-/- skin grafts 
onto C57BL/6 IL-4Rα-/- recipients was 44.45% longer with HES treatment compared 
to untreated controls (hazard ratio 0.347; p = 0.046) (Figure 3-8, B). Inherent 
variability within the skin grafting model (e.g. trauma caused by individual mice 
attempting to remove dressings, etc) generally necessitates greater experimental 
numbers than were available for this experiment for robust conclusions to be drawn. 
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However, from the limited data available, it does appear that HES-mediated allograft 
protection is not wholly dependent on a Th2 alloimmune response.  
Flow cytometric analysis of the allograft draining lymph node revealed a significant 
increase in Foxp3+ Treg with HES treatment compared to untreated allograft 
recipients, both in wild type animals (1.16 fold change; p = 0.012) and IL-4Rα-/- 
(1.26 fold change; p = 0.019) (Figure 3-8, C+E). The proportion of Treg was not 
significantly increased in the spleens of allograft recipients treated with HES 
compared to untreated recipients, in wild type mice but was in IL-4Rα-/- animals (1.2 
fold change; p = 0.03) (Figure 3-8, D). 
 
3.2.9 H. polygyrus infection and HES suppress expression of 
Tbet by CD4+ T cells 
As discussed in section 1.1.3.4, Th1 CD4+ T cells play a fundamental role in 
mediating allograft rejection. To assess the impact of H. polygyrus and HES in 
mitigating against an allogeneic Th1 response, cell populations from the spleen and 
allograft draining lymph node of skin graft recipient animals were analysed by flow 
cytometry for expression of the transcription factor Tbet. Two experiments were 
performed under identical conditions to allow for cellular analysis at 7 and 21 days 
after transplantation.  
Full-thickness BALB/c skin grafts were transplanted on to C57BL/6 mice in the 
following experimental groups: no treatment, implantation of an intraperitoneal 
osmotic minipump eluting 2.6 µg/day of HES immediately prior to transplantation 
and infection with 200 H. polygyrus stage 3 larvae by oral gavage immediately prior 
to transplantation. Syngeneic C57BL/6 to C57BL/6 skin grafts were also performed 
in each experiment to provide control cell populations.  
Tbet expression by CD4+ T cells was significantly elevated in the spleen and 
allograft draining lymph node of all mice that received an allogeneic graft with no 
treatment compared to syngeneic control skin grafts (Figure 3-9, A-D). Changes in 
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Tbet expression were observed as a shift in fluorescence intensity and so positive 
populations were determined by gating against a fluorescence minus one control 
(Figure 3-9, E). 
HES and H. polygyrus infection were both found to suppress Tbet expression by 
CD4+ T cells in the spleen and allograft draining lymph node. A summary of the 
mean proportions of CD4+Tbet+ T cells, together with fold change as a result of 
treatment and associated p values (determined by one-way ANOVA with Dunnett’s 




Allograft	  only	  	  
	  
%CD4+Tbet+	  	  






compared	  to	  no	  





compared	  to	  no	  
treatment;	  p	  value)	  
Day	  7	  LN	   61.75	   44.84	  
(0.73;	  p	  =	  0.0012)	  
40.23	  
(0.65;	  p	  <	  0.0001)	  
Day	  7	  Spleen	   19.72	   11.23	  
(0.57;	  p	  =	  0.0001)	  
12.29	  
(0.62;	  p	  =	  0.0003)	  
Day	  21	  LN	   59.62	   44.9	  
(0.75;	  p	  =	  0.0016)	  
34.75	  
(0.58;	  p	  <	  0.0001)	  
Day	  21	  Spleen	   52.79	   44.83	  
(0.85;	  p	  =	  0.0844)	  
37.97	  
(0.72;	  p	  =	  0.0019)	  
Table 3-2 Tbet expression by CD4+ T cells of allograft recipients (comparison following 
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3.2.10 H. polygyrus infection and HES suppress expression of 
ROR-γt by CD4+ T cells 
Th17 CD4+ T cells have also been shown to mediate allograft rejection in multiple 
experimental transplant models82,83,86 (as discussed in section 1.1.3.6). Given that 
HES has previously been shown to exert TGF-β-like activity233 and that the Th17 
phenotype can be generated in vitro from naïve CD4+ T cells stimulated in the 
presence of TGF-β and IL-6, one might reasonably hypothesise that HES (and H. 
polygyrus) could expand harmful alloreactive Th17 cells within the inflammatory 
context of a rejecting allograft. 
To address this concern, the CD4+ T cell populations isolated from allograft recipient 
animals described in 3.2.9 (from spleen and allograft draining lymph node, with or 
without treatment with HES or H. polygyrus) were stained for expression of the Th17 
transcription factor, ROR-γt (Figure 3-10).  Compared to recipients of a syngeneic 
skin graft, ROR-γt expression was markedly elevated in untreated allograft recipients 
21 days after transplantation (2.16 fold change in allograft draining lymph node 
CD4+ T cells, p = 0.0002, and a 2.63 fold change in splenic CD4+ T cells, p = 0.002). 
Treatment with H. polygyrus infection suppressed ROR-γt expression in CD4+ T 
cells within the spleen and lymph node at both day 7 and day 21 post-transplantation. 
Likewise, treatment with HES suppressed expression of ROR-γt by splenic CD4+ T 
cells at 21 days post transplantation and did not increase ROR-γt expression in the 
lymph node or spleen at the other time points assessed. A summary of the mean 
proportions of CD4+ROR-γt+ T cells, fold change with treatment and associated p 
values (determined by one-way ANOVA with Dunnett’s multiple comparisons test) 
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population	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  only	  	  
	  
%CD4+ROR-­‐γt+	  	  





compared	  to	  no	  





compared	  to	  no	  
treatment;	  p	  value)	  
Day	  7	  LN	   6.19	   5.1	  
(0.82;	  p	  =	  0.1932)	  
5.0	  
(0.81;	  p	  =	  0.0298)	  
Day	  7	  Spleen	   6.24	   5.4	  
(0.86;	  p	  =	  0.1461)	  
4.9	  
(0.79;	  p	  =	  0.0215)	  
Day	  21	  LN	   26.85	   17.4	  
(0.65;	  p	  =	  0.2383)	  
9.5	  
(0.35;	  p	  =	  0.0215)	  
Day	  21	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   7.5	  
(0.5;	  p	  =	  0.0032)	  
5.6	  
(0.37;	  p	  =	  0.0004)	  
Table 3-3 ROR-γt expression by CD4+ T cells of allograft recipients (comparison following 
treatment with H. polygyrus and HES) 
 
3.2.11 H. polygyrus infection and HES exert different effects 
on expression of GATA3 by splenic CD4+ T cells 
In light of the known ability of infection with H. polygyrus to induce a strong Th2 
response357 and the novel finding of its ability to polarise the alloimmune response 
towards a Th2 phenotype, a plausible hypothesis at this stage might be that 
suppression of Th1 and Th17 alloimmune responses by H. polygyrus and HES were 
as a result cross-regulation from a simultaneous Th2 response. However, both H. 
polygyrus and HES also induce Foxp3+ Treg (Figure 3-8, C) and, crucially, the 
ability of HES to protect allografts from rejection is preserved in IL-4Rα-/- mice. 
CD4+ T cells isolated from allograft recipient mice described in 3.2.9 (receiving no 
treatment, continuous HES infusion, or infection with H. polygyrus) were further 
analysed for expression of GATA3 to identify the proportion of cells that had 
differentiated into the Th2 phenotype. Within the allograft draining lymph node, 
treatment with both HES and H. polygyrus infection suppressed GATA3 expression 
compared to untreated allograft recipients (0.68 fold change, p = 0.0164 and 0.48 
fold change, p = 0.0004, respectively) (Figure 3-11, A). However, within the splenic 
CD4+ T cell population, treatment with HES and H. polygyrus precipitated opposite 
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effects on GATA3 expression: whilst HES was suppressive (0.78 fold change, p = 
0.011), H. polygyrus infection induced a marked increase (1.77 fold change, p < 
0.0001) (Figure 3-11, B+C).  
GATA3 expression by CD4+ T cells was significantly elevated in untreated allograft 
recipients compared to syngeneic skin graft recipient control mice, both in the 
allograft draining lymph node (3.16 fold change, p < 0.0001) and spleen (1.57 fold 
change, p = 0.0006) (Figure 3-11, A+B).  
 
3.2.12 H. polygyrus infection induces a Th2 shift that is donor 
alloantigen-specific; HES does not 
Following the finding of differential effects of HES and H. polygyrus infection on 
GATA3 expression by CD4+ T cells (Figure 3-11, B), splenocytes harvested from 
allograft recipients 21 days after transplantation were restimulated under multiple 
conditions in parallel for 72 hours at 37°C. Experimental conditions were the same as 
those described in section 3.2.9 (allografts with no treatment, continuous HES 
infusion, or infection with H. polygyrus, in addition to syngeneic graft controls). 
Restimulation with irradiated BALB/c (donor allogeneic) cells revealed a significant 
reduction of IFN-γ production (measured in the culture supernatant by ELISA) by 
splenocytes from allograft recipients treated with HES compared to those that 
received no treatment (0.58 fold change, p = 0.0005). IFN-γ production by 
splenocytes from H. polygyrus-treated allograft recipients compared to untreated 
allograft recipients was even further reduced (0.47 fold change, p < 0.0001). This 
pattern was similar to that of IFN-γ production following restimulation with soluble 
CD3 (Figure 3-12, A) and to expression of Tbet by CD4+ T cells 21 days after 
transplantation (Figure 3-9, B+D). 
Measurement of IL-4 following restimulation with irradiated BALB/c (donor 
allogeneic) cells revealed a marked increase in production by splenocytes from H. 
polygyrus-treated allograft recipients compared to untreated allograft recipients (6.02 
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fold change, p = 0.0002; Figure 3-12, B). However, no increase in IL-4 production 
was seen in splenocytes from HES-treated allograft recipients under the same 
restimulation conditions (0.28 fold change, p = 0.46). This finding provides 
corroborative evidence of the key difference between treatment with HES and H. 
polygyrus infection in inducing Th2 differentiation indicated by GATA3 expression 
(Figure 3-11, B) and, further, indicates that this difference in CD4+ phenotype 
induction affects the alloreactive T cell population. 
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Figure 3-1  H. polygyrus and HES prolong survival of fully-allogeneic skin grafts
(A) Appearances of full-thickness BALB/c to C57BL/6 full-thickness skin grafts. Grafts of 
1 cm2 tail skin were transplanted onto the recipient animal's left flank and monitored daily 
from day 7 (upon removal of dressings) onwards. The end point for rejection was allograft 
dehiscence (as shown) or complete necrosis of >95% of the allograft surface area.
(B) Kaplan-Meier curve of full-thickness skin graft survival: allograft only (BALB/c to 
C57BL/6 skin graft, n = 26), allograft + H. polygryus (BALB/c to C57BL/6 skin graft with 
simultaneous infection with 200 H. polygyrus stage 3 larvae by oral gavage, n = 28), and 
syngeneic grafts (C57BL/6 to C57BL/6 skin graft controls, n = 6). Mantel-Cox comparison 
of allograft vs. allograft + H. polygyrus survival curves: p < 0.0001. Data shown 
comprised of four independent experiments.
(C) Kaplan-Meier curve of full-thickness skin graft survival: allograft only (BALB/c to 
C57BL/6 skin graft, n = 13), allograft + H. polygryus (BALB/c to C57BL/6 skin graft with 
simultaneous infection with 200 H. polygyrus stage 3 larvae by oral gavage, n = 14), 
allograft + HES (BALB/c to C57BL/6 skin graft with simultaneous implantation of an 
intraperitoneal osmotic minipump eluting 2.6 µg/day of HES, n = 13) and syngeneic grafts 
(C57BL/6 to C57BL/6 skin graft controls, n = 3). Mantel-Cox comparison of allograft vs. 
























































grade assigned to the graft at the time the biopsy was
taken. As can be seen in Fig. 1A, acute rejection was
ongoing in 21 (39%) of 54 skin biopsy specimens ob-
tained from flaps which appeared normal on visual
inspection. Of the 17 biopsies with histologic Grade 1
rejection, 3 were Day 0 specimens and 9 were obtained
from grafts that had demonstrated prior visual evi-
dence of rejection (! Grade 1). In the remaining 5
specimens from two pigs (Nos. 2 and 8), acute rejection
was subsequently detectable by visual criteria (!
Grade 1) when the histologic grade was 2. Finally, in
all 4 biopsies with visual Grade 0/histologic Grade 2 or
3, rejection was detectable by inspection of the graft at
the time of prior biopsy from the same animals dem-
onstrating the same or lower histologic grade.
Of 23 biopsy specimens in grafts with visual Grade 1
rejection, 4 (18%) had no evidence of rejection histolog-
ically (Fig. 1B). Interestingly, these specimens were
obtained from three grafts which did indeed develop
biopsy-proven histologic Grade 1 or 2 skin rejection 3 to
5 days later. In contrast, 7 specimens (30%) demon-
strated a more advanced rejection grade (2 or 3) histo-
logically. Twenty (96%) of 21 biopsies taken from flaps
with visual Grade 2 rejection were noted to be within
!1 histologic grade on pathologic examination (Fig.
1C). Only a single specimen was found to be rejection-
free by histologic criteria. Finally, specimens obtained
from grafts with visual Grades 3 and 4 were highly
predictive of the presence of moderate to severe (!
Grade 2) histologic rejection (Figs. 1D and 1E). In fact,
the biopsy specimens with visual Grade 3/histologic
Grade 1 and visual Grade 4/histologic Grade 2 were
both taken from the same pig (No. 7) at the time of
development of a large seroma within the flap, likely
accounting for the observed discrepancy between the
scoring systems.
Table 4 examines the clinical usefulness of the rejec-
tion grading systems with regard to detection of acute
rejection in the treatment group. In 3 of the 10 animals
(Nos. 5, 6, and 9), the first visual and histologic signs of
rejection appeared simultaneously. In two pigs (Nos. 1
and 3), visual signs of rejection preceded histologic
diagnosis by 3 and 5 days, respectively, and rejection
was of mild severity (Grade 1) when it did appear on
biopsy. In 5 animals, a histologic picture of mild Grade
1 rejection appeared on biopsy before any noticeable
changes in the skin surface. In 3 of these cases (Nos.
10, 7, and 4), histologic rejection as defined by our
criteria was present on Day 0 with visual changes not
evident until Days 2, 4, and 7, respectively. However,
by the time rejection was first noted to be present by
visual criteria, the rejection process had not progressed
histologically in 2 of the 3 animals (still Grade 1) and
actually reversed in 1 (Grade 0). In the remaining 2
cases (Nos. 2 and 8), rejection was already of moderate
severity (Grade 2) at the time when it first became
evident by visual criteria (on Days 10 and 68, respec-
tively), and was potentially diagnosable when it was
still Grade 1 by earlier biopsy. Pig No. 2 did ultimately
lose the graft from rejection on Day 29, with all biop-
sies from Day 2 on demonstrating at least Grade 1
rejection. Interestingly, pig No. 8 demonstrated an in-
consistent picture of Grade 1 alternating with Grade 0
rejection on biopsy specimens from Days 7 to 61 post-
operatively, with only specimens from Days 68 to 90
consistently showing Grade 2 rejection.
DISCUSSION
The skin is felt to be more susceptible to rejection
than other extremity tissues and visceral organs be-
TABLE 1
Visual Scoring System for Skin Rejection
of a CTA Flap






0 0–2 Pink """ —
1 2 Slight red """ —
2 2–4 Red "" —
3 4 Red/purple " "/—
4 7 Blue purple — "
a POD, postoperative day.
TABLE 2
Histological Scoring System for Skin Rejection of a CTA Flap





0 0–2 None None None None
1 2 None/mild None/mild Mild None/mild
2 2–4 Moderate focal Mild/moderate Mild/moderate Mild
3 4 Moderate diffuse Moderate Moderate Moderateb
4 4–7 Severe/necrosis Severe/necrosis Severe/necrosis Severe/necrosis
a POD, postoperative day.
b Focal necrosis may be present.
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Scoring: Dr Thomas Brenn, Consultant Dermatopathologist, WGH
Figure 3-2  H. polygyrus and HES ameliorate histological features of fully-allogeneic skin 
graft rejection
(A) Zdichavsky histological score of allograft rejection (each graft is accorded a score according to 
the mean value for the four parameters shown).
(B) Representative haematoxylin and eosin-stained histology sections of skin grafts 7 days after 
transplantation (from top: BALB/c to C57BL/6 allograft with no treatment, BALB/c to C57BL/6 
allograft with simultaneous implantation of intraperitoneal osmotic minipump eluting 2.6 µg/day of 
HES, BALB/c to C57BL/6 skin graft with simultaneous infection with 200 H. polygyrus stage 3 
larvae by oral gavage and C57BL/6 to C57BL/6 syngeneic skin graft controls. 
(C) Zdichavsky scores (mean ± SEM) of the experimental groups described in (B); statistical 
significance assessed by the Kruskal-Wallis test. Data shown is comprised of two independent 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Day 21 - LN: Foxp3 MFI




















Day 7 - LN: CD4+Foxp3+PD-1+


















Day 7 - LN: CD4+CD25+Foxp3+


















Day 7 - LN: CD4+Foxp3-PD-1+
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Figure 3-4  HES expands Foxp3+ Treg populations in vivo and PD-1 expression by 
Foxp3- effector CD4+ T cells
Full-thickness BALB/c to C57BL/6 skin grafts were performed for two experimental groups - 
allograft only (no additional treatment; n = 4) and allograft immediately preceded by 
implantation of a subcutaneous osmotic minipump eluting 2.6 µg/day of HES (n =4). Flow 
cytometric analysis of cells within the allograft draining (inguinal) lymph node are shown. (A) 
Treg - %CD4+CD25+Foxp3+ cells of all CD4+ cells. (B) Foxp3 mean fluorescence intensity (% 
of all CD4+Foxp3+ cells). (C) PD-1 expression (% of CD4+Foxp3- cells). (D) PD-1 expression 


























































































































































































































































































Figure 3-5  H. polygyrus and HES suppress peripheral blood serum inflammatory 
cytokines following allogeneic skin grafting
Full-thickness allogeneic (BALB/c to C57BL/6) and syngeneic control (C57BL/6 to 
C57BL/6) skin grafts were performed with the following experimental conditions: allograft 
only, allograft + HES (allograft immediately preceded by implantation of an intraperitoneal 
osmotic minipump eluting 2.6 µg/day of HES) and allograft + H. polygryus (allograft 
immediately preceded by infection with 200 H. polygyrus stage 3 larvae by oral gavage). 
Peripheral blood serum cytokines (measured by cytokine bead array) 7 days after 
transplantation are shown. Statistical significance assessed by one-way ANOVA with 







































































































































































Figure 3-6 H. polygyrus-infected allogeneic skin graft recipients develop a shift from a 
Th1 and Th17 allogeneic response to Th2 upon restimulation
(A) Splenocytes were harvested from C57BL/6 mice 21 days after transplantation of a full-
thickness BALB/c skin graft. Allograft recipients either received no treatment (n = 8) or were 
infected with 200 stage 3 H. polygyrus larvae immediately prior to skin grafting (n = 9). Isolated 
splenocytes (106) were restimulated ex-vivo for 72 hours at 37°C in duplicate with 2.5 x105, 5 
x 105, 1 x 106 irradiated (30 Gy) BALB/c (donor strain alloantigen) splenocytes or complete 
RPMI media as a control. (B) Restimulation supernatant IFN-γ concentration measured by 
ELISA. (C) Restimulation supernatant IL-17 concentration measured by ELISA. (D) 
Restimulation supernatant IL-4 concentration measured by ELISA. Data shown are 
representative of two similar experiments. Statistical significance assessed by one-way 
ANOVA with Sidak's multiple comparison test.
BALBc to C57BL/6 !
skin grafting!
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Figure 3-7  H. polygyrus-induced Th2 shift is donor alloantigen-specific
(A) As before in figure 3-6, spleens were harvested from C57BL/6 mice 21 days after transplantation 
of a full-thickness BALB/c skin graft. Allograft recipients either received no treatment (n = 5) or were 
infected with 200 stage 3 H. polygyrus larvae immediately prior to skin grafting (n = 6). Isolated 
splenocytes (106) were restimulated ex-vivo for 72 hours at 37°C in duplicate with the following 
conditions (from left): soluble CD3 (1 µg/ml), 106 irradiated BALB/c (donor strain alloantigen) 
splenocytes,  106 irradiated CBA (third party strain alloantigen) splenocytes, 106 irradiated C57BL/6 
(recipient strain syngeneic antigen) splenocytes, or complete RPMI media. (B) Restimulation 
supernatant IFN-γ concentration measured by ELISA. (C) Restimulation supernatant IL-4 
concentration measured by ELISA. (D) Restimulation supernatant IL-10 concentration measured by 
ELISA. Data shown are representative of two similar experiments. Statistical significance assessed by 
multiple unpaired t tests.



























































































Skin graft survival: 













Figure 3-8  HES-mediated allograft protection is not Th2-dependent
(A) Kaplan-Meier curve of full-thickness skin graft survival from BALB/c donor mice to wiild type 
C57BL/6 recipients, with the following experimental groups: allograft only (n = 6), allograft + HES 
(skin graft immediately preceded by implantation of an intraperitoneal osmotic minipump eluting 
2.6 µg/day of HES; n = 7) and allograft + H. polygryus (skin graft with immediately preceded by 
infection with 200 H. polygyrus stage 3 larvae by oral gavage, n = 8). Mantel-Cox comparison of 
survival curves: allograft vs. allograft + H. polygyrus, p = 0.0003; allograft vs. allograft + HES, p = 
0.002.  
(B) Kaplan-Meier curve of full-thickness skin graft survival from BALB/c donor mice to IL-4 
receptor deficient C57BL/6 (IL-4ra-/-) recipients, with the following experimental groups: allograft 
only (n = 5) and allograft + HES (identical administration to (A); n = 4). Mantel-Cox comparison of 
survival curves: allograft vs. allograft + HES, p = 0.046.
(C) Percentage of CD4+ T cells within the allograft draining lymph node expressing Foxp3 21 
days after transplantation. (D) Percentage of CD4+ T cells within the recipient mouse spleen 
expressing Foxp3 21 days after transplantation. 
(E) Representative flow cytometry plots from (C).
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Day 7 - Spleen: CD4+Tbet+ 






































Day 21 - LN: CD4+Tbet+ 




































Day 21 - Spleen: CD4+Tbet+ 
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FMO control Syngeneic graft Allogeneic graft Allogeneic graft + HES
Allogeneic graft 
+ H. polygyrus
0.508 35 56.4 36.7 35.3
Figure 3-9 H. polygyrus and HES suppress expression of Tbet by CD4+ T cells
Full-thickness allogeneic (BALB/c to C57BL/6) and syngeneic control (C57BL/6 to C57BL/6) skin 
grafts were performed with the following experimental condition : allograft only, allograft + HES 
(allograft immediately preceded by implantation of an intraperitoneal osmotic minipump eluting 2.6 µg/
day of HES) and allograft + H. polygryus (allograft immediately preceded by infection with 200 H. 
polygyrus stage 3 larvae by oral gavage). Two independent experiments were performed to allow for 
analysis of splenic and allograft draining lymph node CD4+ T cell populations at 7 and 21 days after 
transplantation. (A) CD4+Tbet+ cells as a percentage of all CD4+ cells within the allograft draining 
lymph node 7 days after transplantation. (B) CD4+Tbet+ cells as a percentage of all CD4+ cells within 
the allograft draining lymph node 21 days after transplantation. (C) CD4+Tbet+ cells as a percentage 
of all splenic CD4+ 7 days after transplantation. (D) CD4+Tbet+ cells as a percentage of all splenic 
CD4+ 21 days after transplantation.  (E) Representative flow cytometry plots and histograms from (B), 
red shaded area indicates the Tbet expression of the allograft only group.
























































Day 7 - LN: CD4+ROR-γt+ 




































Day 7 - Spleen: CD4+ROR-γt+ 








Figure 3-10  H. polygyrus infection and HES suppress expression of ROR-γt by CD4+ T cells
Full-thickness allogeneic (BALB/c to C57BL/6) and syngeneic co trol (C57BL/6 to C57BL/6) skin grafts 
were performed with the following experimental conditions: allograft only, allograft + HES (allograft 
immediately preceded by implantation of an intraperitoneal osmotic minipump eluting 2.6 µg/day of HES) 
and allograft + H. polygryus (allograft immediately preceded by infection with 200 H. polygyrus stage 3 
larvae by oral gavage). Two independent experiments were performed to allow for analysis of splenic 
and allograft draining lymph node CD4+ T cell populations at 7 and 21 days after transplantation. (A) 
CD4+ROR-γt+ cells as a percentage of all CD4+ cells within the allograft draining lymph node 7 days after 
transplantation. (B) CD4+ROR-γt+ cells as a percentage of all CD4+ cells within the allograft draining lymph 
node 21 days after transplantation. (C) CD4+ROR-γt+ cells as a percentage of all splenic CD4+ 7 days 
after transplantation. (D) CD4+ROR-γt+ cells as a percentage of all splenic CD4+ 21 days after 
transplantation.  (E) Representative flow cytometry plots and histograms from (B), red shaded area 




































Day 21 - LN: CD4+ROR-γt+ 





































Day 21 - Spleen: CD4+ROR-γt+ 
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Figure 3-11  H. polygyrus infection and HES exert different effects on expression of 
GATA3 by splenic CD4+ T cells
(A) CD4+ T cells from the allograft draining (inguinal) lymph node of C57BL/6 mice 21 
days after transplantation of a full-thickness BALB/c skin graft or syngeneic C57BL/6 skin 
graft control. Experimental groups were as follows: allograft only (BALB/c to C57BL/6 skin 
graft, n = 6), allograft + HES (BALB/c to C57BL/6 allograft immediately preceded by 
implantation of an intraperitoneal osmotic minipump eluting 2.6 µg/day of HES, n = 6) 
and allograft + H. polygryus (BALB/c to C57BL/6 skin graft immediately preceded by 
infection with 200 H. polygyrus stage 3 larvae by oral gavage, n = 6). CD4+GATA3+ cells 
as a percentage of total CD4+ cells shown.
(B) CD4+ T cells from the spleen of the animals described in (A). CD4+GATA3+ cells as a 
percentage of total CD4+ cells shown.
(C) Representative flow cytometry plots (GATA3+ gating of CD4+ cells shown, from splenic 
populations in (B)).
Statistical significance assessed by one-way ANOVA with Dunnett's multiple comparisons 
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3.3 Discussion 
 
The results of experiments described in this chapter allow a number of novel 
conclusions to be drawn. First, treatment with H. polygyrus infection can 
successfully ameliorate allograft rejection. Infection immediately prior to the 
transplant surgery is sufficient; no period of prophylactic therapy is needed. 
Secondly, live infection with the parasite is not necessary to achieve allograft 
protection – treatment with a continuous infusion of HES also improves allograft 
survival and reduces histological features of rejection compared to allografts without 
treatment. Thirdly, in the presence of a fully-allogeneic transplant, both H. polygyrus 
and HES promote Foxp3+ Treg differentiation and suppress Th1 and Th17 effector 
CD4+ T cell phenotype differentiation. Finally, whilst allograft recipients infected 
with H. polygyrus experience a phenotypic switch of alloreactive CD4+ T cells from 
a Th1 to Th2 subtype, allograft recipients treated with HES do not, and this Th2 
response is not necessary for allograft protection. 
Allogeneic skin grafts stimulate a particularly aggressive immune response compared 
to other organ allografts138,358 and therefore present a significant challenge for 
tolerance induction therapies to overcome. For example, treatment with exogenous 
IL-2 complex enables complete tolerance (indefinite survival) of fully-allogeneic 
islet cell allografts293 but has no impact on the same strain combination of full-
thickness skin grafts (Prof Onur Boyman, personal communication). Functional 
survival scoring of the BALB/c to C57BL/6 full-thickness skin graft model used for 
many of the experiments within this chapter may therefore underrepresent the 
potential benefit of the helminth-derived treatments under investigation. However, 
the consistently robust alloimmune response generated with this model provides an 
excellent platform upon which underlying mechanisms of helminth-mediated 
immunomodulation can be investigated. Likewise, a fully-allogeneic (BALB/c to 
C57BL/6) transplant combination was employed throughout this chapter so that 
vigorous alloimmune responses could be generated for further investigation and 
serial experiments to optimise grafting techniques or treatment conditions could be 
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performed within a feasible timescale (3-4 weeks). Now that a reliable experimental 
protocol has been established, further refinement in future experiments with 
transplants across less severe allogeneic barriers will likely provide greater 
sensitivity to detect relevant immunomodulatory effects. 
As mentioned in section 3.1, full-thickness skin grafts are dependent on a 
microvascular blood supply and therefore tend to reject in a relatively stochastic 
manner. The inherent variability in this process is particularly apparent on 
histological examination at day 7 after transplantation, where individual grafts either 
resembled normal healthy skin, or were very severely inflamed (seldom between the 
two extremes) (Figure 3-2). The murine heterotopic cardiac transplantation model 
(where the left side of a donor heart is anastomosed onto a recipient animal’s 
abdominal aorta and vena cava) is fully-vascularised and therefore grafts undergo a 
more nuanced rejection process that more closely replicates the situation in human 
solid organ transplantation. Plans had been made to adopt this technique in 
Edinburgh following a period of training under the supervision of Mr Gavin 
Pettigrew at the University of Cambridge; however, quarantine concerns 
subsequently prevented the presence of H. polygyrus-infected animals in the 
microsurgical facility. Now that a recombinant H. polygyrus immunomodulator has 
been created (TGM, chapter 5), future experiments to assess the impact of TGM in 
the vascularised allograft model in Cambridge are being planned. 
Quantitative comparison of the relative efficacy of HES and live H. polygyrus 
infection in specific immunomodulatory mechanisms (e.g. suppression of Tbet) is 
difficult because the rate of production, constituent components and location of 
delivery of secreted products that comprise HES all vary throughout the natural 
history of an infection. In addition, wild type C57BL/6 mice tend to display 
significant inter-individual variation in adult worm burdens despite an identical 
inoculum of stage 3 larvae354 (Figure 4-3, I). However, it is clear that many of the 
immunomodulatory actions of H. polygyrus can be successfully recapitulated with 
HES administration, including: expansion of Foxp3+ Treg (Figure 3-8, C+D), 
suppression of Tbet expression (Figure 3-9), suppression of ROR-γt expression 
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(Figure 3-10) and suppression of IFN-γ production from alloreactive splenocytes 
(Figure 3-12). 
The observation that H. polygyrus infection potently induces GATA3 expression by 
CD4+ T cells in direct contrast to its suppression by HES (Figure 3-11) is a novel 
finding. Enhanced IL-4 production upon restimulation with donor allogeneic cells is 
also specific to allograft recipients treated with H. polygyrus infection, indicating that 
the difference between the Th2 polarising influence of H. polygyrus infection and 
HES is directly affecting the alloreactive T cell population of recipient animals. 
Preserved allograft protection with HES treatment in IL-4Rα-/- mice confirmed that 
protection afforded by HES is not dependent on a Th2 response (Figure 3-8). Finally, 
the finding that GATA3 expression by CD4+ T cells is significantly elevated in 
untreated allograft recipients compared to recipients of syngeneic control grafts 
(Figure 3-11) might suggest that H. polygyrus infection protects transplanted 








The role of helminth infections in ameliorating autoimmune disease has been subject 
to a much greater degree of investigation than in the field of transplantation. As 
discussed in section 1.2.3, observational human studies have shown convincing 
inverse associations between the natural prevalence of helminth infection and 
autoimmunity199. In addition, striking interventional cohort studies performed by 
Correale et al207,208 demonstrated a significantly lower frequency of clinical relapse 
and demyelinating lesions in patients with relapsing-remitting MS and concomitant 
helminth infection compared to a matched uninfected cohort. When helminth 
infection was cleared pharmacologically, both parameters of disease activity 
increased to the rate of uninfected patients, suggesting a causal relationship208. 
Preliminary clinical trials of therapeutic infection with live helminth larvae have so 
far failed to demonstrate a benefit, but they are understandably constrained by safety 
considerations in their scope and choice of helminth species (as discussed in sections 
1.2.5-6). No clinical trials of treatment with helminth-derived immunomodulatory 
agents have yet been performed. 
Of the 14 published studies that have investigated the effects of helminths on EAE 
(Table 1-1), 5 of these have involved treatment with helminth-derived soluble 
products (from S. japonicum229, S. mansoni230, T. spiralis226,227, T. suis227, and the 
schistosome glycan, lacto-N-fructopentaose III (LNFPIII)228). Treatment with these 
soluble mediators was capable of reducing the maximal severity of disease in EAE, 
but not of reducing the incidence or duration of disease. All have been shown to 
strongly induce Th2 responses and all except LNFPIII required an extended period of 
prophylactic administration (2 – 4 weeks) in order to influence the disease course of 
EAE. 
Two studies have been published that investigate the potential for H. polygyrus to 
ameliorate EAE. First, Wilson et al demonstrated that adoptive transfer of CD4+ or 
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CD19+ cells from the mesenteric lymph nodes of H. polygyrus-infected mice into 
C57BL/6 recipients had the effect of suppressing the maximal disease severity of 
EAE (cells were transferred immediately prior to induction of EAE)232. More 
recently, Donskow-Lysoniewska et al have shown that active infection with H. 
polygyrus powerfully suppresses disease and, unlike other helminth species that have 
been investigated in this context, H. polygyrus is capable of treating established 
disease (precipitating a marked reduction in clinical disease severity within 48 hours 
of infection)218. Investigation of the ability of HES to ameliorate EAE has so far not 
been reported. 
The aims of this chapter are to assess the feasibility of moving from infection with H. 
polygyrus toward treatment with HES and to investigate the underlying mechanisms 
that might account for any differential therapeutic efficacy between the two. 
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4.2 Results 
 
4.2.1 H. polygyrus infection suppresses experimental 
autoimmune encephalomyelitis (EAE) 
To assess the impact of H. polygyrus infection on the development and progression 
of EAE, comparison was first made between C57BL/6 mice receiving no treatment 
and an experimental group that were infected with 200 stage 3 H. polygyrus larvae 
by oral gavage. EAE was induced by immunisation with pMOG35-55 in complete 
Freund’s adjuvant (CFA) followed by two administrations of pertussis toxin, as 
outlined in Figure 4-1, A. 
Each mouse was assessed according to the classical EAE scoring system described in 
Table 2-1 and the mean scores for each day are shown in Figure 4-1, B. Daily 
monitoring revealed an incidence of classical EAE symptoms of 7 out of 11 
untreated animals, whilst none of the H. polygyrus-infected animals showed any sign 
of disease (Figure 4-1, C; p = 0.00047 as assessed by Fisher’s exact test). Analysis of 
the maximum disease score reached by each animal revealed a mean score of 1.73 (± 
0.47) in the untreated group compared to 0 in the H. polygyrus-infected group 
(Figure 4-1, C; p = 0.0047 as assessed by the Mann-Whitney U test). 
 
4.2.2 H. polygyrus infection suppresses pMOG-specific Th1 
and Th17 responses 
At the end of the clinical disease course illustrated in Figure 4-1, B (22 days after 
immunisation), the animals were culled and splenocytes were isolated for ex-vivo 
restimulation with pMOG to assess antigen-specific recall responses. Following 
suspension in complete RPMI media, 8 x 105 splenocytes were cultured in duplicate 
for 72 hours at 37 °C with ½log dilutions of pMOG35-55, from a maximum 
concentration of 30 µM. Cytokine concentrations within the culture supernatants 
were then determined by ELISA. 
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Upon restimulation, the concentrations of IFNγ (Figure 4-2, A) and IL-17 (Figure 4-
2, B) produced by splenocytes from animals that had been infected with H. polygyrus 
were both significantly lower than those from uninfected animals (p < 0.0001 for 
both cytokines, as assessed by 2-way ANOVA). By contrast, the concentration of IL-
4 produced by splenocytes from H. polygyrus-infected animals was reciprocally 
increased compared to splenocytes from uninfected controls (Figure 4-2, C). This 
pattern of an antigen-specific shift from Th1 and Th17 responses towards Th2 is very 
similar to than seen with donor allogeneic restimulation following skin grafting 
(Figure 3-6). Although the concentration of IL-4 produced in culture by splenocytes 
from H. polygyrus-infected animals following maximal pMOG restimulation is only 
2.67-fold higher than splenocytes from the same animals cultured in media alone, 
this effect is highly significant when compared to splenocytes from uninfected 
control animals (p < 0.0001, as assessed by two-way ANOVA). 
 
4.2.3 H. polygyrus-mediated protection from EAE is mostly 
Th2-dependent 
Following the observation of a pMOG-specific shift towards a Th2 response (Figure 
4-2), further experiments were performed in wild-type C57BL/6 mice and IL-4Rα-/- 
C57BL/6 mice to assess the functional significance of this effect. As before, EAE 
was induced by immunisation with pMOG in complete Freund’s adjuvant (CFA) 
followed by two administrations of pertussis toxin (outlined in Figure 4-1, A). There 
were therefore four experimental groups: wild-type C57BL/6 with no treatment (n = 
7), wild-type C57BL/6 infected with 200 stage 3 H. polygyrus larve (n = 7), IL-4Rα-/- 
with no treatment (n = 7) and IL-4Rα-/- infected with 200 stage 3 H. polygyrus larvae 
(n = 6). 
Each mouse was assessed according to the classical EAE scoring system described in 
Table 2-1 and the mean scores for each day are shown in Figure 4-3, A (wild-type) 
and Figure 4-3, B (IL-4Rα-/-). Comparison reveals a striking difference: wild-type 
animals are conferred considerable protection from EAE with H. polygyrus infection 
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(evidenced by a delayed onset and reduction in maximal disease severity), whilst the 
effect of H. polygyrus infection on IL-4Rα-/- animals is very much diminished, with a 
small delay in disease onset only.  
The incidence of symptomatic disease (score > 0) in wild-type animals was 6/7 with 
no treatment compared to 2/7 with H. polygyrus infection (Figure 4-3, C; p = 0.051), 
whilst the incidence in IL-4Rα-/- animals with no treatment was 6/7 with no treatment 
and 4/6 with H. polygyrus infection (Figure 4-3, D; p = 0.437).  
The mean maximum disease score of wild-type untreated animals was 4.7-fold 
greater than that of wild-type mice treated with H. polygyrus infection (Figure 4-3, E; 
p = 0.026), whilst the mean maximum score of treated and untreated IL-4Rα-/- mice 
showed no significant difference (Figure 4-3, F). The duration of symptomatic 
disease was not significantly reduced with H. polygyrus infection in wild-type mice 
or IL-4Rα-/- mice (Figure 4-3, G+H). 
The worm burden (number of adult worms within the duodenum and proximal 
jejunum) for each mouse was also assessed and while average numbers did not differ 
significantly, the range was found to be much greater in the wild-type animals (39 - 
172) compared to IL-4Rα-/- (98 – 115).  
Finally, the proportions of Foxp3+ Treg within the splenic CD4+ T cell population 
were assessed and no significant difference was seen at this late time point (26 days 
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4.2.4 H. polygyrus infection induces ST2 expression by 
Foxp3- effector CD4+ T cells via a Th2-dependent 
mechanism 
At the end of the EAE disease course described in section 4.2.3 (Figure 4-3, A+B), 
splenocytes were isolated from wild-type C57BL/6 and IL-4Rα-/- mice for further 
analysis by flow cytometry. 
H. polygyrus infection induced a 5-fold increase in expression of the transcription 
factor GATA3 in wild-type mice (Figure 4-4, A+C; p < 0.0001), but this effect was 
diminished in IL-4Rα-/- mice (to a 1.57-fold increase in expression, p = 0.011). MFI 
of GATA3 expression of all CD4+ cells showed the same relationship (Figure 4-4, 
B), indicated the impaired ability of IL-4Rα-/- mice to mount an effective Th2 
response to H. polygyrus infection. 
Expression of the IL-33 receptor, ST2, was also assessed and found to be 
significantly increased in response to H. polygyrus infection in wild type mice, but 
not IL-4Rα-/- (Figure 4-4, D+F), indicating a Th2-dependent mechanism. ST2 
expression by Foxp3+ Treg was unaffected by H. polygyrus infection in wild-type 
and IL-4Rα-/- mice (Figure 4-4, E+F). 
 
4.2.5 H. polygyrus infection induces PD-1 expression by 
Foxp3- effector CD4+ T cells via a Th2-independent 
mechanism 
The splenic CD4+ T cell populations described in 4.2.4 (from wild-type C57BL/6 and 
IL-4Rα-/- mice 26 days after induction of EAE) were also assessed for expression of 
Programmed Cell Death Protein 1 (PD-1).  
H. polygyrus infection was found to significantly increase expression of PD-1 by 
Foxp3- effector CD4+ T cells in wild-type C57BL/6 mice and to an even greater 
extent in IL-4Rα-/- mice (1.4-fold and 1.84-fold increases, respectively), indicating a 
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Th2-independent mechanism (Figure 4-5, A+C). As with ST2, PD-1 expression by 
Foxp3+ Treg was unaffected by H. polygyrus infection in wild-type and IL-4Rα-/- 
mice (Figure 4-5, B+C). 
 
4.2.6 HES delays the onset of EAE, but is less effective than 
H. polygyrus infection in suppressing disease 
In order to deconstruct the effects of HES from the physical presence of H. polygyrus 
with live infection, C57BL/6 mice were divided into two experimental groups: one 
receiving an intraperitoneal osmotic minipump eluting 2.64 µg of HES per day and 
the other undergoing a laparotomy without minipump insertion (sham surgery) to 
control for the possible effect of a cortisol stress response. After 24 hours, both 
groups were subjected to the same EAE induction protocol as before (immunisation 
with pMOG and CFA, followed by two injections of pertussis toxin, as described in 
section 2.5). At this stage, the maximum duration of HES administration was limited 
to 14 days, due to a relative ceiling in the concentration of HES that could be 
achieved by ultrafiltration (as described in section 2.3.3). 
The animals were assessed on a daily basis according to the classical EAE scoring 
system described in Table 2-1 and the mean scores for each day are shown in Figure 
4-6, A. The morphology of the EAE curve for animals treated with HES via 
minipump bears a very close resemblance to that of IL-4Rα-/- mice treated with H. 
polygyrus infection. The incidences of symptomatic disease and maximal disease 
severity scores were not significantly different between experimental groups (Figure 
4-6, B+C). However, treatment with HES did significantly delay the onset of disease 
(by a mean of 2.15 days, p = 0.0049; Figure 4-6, D) and therefore also reduce the 
total duration of symptomatic disease (Figure 4-6, E). 
The proportions of Foxp3+ Treg within the splenic CD4+ T cell population were 
assessed and no significant difference was seen at this late time point (23 days after 
immunisation) (Figure 4-6, F).  
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4.2.7 HES promotes expression of PD-1 and ST2 by CD4+ 
Foxp3- effector T cell populations 
At the end of the EAE disease course described in section 4.2.6 (Figure 4-6, A), 
splenocytes were isolated from HES-treated and untreated mice for further analysis 
by flow cytometry. 
Analysis of the CD4+ T cell population revealed a 2.71-fold increase in PD-1 
expression by Foxp3- effector cells (p = 0.0003; Figure 4-7, A+C). PD-1 expression 
by Foxp3+ Treg was not significantly changed (Figure 4-7, B). Expression of ST2 
followed the same pattern, with a 4.02-fold increase within the Foxp3- effector cell 
population (p < 0.0001; Figure 4-7, D+F), but no significant change within the Treg 
population (Figure 4-7, E). 
 
4.2.8 HES suppresses colitis following adoptive transfer of 
naïve CD4+Foxp3- T cells into RAG1-/- recipients 
Another established model of T cell-mediated immunopathology is the T cell transfer 
model of colitis, which facilitates multiple functional outcome measures and 
objective histological assessment of pathology359. To assess the impact of HES in 
ameliorating colitis, RAG1-/- mice were divided into two experimental groups – 
receiving either no treatment, or a continuous infusion of HES via an intraperitoneal 
osmotic minipump eluting 2.64 µg/day for 14 days (maximum possible duration of 
HES administration was determined by the concentration that could be achieved). 
One day after minipump surgery (day 0), naïve CD4+ T cells were isolated from the 
spleen and peripheral lymph nodes of Foxp3-GFP reporter mice by MACS CD4+ 
positive selection followed by FACS, gating: CD4+CD25-GFP-. Following sorting, 5 
x 105 cells were adoptively transferred IV into each RAG1-/- mouse. Recipient 
RAG1-/- mice were monitored on a regular basis and treatment with HES was shown 
to ameliorate disease as evidenced by maintenance of mean body weight more than 
21 days after T cell transfer (Figure 4-8, A), a 0.42-fold change in mean pathology 
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scores (p = 0.04; Figure 4-8, B) and consistently lower mean Disease Activity Index 
scores over time (Figure 4-8, C).  
 
4.2.9 HES induces Foxp3 expression in adoptively 
transferred antigen-specific T cell populations 
For a more focussed analysis of the underlying mechanisms through which H. 
polygyrus infection and HES can modulate immune responses that are relevant to 
EAE and autoimmunity in general, the effects exerted on an adoptively transferred 
antigen-specific CD4+ T cell population were assessed. 
CD4+ T cells from DO11.10 transgenic mice (BALB/c background) are characterised 
by a T cell receptor that specifically recognises ovalbumin (OVA) peptide antigen 
that is traceable by flow cytometry (cells are KJ1-26+). For this experiment, CD4+ T 
cells were isolated from the spleens of female DO11.10 mice by MACS positive 
selection and then further purified for naïve T cells by FACS (gating on CD4+KJ1-
26+CD25-CD62Lhi). Recipient female wild-type BALB/c mice were divided into 
three experimental groups: sham surgery (laparotomy without minipump insertion), 
implantation of an intraperitoneal osmotic minipump eluting 2.64 µg of HES per day, 
or infection with 200 H. polygyrus stage 3 larvae by oral gavage. 106 Naïve DO11.10 
CD4+ T cells were adoptively transferred into recipient mice by intravenous injection 
24 hours after surgery or infection. After a further 24 hours, recipient mice were 
immunised with pOVA323-339 in CFA by bilateral subcutaneous hind limb injections 
(in an identical fashion to immunisation with pMOG for induction of EAE). 
Recipient mice were culled five days after immunisation for analysis of splenic and 
inguinal lymph node CD4+ T cell populations by flow cytometry (experimental 
design outlined in Figure 4-9, A). 
The total number of DO11.10 cells recovered from the inguinal lymph node of HES-
treated animals was significantly reduced compared to untreated controls (0.25-fold 
change, p = 0.015; Figure 4-9, B), whilst animals infected with H. polygyrus showed 
the same trend, but the difference was not statistically significant (0.5-fold change, p 
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= 0.141, Figure 4-9,B). The number of DO11.10 cells recovered from the spleens of 
recipient animals was not significantly changed following treatment with HES or H. 
polygyrus infection. 
The proportion of Foxp3+ Treg as a percentage of the transferred DO11.10 CD4+ T 
cell population was significantly increased following treatment with HES (1.82-fold 
change, p = 0.036, Figure 4-9, C). Again, animals treated with H. polgygrus showed 
the same trend, but the difference was not statistically significant (1.45-fold change, 
p = 0.273; Figure 4-9, C). The Foxp3+ Treg percentage of recovered DO11.10 CD4+ 
T cell from the spleens of recipient animals was not significantly changed by either 
treatment (Figure 4-9, D). 
 
4.2.10 H. polygyrus infection and HES suppress proliferation 
of Foxp3- effector CD4+ T cells in adoptively transferred 
antigen-specific T cell populations 
The adoptively transferred DO11.10 CD4+ T cell population described in section 
4.2.9 was further analysed for cellular proliferation by staining for the nuclear 
protein, Ki67. 
Proliferation of Foxp3+ Treg within the transferred cell population recovered from 
the inguinal lymph nodes and spleen was not significantly changed by treatment with 
HES or H. polgyurus infection (Figure 4-10, A+B). 
By contrast, treatment with HES suppressed proliferation (as assessed by Ki67 
expression) of Foxp3- effector CD4+ T cells within the transferred cell population, 
both those recovered from the inguinal lymph node (0.59-fold change, p = 0.028; 
Figure 4-10, C+E) and from the spleen (0.75-fold change, p = 0.043). H. polygyrus 
infection showed an almost identical effect, with suppression of Ki67 expression by 
transferred CD4+Foxp3- cells in both the inguinal lymph node (0.61-fold change, p = 
0.042, Figure 4-10, C+E) and the spleen (0.61-fold change, p = 0.007; Figure 4-10, 
D). 
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4.2.11 Identification and recombinant production of the TGF-β 
mimic within HES 
Since the confirmation of TGF-β activity within HES233, much attention has focussed 
on the identification of the component molecule mediating this effect. Given the 
considerable number of proteins and other molecules within HES, and the fact that 
none has any resemblance of TGF-β, a reductionist approach was required. As shown 
in Figure 4-11, the components of HES were separated by charge and size 
fractionation so that individual fractions could be assessed for TGF-β activity (with 
the MFB-F11 bioassay, described in Figure 5-1). One fraction from each technique 
was found to be active and 23 common component molecules were subsequently 
identified. Each of these was then optimised for expression in a HEK293 cell line 
with pSecTag2 vectors. At the end of this process (November 2014), one molecule, 
named the TGF-β mimic (TGM), was found have a near-perfect correlation with 
abundance on fractionation and TGF-β bioassay activity. TGM has a predicted 
molecular weight of 48.9 kDa, it bears little sequence homology with any other 
known peptide and it forms the basis of Chapter 5. 
 
4.2.12 Transcriptome microarray analysis of in vivo stimulated 
antigen-specific CD4+ T cells 
In assessing the impact of TGM on autoimmunity, high-throughput analysis of gene 
expression in response to treatment was adopted as a strategy to identify the broadest 
possible spectrum of immunomodulatory mechanisms that are potentially invoked by 
this protein and to guide the direction of further investigation. Microarray analysis 
also presented the potential to identify key differences between the mechanisms of 
action behind treatment with H. polygyrus infection, HES and TGM. 
Whilst H. polygyrus and HES are known to act on several innate and adaptive 
immune cell populations, this experiment focussed specifically on CD4+ T cells so 
that sufficient resolution could be achieved to aid the functional interpretation of the 
changes in gene expression observed. For the same reason, analysis of an antigen-
specific CD4+ T cell population was chosen. This did dramatically reduce the 
 
4. Autoimmunity  134 
number of cells that could be recovered for RNA extraction and analysis, but offered 
the potential benefit of considerably improved precision; changes in gene expression 
observed within this cell population were directly relevant mechanistically. 
In light of these considerations, the following experiment was performed (Figure 4-
12): treatment of wild-type BALB/c recipient mice in four experimental groups: 
intraperitoneal PBS-eluting minipump (control), intraperitoneal HES-eluting 
minipump (2.6 µg/day), intraperitoneal TGM-eluting minipump (79.2 ng/day) and 
inoculation with 200 L3 H. polygyrus by oral gavage (n = 5 per group; treatment 
conditions initiated on day -2). On day -1, antigen-specific CD4+ T cells were 
isolated from the spleens of female DO11.10 (KJ1-26+) mice by MACS positive 
selection and then further purified by FACS (gating CD4+KJ1-26+CD25-CD62Lhi). 
106 cells were then adoptively transferred (IV) into each of the wild-type BALB/c 
mice that had commenced treatment the previous day.  On day 0, each mouse was 
immunised with 20 µg pOVA (the cognate antigen for DO11.10 cells) and CFA 
containing 50 µg heat-killed M. tuberculosis. Five days after immunisation, the 
animals were culled and the transferred DO11.10 CD4+ T cell population was 
recovered by FACS (gating CD4+KJ1-26+). Cells were sorted into RNAlater and 
snap frozen on dry ice. 
Preparation of RNA for microarray analysis was performed by Dr Bob Holt (Hologic 
Ltd). RNA was prepared (amplified, fragmented, labelled and hybridised) with an 
Affymetrix GeneChip® Pico kit (according to the manufacturer’s instructions). 
Following assessment of RNA quality after amplification, the optimal 3 samples (of 
5) from each experimental group was selected for analysis on an Affymetrix 
GeneChip® Mouse Transcriptome Pico Assay 1.0.  
The Affymetrix Pico Assay is specifically designed for use with small cell samples 
and to therefore function effectively with as little as 100 pg of total RNA (as few as 
10 cells). Each of the biological replicates for this experiment was comprised of 
more than 104 cells, yet technical issues relating to low RNA yields affecting the 
array were reported and the subsequent gene expression data produced unfortunately 
exhibits such a degree of variability as to preclude meaningful comparison. A 
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summary of gene expression comparisons from this experiment is included in 
appendix B; raw p values are shown, but when corrected for the number of 
comparisons made, none of the changes in gene expression reported are statistically 
significant. Plans to repeat this experiment are underway. 
Fortunately, other approaches to characterise TGM-mediated immunomodulation 

































































Figure 4-1 H. polygyrus infection suppresses experimental autoimmune encephalomyelitis 
(EAE)
(A) Experimental design: C57BL/6 mice were immunised wtih 100 µg pMOG35-55 and Complete 
Freund’s Adjuvant containing 50 µg heat-killed M. tuberculosis via bilateral hind limb subcutaneous 
injection. Pertussis toxin (PTX, 200ng in 500 µl) was administered by intraperitoneal injection at the 
time of immunization and again 48 hours later. Animals were separated into two experimental groups 
- one received no treatment and the other was infected with 200 H. polygyrus stage 3 larvae by oral 
gavage immediately prior to immunisation. Animals were monitored on a daily basis and accorded a 
score for clinical progression of disease (as per Table 2-1). (B) Mean clinical EAE disease scores over 
time (scoring system: Table 2-1). (C) Incidence of clinically symptomatic disease (i.e. animals with a 
score > 0). (D) Maximum disease score achieved by each animal at any point over the study period.
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Figure 4-2  H. polygyrus infection suppresses pMOG-specific Th1 and Th17 
responses
At the end of the disease course shown in Figure 4-1, B (22 days after immunisation), 
splenocytes were isolated from the two experimental groups of animals - pMOG EAE with 
no treatment (n = 11) and pMOG EAE with simultaneous H. polygyrus infection (n = 9). 
Isolated splenocytes (8 x 105) were restimulated ex-vivo for 72 hours at 37°C in duplicate 
with variable concentrations of pMOG suspended in complete RPMI media as shown. (A) 
Restimulation supernatant IFNγ concentration measured by ELISA. (B) Restimulation 
supernatant IL-17 concentration measured by ELISA. (C) Restimulation supernatant IL-4 
concentration measured by ELISA.
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Figure 4-3  H. polygyrus-mediated protection from EAE is partially Th2-dependent
Experimental design:  pMOG EAE was established as before (Figure 4-1, A), but in parallel 
groups of wild type C57BL/6 and IL-4 receptor deficient (IL-4Rα-/-) C57BL/6 mice. Animals 
received either no treatment (WT: n = 7; IL-4Rα-/-: n = 7) or were infected with 200 H. 
polygyrus stage 3 larvae by oral gavage immediately prior to immunisation (WT: n = 7; 
IL-4Rα-/-: n = 6). Animals were monitored on a daily basis and accorded a score for 
clinical progression of disease (as per Table 2-1). (A and B) Mean clinical EAE disease 
scores over time (scoring system: Table 2-1). (C and D) Incidence of clinically 
symptomatic disease (i.e. animals with a score > 0). (E and F) Maximum disease score 
achieved by each animal at any point over the study period.
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Figure 4-3  [Continued]
(G and H) Duration of symptomatic disease (from onset until recovery or the end of the study 
period). (I) Worm burden as assessed by the number of adult worms retrieved from the 
duodenum and jejunum at the end of the study period. (J) Percentage Foxp3+ Treg of all 
CD4+ T cells resident in the spleen (representative flow cytometry plots shown in Figure 4-4, 
F).
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Figure 4-4  H. polygyrus infection induces ST2 expression by Foxp3- effector CD4+ T cells via 
a Th2-dependent mechanism
Flow cytometric analysis of CD4+ T cells isolated from the spleens of wild type C57BL/6 and 
IL-4Rα-/- mice with either no treatment or H. polygyrus infection immediately prior to immunisation 
with pMOG to initiate EAE (Figure 4-3). Splenocytes were isolated 26 days after immunisation.
(A) Percentage GATA3 expression (of all splenic CD4+ cells). (B) MFI of GATA3 expression (of all 
splenic CD4+ cells). (C) Representative flow cytometry plots of (A). (D) Percentage ST2 expression 
(of all splenic CD4+Foxp3- cells). (E) Percentage ST2 expression (of all splenic CD4+Foxp3+ cells). 



















































Figure 4-5  H. polygyrus infection induces PD-1 expression by Foxp3- 
effector CD4+ T cells via a Th2-independent mechanism
Flow cytometric analysis of CD4+ T cell populations isolated from the spleens of mice 
from the experiment described in Figure 4-3 (pMOG EAE in parallel groups of wild 
type C57BL/6 and IL-4Rα-/- C57BL/6 mice, with animals receiving either no 
treatment, or infection with 200 H. polygyrus stage 3 larvae by oral gavage 
immediately prior to immunisation).
(A) PD-1 expression (% of CD4+Foxp3- cells). (B) PD-1 expression (% of 
CD4+Foxp3+ cells). (C) Representative flow cytometry plots from (A).
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Figure 4-6  HES delays the onset of EAE, but is less effective than H. polygyrus infection in 
suppressing disease
Experimental design: C57BL/6 mice were immunised with 100 µg pMOG and Complete Freund’s 
Adjuvant containing 50 µg heat-killed M. tuberculosis via bilateral hind limb subcutaneous injection. 
Pertussis toxin (PTX, 200ng in 500 µl) was administered by intraperitoneal injection at the time of 
immunistation and again 48 hours later. Animals were separated into two experimental groups - one 
received an intraperitoneal osmotic minipump eluting 2.6 µg/day of HES for 14 days, the other 
underwent an identical laparotomy with no minipump as a sham surgery control. Surgery was 
performed one day prior to immunisation (day -1). Animals were monitored on a daily basis and 
accorded a score for clinical progression of disease (as per Table 2-1). (A) Mean clinical EAE disease 
scores over time (scoring system: Table 2-1). (B) Incidence of clinically symptomatic disease (i.e. 
animals with a score > 0). (C) Maximum disease score achieved by each animal at any point over the 
study period. (D) Time until onset of symptomatic disease. (E) Duration of symptomatic disease. (F) 
Percentage Foxp3+ Treg of all CD4+ T cells resident in the spleen (representative flow cytomtetry plots 





























































































































































































































































































































































































































































































































































































































































































































































































Figure 4-8  HES suppresses colitis following adoptive transfer of naive CD4+Foxp3- T cells into 
RAG1-/- recipients
Experimental design: naive effector CD4+ T cells were isolated from the spleen and peripheral lymph 
nodes of Foxp3-GFP reporter mice by positive MACS selection for CD4+, followed by FACS, gating: 
CD4+CD25-GFP-. Following isolation, 5x105 T cells were adoptively transferred into RAG1-/- recipients. 
Recipient mice received either no treatment or a 14-day infusion of HES via an intraperitoneal 
minipump (eluting 2.6 µg/day of HES). Animals were monitored regularly throughout the experiment 
and colonic specimens were then prepared for histological assessment.
(A) Percentage change from body weight at the start of the experimental period.
(B) Colon histology scores, according to the scoring system described in Section 2.6.2
(C) Progression of Disease Activity Index scores over time (as described in Section 2.6.3).
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Figure 4-9 HES induces Foxp3 expression in adoptively transferred antigen-specific T cell 
populations
(A) Experimental design. Three experimental groups; Day -2: inoculation with 200 L3 H. polygyrus by 
oral gavage, insertion of intraperitoneal HES-eluting minipump and sham laparotomy control. Day -1: 
adoptive transfer (IV) of 106 naive CD4+ DO11.10 T cells. Day 0: immunisation with 20 µg pOVA and 
CFA containing 50 µg heat-killed M. tuberculosis. Day 5: cull and preparation of single cell 
suspensions from spleen and inguinal lymph nodes for analysis by flow cytometry.
(B) Number of adoptively transferred cells detected on day 5 detected in inguinal LNs and (C) 
spleen.










































































Figure 4-10 H. polygyrus infection and HES suppress proliferation of Foxp3- 
effector CD4+ T cells in adoptively transferred antigen-specific T cell populations
(A) CD4+Foxp3+ (Treg) percentage of total DO11.10 transferred cell population in 
inguinal lymph nodes and (B) spleen.
(C) Ki67+ percentage of DO11.10 Treg population in inguinal lymph nodes and (D) 
spleen.



























































Figure 4-11 Identification and recombinant production of the TGF-β mimic with HES (adapted 
from McSorley & Maizels)
Summary of experimental approach (Kara Fibley, Henry McSorley & Rick Maizels) culminating in the 
discovery of the TGF-β-like molecule within HES, named the TGF-β mimic (TGM), in November 
2014.
TGF-β activity assessed by culture with the MFB-F11 reporter cell line (described in Figure 5-1). 
Empai - exponentially modified protein abundance index.
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4.3 Discussion 
 
Infection with H. polygyrus powerfully supresses EAE in wild-type C57BL/6 mice 
and, unlike a number of other helminths that have been investigated for this 
ability219-221,223, no period of prophylactic treatment is necessary to achieve 
protection (i.e. infection on the day of immunisation with pMOG is sufficient to 
considerably reduce the incidence of symptomatic disease, Figure 4-1). Ex-vivo 
recall assays demonstrated that H. polygyrus infection in EAE induces a significant 
pMOG-specific shift from Th1 and Th17 responses towards a Th2 profile. Further 
assessment of the ability of H. polygyrus infection to ameliorate EAE with parallel 
wild-type C57BL/6 and IL-4Rα-/- experimental groups revealed that a large degree of 
the protection afforded by H. polygyrus is indeed Th2-dependent. Treatment with 
HES was much less efficacious in suppressing EAE in wild-type C57BL/6 mice than 
infection with H. polygyrus and the degree of protection afforded to HES-treated 
wild-type animals closely resembled that of IL-4Rα-/- mice treated with H. polygyrus 
infection. 
It is well established that H. polygyrus secretes a diverse array of immunomodulatory 
agents288 and any treatment with HES or therapeutic infection is therefore likely to 
engage multiple regulatory mechanisms in parallel. Accurate identification of the 
pathophysiological processes that are unique to H. polygyrus infection over and 
above administration of HES alone is not straightforward. First, the ‘secretome’ of 
stage 4 larvae (L4) is compositionally distinct from that of adult H. polygyrus 
worms360. Whether any of the additionally secreted, or omitted, components of L4 
secreted products are functionally significant is currently unknown. Secondly, 
delivery of HES by continuous infusion via an osmotic minipump provides the 
closest possible surrogate of HES secretion from H. polygyrus infection. However, in 
addition to a difference in the precise site of administration, the composition of HES 
secreted by adult H. polygyrus worms in vivo may be different to that secreted in 
vitro and numerous mediators may be lost during the HES production process or 
degraded during prolonged storage within the minipump prior to elution. Thirdly, 
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infection with H. polygyrus has been shown to markedly alter the gut microbiota361, 
but whether this effect is due to antimicrobial products within HES, or in response to 
epithelial disruption by H. polygyrus and the reaction to it, is currently unknown. 
Finally, the physical trauma caused by larval migration into the duodenal submucosa 
and their subsequent eruption back into the intestinal lumen undoubtedly stimulate a 
further immune response68, but attempts to study this in isolation by irradiating 
larvae (so that they can still migrate to the submucosa, but not mature into adulthood) 
have been frustrated by the continued ability of larvae to still secrete soluble 
products, even after considerable radiation exposure362. 
Data from Chapter 3 revealed that treatment with H. polygyrus infection induced an 
increase in serum IL-5 concentration (Figure 3-5) and marked Th2 deviation upon 
antigen restimulation (Figure 3-12), in contrast to treatment with an infusion of HES 
over the same period that did not. With the caveats described above notwithstanding, 
these observations suggest that the physical trauma caused by infection with H. 
polygyrus larvae induces a strong Th2 response, whilst exposure to HES alone does 
not. The striking similarity of the clinical course of EAE in wild-type mice treated 
with HES (Figure 4-6, A) to that of IL-4Rα-/- mice treated with H. polygyrus 
infection (Figure 4-3, B) also supports this hypothesis: IL-4Rα-/- animals treated with 
H. polygyrus are subject to the immunomodulatory effects of HES that is secreted, 
but not the strong Th2 response normally generated by the physical presence of the 
worms. Further, third stage H. polygyrus larvae migrate to the duodenal submucosa 
within 24 hours of infection357 and, if this is the origin of a strong Th2 response, then 
the relatively unique ability of H. polygyrus to suppress established EAE within 48 
hours of infection218 could be accounted for. 
PD-1 plays a critical role in regulating EAE363 and increased expression of PD-1 by 
Foxp3- effector CD4+ T cells was induced by HES in wild-type C57BL/6 mice 
(Figure 4-7, A) and by H. polygyrus infection in IL-4Rα-/- mice (Figure 4-5, A). This 
suggests that PD-1 is an immunoregulatory mechanism induced by HES in a Th2-
independent fashion and may therefore account for the small, but significant, degree 
of protection that is afforded to IL-4Rα-/- mice by H. polygyrus and wild-type 
animals by HES. 
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Expression of the IL-33 receptor complex, ST2 (IL-1 receptor-like 1) was increased 
by both HES and H. polygyrus infection in wild type C57BL/6 mice, specifically in 
the Foxp3- effector CD4+ T cell population. ST2 expression can facilitate Th2 
polarisation and has been shown to play an important role in adaptive immunity to 
intestinal nematodes364. The fact that H. polygyrus-induced expression of ST2 was 
completely ablated in IL-4Rα-/- mice (Figure 4-4, D+F), but still inducible by HES in 
wild-type animals (Figure 4-7, D+F) indicates that HES does induce Th2-dependent 
mechanisms albeit at a comparatively low level to that of live infection. 
The observation of a very small range and variance of adult H. polygyrus worm 
burdens in IL-4Rα-/- mice contrasting the wide range and variance of worm burden in 
wild-type C57BL/6 mice (Figure 4-3, I) is a consistent finding across multiple 
experiments. This suggests that the variance in worm burden in wild-type animals is 
not due to inconsistency in the inoculum of L3 larvae, but as a result of the immune 
response of the host. However, the worm burdens of individual mice have not yet 
yielded any correlation with functional outcome. For example, wild-type animals 
with the highest worm burden may be exposed to a greater concentration of HES 
(assuming each adult worm produces approximately equal amounts) and therefore 
experience the greatest degree of protection from EAE; the high worm burden may 
be a manifestation of successful modulation of the host immune response. 
Conversely, animals with the lowest worm burdens may have established the 
strongest Th2 response and therefore achieve a greater degree of protection from 
EAE as a result of cross regulation. Further study with a greater number of subjects 
is required. 
Finally, H. polygyrus and HES are known to powerfully induce Foxp3+ Treg233 and 
this is another possible mechanism of protection from EAE that needs further 
investigation with assessment of T cell populations in the periphery and central 
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5 The TGF-β mimic - TGM 
 
5.1 Introduction 
The known ability of H. polygyrus and HES to promote Foxp3+ Treg 
differentiation233 without demonstrable adverse immunological sequelae presents the 
possibility of hitherto unidentified immunomodulators that could be used as novel 
therapeutic agents. As previously discussed, clinical trials of ex-vivo expansion and 
reinfusion of autologous human Treg are currently underway but face a number of 
challenges, including accurate identification of human Treg by cell surface markers, 
the possibility of infused Treg reverting to an alloantigen-specific effector T cell 
phenotype and the requirement for considerable logistical arrangements that would 
likely limit translation of this approach into routine clinical care365. The prospect of a 
pharmacological therapy to promote Treg differentiation in vivo therefore offers 
several potential advantages. 
Although TGF-β is fundamental to the induction of peripheral Foxp3+ Treg 
differentiation317, deleterious consequences of exogenous administration including 
interstitial fibrosis and expansion of Th17 cells have tempered optimism for 
therapeutic exploitation. In addition, the regulation of TGF-β signalling is inherently 
complex and dependent on numerous interrelating factors, such that the 
pharmacokinetics of exogenous TGF-β are difficult to predict. H. polygyrus appears 
to have successfully negotiated this path, modulating the immune response of its host 
with TGF-β activity in HES that promotes its own ongoing survival233, but is 
simultaneously not overtly detrimental to the long term wellbeing of its host. 
Following the recent identification and recombinant synthesis of a TGF-β mimic 
within HES (TGM), this chapter seeks to identify the mechanisms by which TGM 
acts and to explore its immunomodulatory capabilities and potential adverse effects 
in comparison to exogenous mammalian TGF-β.  
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5.2 Results 
 
5.2.1 TGM and HES stimulate enhanced TGF-β signalling as 
detected by MFB-F11 TGF-β Bioassay 
The MFB-F11 cell line was developed by Tesseur et al by transfecting TGFb1-/- 
fibroblasts with a TGF-β-responsive reporter plasmid containing a secreted 
embryonic alkaline phosphatase reporter gene (SBE-SEAP)351, such that TGF-β 
signalling is proportional to the amount of alkaline phosphatase secreted and can be 
measured using a p-nitrophenyl phosphate substrate and absorbance at 405 nm (as 
described in section 2.10; Figure 5.1, A) 
Comparison of the relative MFB-F11 signal generated by half-log dilution gradients 
of TGF-β, TGM and HES reveals that all three induced alkaline phosphatase in a 
dose-dependent manner (Figure 5.1, B). The activity of TGM and TGF-β reached 
relative plateaus at higher concentrations, with TGM consistently inducing a 
significantly higher MFB-F11 signal than TGF-β, e.g. at 100 ng/ml, TGM = 2.46 ± 
0.16 and TGF-β = 1.48 ± 0.02, p = 0.02. The MFB-F11 signal stimulated by HES 
also exceeded the relative plateau of the TGF-β-induced signal, but required several 
log-fold higher concentrations to achieve the same signal as TGM. 
Following subsequent confirmation by gel filtration of TGM acting as a dimer, the 
MFB-F11 activity induced by TGM and TGF-β was reanalysed and presented 
against molar concentration for more accurate comparison (Figure 5.1, C; calculation 
described in section 5.2.5). As the components and relative composition of HES is 
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5.2.2 TGM Induces Greater Phosphorylation of Smad2 than 
TGF-β 
The enhanced MFB-F11 signal generated by TGM compared to TGF-β could be 
reflective of enhanced intracellular signalling arising from the TGF-β receptor 
complex, or an anomalous finding that is specific to the TGFb1-/- cells on which the 
MFB-F11 bioassay is based. In order to test this, splenocytes from wild type 
C57BL/6 mice were suspended in DMEM-2.5 and incubated for 18 hours at 37°C 
with 20 ng/ml TGF-β, 20 ng/ml TGM or DMEM-2.5 only (the concentration of 20 
ng/ml was chosen as a level at which both TGM and TGF-β reach a saturation 
plateau of MFB-F11 signal). The cells were then harvested and relative amounts of 
Smad2 and phospho-Smad2 were assessed by western blotting, as described in 
section 2.17. 
At 20 ng/ml TGF-β, the MFB-F11 signal had reached a relative plateau of maximal 
activity (Figure 5-1). Western blotting showed that 20 ng/ml TGF-β induces 
phosphorylation of Smad2, but that the level of Smad2 phosphorylation is higher 
with 20 ng/ml TGM (Figure 5-2, A-C). To address the possibility of loading error, 
the blot for phospho-Smad2 was stripped and reprobed to assess the total Smad2 
protein present (Figure 5-2, D); normalisation of phospho-Smad2 to total Smad2 
shows an identical trend (Figure 5-2, E). 
 
5.2.3 TGM initiates signalling via the Type I TGF-β receptor, 
but is not neutralised by pan-vertebrate anti-TGF-β 
monoclonal antibody 
To assess the mechanism of action of TGM, MFB-F11 cells were first co-cultured 
with TGM or TGF-β and 100 µg/ml pan-vertebrate anti-TGF-β antibody (clone 
1D11) or MOPC-21 murine IgG control. Anti-TGF-β antibody considerably 
inhibited the MFB-F11 signal generated from TGF-β, but had no impact on TGM 
(Figure 5-3, A and B). Next, a potent inhibitor of the Type I TGF-β receptor kinase, 
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SB431542, was added to culture (5 µM final concentration) and found to completely 
ablate the MFB-F11 signal from both TGF-β and TGM (Figure 5-3, C and D).  
Seven mammalian variants of the Type I TGF-β receptor have been identified and 
are known as activin receptor-like kinases (ALK) 1-7. Of these, SB431542 inhibits 
ALK4, ALK5 and ALK7366. TGF-β and the majority of other TGF-β superfamily 
ligands signal through ALK5. 
This experiment demonstrated that TGM ligates a TGF-β receptor complex that 
incorporates ALK4, ALK5 or ALK7, but is sufficiently structurally distinct from 
TGF-β as to avoid the binding of an antibody that recognises bovine, murine and all 
three human forms of TGF-β. 
 
5.2.4 TGM inhibits proliferation of naive CD4+ responder T 
cells 
Having established that TGM ligates the TGF-β receptor complex, the functional 
significance of this was first explored by assessing if TGM could inhibit in vitro 
CD4+ T cell proliferation in a similar fashion to TGF-β367. A naïve CD4+ responder T 
cell population was isolated from Foxp3-GFP transgenic mice by CD4 MACS 
positive selection, followed by flow cytometric sorting, gating on CD4+CD25-GFP-
CD62Lhi. Proliferation was assessed by thymidine incorporation after 72 hours (Figure 
5-4, A-B; method – section 2.9). 
TGM was found to inhibit CD3-mediated proliferation of naïve murine CD4+ T cells in a 
concentration-dependent fashion, with a maximal observed suppression of 88.2% at a 
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5.2.5 TGM induces de novo Foxp3 expression in naive CD4+ T 
cells and induces greater Foxp3 expression than TGF-β 
at high concentrations 
H. polygyrus  and HES have previously been shown to induce Foxp3+ Treg in vitro 
and in vivo233. After demonstrating that TGM acts in a TGF-β-like fashion and 
stimulates enhanced downstream signalling (as evidenced by MFB-F11 bioassay 
signal and phosphorylation of Smad2), the next set of experiments was designed to 
establish a) if TGM could induce Foxp3+ Treg differentiation in vitro and b) if the 
previously observed evidence of enhanced intracellular signalling would be reflected 
in the level of Foxp3 expression. 
CD4+CD25-GFP-CD62Lhi cells were isolated by MACS and FACS sorting as before 
(section 5.2.4) and cultured for 96 hours in Treg polarising conditions (section 2.11) with 
half-log dilution gradients of TGF-β or TGM. TGM was found to effectively induce 
Foxp3+ Treg differentiation: 390 nM (38.1 ng/ml) induced Treg conversion in 
90.65% (± 3.55%) of all CD4+ cells, compared to 79.65% (± 2.55%) induced by 390 
nM (10 ng/ml) TGF-β (Figure 5-5, A-C). Further, the mean fluorescence intensity of 
Foxp3 expression induced by high concentrations of TGM was found to be greater 
than that of the equivalent concentration of TGF-β (Figure 5-5, D-E). This result 
correlates with previous experiments showing evidence of ‘enhanced’ intracellular 
TGF-β signalling achieved by TGM compared to TGF-β itself. 
 
5.2.6 TGM inhibits pro-inflammatory cytokine production 
from CD3/CD28-stimulated CD4+ T cells  
In addition to analysis of Foxp3 expression, culture supernatants from the Treg 
induction assays described previously (section 5.2.5) were tested for the presence of 
IFNγ, IL-13, IL-17 and TNFα by cytokine bead array (section 2.16). All four 
cytokines were powerfully inhibited by TGM and TGF-β in a concentration-
dependent fashion (Figure 5-6), indicating another mechanism through which TGM 
can suppress inflammation. 
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5.2.7 TGM-induced Foxp3 expression is dependent on the 
Type I TGF-β receptor  
To further characterise the mechanism of TGM-mediated Foxp3 expression, Treg 
induction assays with TGM and TGF-β (section 2.11) were repeated with the 
addition of SB431542 inhibitor, pan-vertebrate anti-TGF-β antibody, or appropriate 
controls. TGF-β-mediated Foxp3 induction was considerably inhibited by both 
SB431542 and anti-TGF-β antibody (Figure 5-7, A and B); in contrast, while TGM-
mediated Foxp3 induction was inhibited by SB431542, anti-TGF-β antibody had no 
effect (Figure 5-7, C and D). This finding confirms that, despite the apparent greater 
efficacy of TGM in inducing Foxp3 compared to TGF-β, TGM-mediated Foxp3 
induction is like mammalian TGF-β, wholly dependent on the Type I TGF-β receptor 
(ALK4, 5 or 7). 
 
5.2.8 TGM-generated Foxp3+ Treg are functionally 
suppressive in vitro 
The level of Foxp3 expression by Treg has previously been shown to directly 
correlate with their suppressive capacity in vitro and in vivo333. Having found that 
high concentrations of TGM induce greater Foxp3 expression in Treg than the 
equivalent concentration of TGF-β, it was hypothesized that TGM-induced Treg are 
functionally more suppressive than TGF-β-induced Treg. 
Treg were generated under identical conditions to the assay performed in Figure 5-5 
with ‘maximal’ concentrations of TGF-β and TGM (10 ng/ml and 38.2 ng/ml, 
respectively). Treg from respective cultures were then isolated by FACS with a 
consistent gating strategy of CD4+CD25+GFP+ cells with a high degree of purity.  As 
a control population, nTreg were isolated from freshly prepared Foxp3-GFP 
transgenic mouse splenocytes using the same gating strategy. 
TGF-β-generated Treg, TGM-generated Treg and nTreg were placed in parallel Treg 
suppression assays with soluble CD3, irradiated APC and CD4+CD25-GFP-CD62Lhi 
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responder cells (as described in section 2.12). Assessment of responder cell 
proliferation by thymidine incorporation demonstrated that TGM-generated Treg are 
functionally suppressive in vitro but, under these conditions, suppressive capacity 
was equivalent to TGF-β-generated Treg (figure 5-8, A-G). 
 
5.2.9 Polyclonal anti-TGM antibody neutralises TGM, but not 
TGF-β or HES 
To further delineate the relative contribution of TGM to the immunosuppressive 
capabilities of HES, a polyclonal rat IgG antibody was raised to the recombinant 
TGM protein (Figure 5-9, A - performed by Yvonne Harcus). Anti-TGM antibody 
(purified IgG fraction) was then added to MFB-F11 bioassay cultures with serial 
dilutions of TGF-β, TGM and HES. Anti-TGM antibody neutralised the MFB-F11 
signal from TGM in a concentration-dependent fashion (Figure 5-9A), but had little 
effect on TGF-β (Figure 5-9 B) and, interestingly, also had little impact on HES 
(Figure 5-9, C). 
Although at first sight, this result would argue (a) that there is no shared epitope 
between TGM and TGF-β, and (b) that HES contains additional ‘TGF-β mimics’ to 
TGM, an important caveat must be noted. The recombinant TGM protein is 
expressed from the pSec-Tag vector which includes both the c-Myc-tag and 6-His-
tag, which may elicit most or all of the polyclonal antibody response. Generation of 
monoclonal antibodies to the TGM itself will be required to resolve this issue. 
 
5.2.10 TGM and TGF-β signal exclusively via the Type II        
TGF-β receptor; HES does not 
The possibility of additional active ‘TGF-β mimics’ was further explored with the 
use of an additional receptor inhibitor – ‘Inducer of Type II TGF-β Receptor 
Degradation-1’ (ITD-1). As previously discussed, TGF-β superfamily ligands signal 
through a TGF-β receptor complex that is formed as a heterodimer containing one 
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type I TGF-β receptor and one type II TGF-β receptor. Five forms of the type II 
TGF-β receptor are known: TGF-β receptor II (TβRII) activin receptor II, activin 
receptor IIb, bone morphogenic protein receptor II (BMPRII) and anti-Müllerian 
hormone receptor II (AMHRII)366. Of these subtypes, ITD-1 specifically induces 
proteolytic degradation of TβRII368 (Figure 5-10, A). 
ITD-1 or an equivalent concentration of DMSO control was added to MFB-F11 
bioassay cultures with serial dilutions of TGF-β, TGM and HES. Interestingly, ITD-1 
completely ablated the MFB-F11 signal generated by TGF-β (figure 5-10, B) and 
TGM (figure 5-10, C), but not that of HES (figure 5-10, D). This result suggests that 
HES does indeed contain one or more active additional TGF-β mimics that signals 
via one of the four type II TGF-β receptor subtypes other than TβRII. Notably, the 
MFB-F11 bioassay does not respond to activin351 and therefore additional ligands 
within HES are likely to act via a TGF-β receptor complex that incorporates BMPRII 
or AMHRII. 
 
5.2.11 TGM inhibits proliferation of human CD4+ T cells 
As TGM is derived from a murine parasite (H. polygyrus) and shares no sequence 
homology with mammalian TGF-β (or any other recognized protein), the degree of 
species-specificity in its mechanism of action was unknown. 
To test this, human CD4+ T cells were isolated from peripheral blood by means of a 
Ficoll gradient followed by MACS positive selection (sections 2.7.2-3). Cells were 
then labelled with CellTrace® violet and placed in culture at 37°C for 96 hours with 
a 1:1 ratio of CD3/CD28 Dynabeads® (section 2.9) and variable concentrations of 
TGM or TGF-β. At the end of the culture period, cells were acquired on a BD LSR 
Fortessa for assessment of proliferation by generational tracing. As shown in Figure 
5-11, TGM was found to inhibit proliferation in a concentration-dependent fashion to 
a similar degree as TGF-β, although in neither case was the effect as profound as 
might have been expected. Addition of SB431542 ablated the suppression of 
 
5. TGM  160 
proliferation, confirming that this effect of TGM (and TGF-β) is mediated via the 
type I TGF-β receptor (Figure 5-11, A). 
 
5.2.12 TGM induces Foxp3 expression in human CD4+ T cells 
Having found that TGM and TGFβ inhibited proliferation of human CD4+ T cells to 
a similar extent, cells from section 5.2.11 were also stained for CD25 (PE) and 
Foxp3 (AF647) expression to assess the ability of TGM to promote human Treg 
differentiation. As shown in Figure 5-12(A) the proportion of CD4+CD25+Foxp3+ 
Treg increased with TGM in a concentration-dependent fashion, to a maximum of 
84% (± 2.5%). The proportion of Treg of all CD4+ cells was similar for TGM and 
TGF-β at equivalent molar concentrations; however, at higher concentrations, the 
mean fluorescence intensity of Foxp3 expression was significantly greater in Treg 
exposed to TGM compared to TGF-β (e.g. at 12nM, MFI of 1369.5 (± 70.5) vs. 1082 
(± 27), p < 0.001; Figure 5-12, B-C). 
 
5.2.13 TGM inhibits proliferation of human CD8+ T cells 
In view of the importance of CD8+ T cells in many immune-mediated pathologies 
including allograft rejection, the impact of TGM on the proliferation of human CD8+ 
T cells was also assessed. CD8+ cells were isolated by MACS positive selection and 
labelled with CellTrace® violet as before (section 5.2.11). Cells were placed in 
culture at 37°C for 96 hours with variable concentrations of CD3/CD28 Dynabeads® 
with or without TGM or TGF-β; at the time of this experiment  the dimeric structure, 
and therefore molarity, of TGM was not known and both proteins were tested at 10 
ng/ml. Notably, TGM effectively suppressed CD8+ T cell proliferation at all 
concentrations of stimulating beads (Figure 5-13).  
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5.2.14 TGM induces myofibroblast differentiation less potently 
than TGF-β 
Despite sharing no sequence homology with TGF-β, work so far presented 
establishes that TGM ligates the TGF-β receptor complex and shows TGF-β-like 
activity on both mouse and human cells. As a result, the pro-fibrotic effect that is 
seen with TGF-β369 was predicted as an adverse effect that might limit the 
therapeutic potential of TGM. 
To address this, a collaboration was established with Dr Hannah Woodcock (Prof 
Rachel Chambers’ laboratory, University College London) to assess the ability of 
TGM to induce myofibroblast differentiation in comparison to TGF-β. 
Macromolecular crowding assays with human lung fibroblasts were performed with 
equivalent molar concentrations of TGM or TGF-β (section 2.14) to assess for 
expression of alpha-smooth muscle actin and extracellular deposition of type I 
collagen. 
This approach revealed that TGM does induce myofibroblast differentiation in 
human lung fibroblasts; however, the dose-response relationship for both alpha-
smooth muscle actin (Figure 5-14, A-C) and type I collagen (Figure 5-15, A-C) 
shows that TGM is less potent in this respect than TGF-β. Most notably, this 
relationship is the opposite of that seen with Foxp3 induction in both mouse and 
human cells. 
 
5.2.15 TGM prolongs survival of fully-allogeneic skin grafts 
To assess the functional impact of TGM in vivo, full-thickness allogeneic skin grafts 
were performed from BALB/c tail skin onto the left flank of C57BL/6 recipient 
mice, that either received no treatment, or an intraperitoneal minipump eluting 79.2 
ng/day of TGM (implanted immediately prior to skin grafting). Dressings were 
removed 7 days after transplantation and grafts were then monitored on a daily basis 
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until complete rejection, which was defined as more than 90% necrosis by surface 
area, or complete dehiscence. 
Treatment with TGM significantly prolonged allograft survival, with a median 
survival time of 13 days compared to 9 days for untreated allograft recipients (p = 
0.0136 as assessed by the Mantel-Cox test) and a hazard ratio of 0.342 (95% CI: 
0.034 – 0.463) (Figure 5-16). 
Control syngeneic (C57BL/6 to C57BL/6) skin grafts showed no signs at all of 
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5.2.16 TGM induces Foxp3 expression by CD4+ T cells in vivo 
To investigate the influence of TGM on the alloimmune response in vivo, cell 
populations from the spleen and allograft draining lymph node of skin graft recipient 
animals were analysed by flow cytometry. Two experiments were performed under 
identical conditions to allow for cellular analysis at 7 and 21 days after 
transplantation.  
Full-thickness BALB/c skin grafts were transplanted on to C57BL/6 mice in two 
experimental groups: no treatment, or implantation of an intraperitoneal osmotic 
minipump 79.2 ng/day of TGM immediately prior to transplantation. Syngeneic 
C57BL/6 to C57BL/6 skin grafts were also performed in each experiment to provide 
control cell populations.  
The mean percentage of CD4+ T cells expressing Foxp3 within the spleen and 
allograft draining lymph node was found to be greater in allograft recipients 
receiving TGM compared to untreated animals. A summary of the proportions of 
CD4+Foxp3+ cells, together with fold change as a result of TGM treatment and 




Allograft	  only	  	  
	  
%CD4+Foxp3+	  	  






compared	  to	  no	  
treatment;	  p	  value)	  
Day	  7	  LN	   14.63	   15.75	  
(1.08;	  p	  =	  0.131)	  
Day	  7	  Spleen	   21.82	   24.67	  
(1.13;	  p	  =	  0.0135)	  
Day	  21	  LN	   14.23	   16.23	  
(1.14;	  p	  =	  0.0042)	  
Day	  21	  Spleen	   18.7	   21.08	  
(1.13;	  p	  =	  0.0025)	  
Table 5-1 Foxp3 expression by CD4+ T cells of allograft recipients (comparison following 
treatment with TGM) 
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5.2.17 TGM suppresses expression of Tbet by CD4+ T cells 
CD4+ T cell populations from the spleen and allograft draining lymph node of skin 
graft recipients described in Section 5.2.16 (BALB/c skin grafts on to C57BL/6 mice 
with either no treatment or 79.2 ng/day of TGM, in addition to C57BL/6 to C57BL/6 
syngeneic control grafts) were assessed for expression of Tbet by flow cytometry. 
Treatment with TGM was found to significantly suppress Tbet expression by CD4+ T 
cells in the spleen and allograft draining lymph node of allograft recipients at both 7 
and 21 days after transplantation. A summary of the proportions of CD4+Tbet+ cells, 
together with fold change as a result of TGM treatment and associated p values (as 




Allograft	  only	  	  
	  
%CD4+Tbet+	  	  






compared	  to	  no	  
treatment;	  p	  value)	  
Day	  7	  LN	   61.75	   33.23	  
(0.54;	  p	  <	  0.0001)	  
Day	  7	  Spleen	   19.72	   11.05	  
(0.56;	  p	  =	  0.0001)	  
Day	  21	  LN	   59.62	   39.3	  
(0.66;	  p	  <	  0.0001)	  
Day	  21	  Spleen	   52.79	   39.6	  
(0.75;	  p	  =	  0.0018)	  
Table 5-2 Tbet expression by CD4+ T cells of allograft recipients (comparison following 
treatment with TGM) 
 
5.2.18 TGM suppresses expression of ROR-γt by CD4+ T cells 
CD4+ T cell populations from the spleen and allograft draining lymph node of skin 
graft recipients described in Section 5.2.16 (BALB/c skin grafts on to C57BL/6 mice 
with either no treatment or 79.2 ng/day of TGM, in addition to C57BL/6 to C57BL/6 
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syngeneic control grafts) were further assessed for expression of ROR-γt by flow 
cytometry. 
Treatment with TGM was found to significantly suppress ROR-γt expression by 
CD4+ T cells in the allograft draining lymph node of allograft recipients 7 days after 
transplantation, and to suppress expression by splenic CD4+ T cells at both 7 and 21 
days after transplantation. A summary of the proportions of CD4+ROR-γt+ cells, 
together with fold change as a result of TGM treatment and associated p values (as 




Allograft	  only	  	  
	  
%CD4+ROR-­‐γt	  +	  	  




%CD4+ROR-­‐γt	  +	  	  
(fold	  change	  
compared	  to	  no	  
treatment;	  p	  value)	  
Day	  7	  LN	   6.18	   3.86	  
(0.62;	  p	  =	  0.0001)	  
Day	  7	  Spleen	   6.24	   5.44	  
(0.87;	  p	  =	  0.0001)	  
Day	  21	  LN	   26.85	   19.11	  
(0.71;	  p	  =	  0.326)	  
Day	  21	  Spleen	   14.93	   5.472	  
(0.37;	  p	  =	  0.0012)	  
Table 5-3 ROR-γt expression by CD4+ T cells of allograft recipients (comparison following 
treatment with TGM) 
 
5.2.19 TGM suppresses expression of GATA3 by CD4+ T cells 
H. polygyrus and HES were previously shown to exert different effects on splenic 
CD4+ T cells in respect to Th2 polarisation (Figure 3-11 and Figure 3-12). To assess 
the impact of TGM on Th2 polarisation, CD4+ T cells from the spleen and allograft 
draining lymph node of skin graft recipients (BALB/c skin grafts on to C57BL/6 
mice with either no treatment or 79.2 ng/day of TGM, in addition to C57BL/6 to 
C57BL/6 syngeneic control grafts) were assessed for GATA3 expression at 21 days 
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after transplantation. Flow cytometric analysis revealed that TGM significantly 
suppresses GATA3 expression by CD4+ T cells in both the allograft draining lymph 
node (0.49-fold change, p < 0.0001) and the spleen (0.73-fold change, p = 0.0093). 
 
5.2.20 TGM suppresses IFNγ and IL-4 production upon 
restimulation 
To assess the affect of TGM on antigen-specific immune responses, splenocytes 
harvested from allograft recipients 21 days after transplantation were restimulated 
under multiple conditions in parallel for 72 hours at 37°C. Experimental conditions 
were the same as those described in section 5.2.19 (allografts with no treatment or 
treatment with 79.2 ng/day TGM by continuous infusion, in addition to syngeneic 
graft controls). 
Restimulation with irradiated BALB/c (donor allogeneic) cells revealed a significant 
reduction of IFN-γ production (measured in the culture supernatant by ELISA) by 
splenocytes from allograft recipients treated with TGM compared to those that 
received no treatment (0.55-fold change, p = 0.0018; Figure 5-21, A). The same 
effect on IFN-γ production was observed following restimulation with soluble CD3 
(0.55-fold change, p < 0.0001; Figure 5-21, A) and correlates with expression of 
Tbet by CD4+ T cells 21 days after transplantation (Figure 5-18, D). 
Measurement of IL-4 following restimulation with irradiated BALB/c (donor 
allogeneic) cells revealed significant suppression of IL-4 production from 
splenocytes of TGM-treated allograft recipients compared to untreated animals 
(0.13-fold change, p = 0.0006; Figure 5-21, B). The same effect was seen following 
restimulation with soluble CD3 and culture with syngeneic C57BL/6 cells (Figure 5-
21, B). TGM-induced suppression of IL-4 secretion is similar to the effect of HES 
(Figure 3-12) and correlates with TGM-induced suppression of GATA3 expression 




















































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5-2  TGM Induces Greater Phosphorylation of Smad2 than TGF-β
(A) Western blots (Smad2 and phospho-Smad2): cell lysates from C57BL/6 splenocytes following 
culture at 37°C for 18 hours. Culture conditions in duplicate: media (DMEM-2.5), media 
supplemented with 20 ng/ml TGF-ß and media supplemented with 20 ng/ml TGM.
(B) Densitometry analysis of bands with Image Studio (version 5, Li-Cor).
(C) Densitometric quantification of phospho-Smad2.
(D) Densitometric quantification of Smad2.
(E) Ratio of phospho-Smad2 normalised to Smad2.














































































































































































































































































































































































































































































































































































Effect of TGM on CD4+Foxp3- T cells
















































% Suppression of CD4+ Tresp
(Co-culture of TGM with αCD3 and irradiated APCs)
Figure 5-4  TGM inhibits proliferation of naive CD4+ responder T cells
(A) Experimental design: a single cell suspension from Foxp3-GFP reporter mouse spleen 
and peripheral lymph nodes was enriched for CD4+ cells by MACS positive selection and 
then sorted for CD4+CD25-GFP-CD62Lhi cells by FACS to provide a naive CD4+ responder 
cell population. The negative fraction of the MACS sort was irradiated (30 Gy) to provide a 
population of APCs without the capacity to proliferate. In triplicate wells of a 96 well plate 
round bottom plate, 104 responder cells were added to 105 APCs, 1 μg/ml CD3 and a 
variable concentration of TGM. Proliferation was assessed by adding thymidine for the last 
18 hours of a 5 day culture at 37°C and measuring H3 incorporation.
(B) Proliferation according to thymidine (H3) incorporation.
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400 pM 126 pM 40 pM 12.6 pM 4 pM 1.26 pM 0.4 pM
Figure 3- Flow cytometric analysis of murine T cells following five days of in vitro stimulation with plate-bound CD3/CD28. T cells from C57BL/6 Foxp3-
GFP reporter mice were FACS sorted: CD4+CD25-Foxp3-CD62Lhi and then placed in culture with 100 U/ml IL-2 and variable concentrations of rhTGF-
β or TGM as shown. (A+B): At equivalent molar concentrations, TGM stimulates a higher mean fluorescence intensity of Foxp3 expression 
compared to TGF-β (400 pM = 10 ng/ml TGF-β = 38.2 ng/ml TGM). (C and D): TGM induces CD4+CD25+Foxp3+ Treg in a dose-dependent 
fashion similar to that of TGF-β.
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Figure 5-5  TGM induces de novo Foxp3 expression in naive CD4+ T cells and induces 
greater Foxp3 expression than TGF-β at high concentrations
(A) CD4+CD25-GFP-CD62Lhi naive T cells were isolated as before (figure 5-4) and stimulated with 
plate-bound CD3/CD28 for 4 days in culture with 100 U/ml IL-2 and variable concentrations of 
TGF-β or TGM. Flow cytometry plots from the end of the culture period (CD4+ population shown).
(B and C) Treg induction (expressed as a percentage of total CD4+ cells)
(D) Histogram overlay showing Foxp3 expression following culture conditions described above 
with comparison of 400 μM TGM, 400 μM TGF-β, or 100 U/ml IL-2 only.


































































































































































































































































































Figure 5-6  TGM inhibits pro-inflammatory cytokine production from CD3/CD28-
stimulated CD4+ T cells 
Concentrations of (A) IFNγ, (B) IL-17, (C) IL-13 and (D) TNFα present in culture 
supernatants from Treg induction assays shown in figure 5-5, measured by 

































































































































































































































































































































































































































































































































































































































































Comparison of iTreg suppressive ability 




















































































































































































































































































Figure 5-8  TGM-generated Foxp3+ Treg are functionally suppressive in vitro
Foxp3+ Treg were generated in vitro (as described in figure 5-4) with 38.2 ng/ml TGM or 10 
ng/ml TGF-β. After four days of culture, CD4+CD25+GFP+ cells were isolated by FACS. A 
single cell suspension was then freshly prepared from Foxp3-GFP mice to provide naive 
CD4+CD25-GFP- responder cells and CD4+CD25+GFP+ tTreg as a control population. Treg 
were cultured with responder cells, irradiated APCs and soluble CD3 for 5 days and 
proliferation was assessed by thymidine incorporation (section 2.9).
(A) Comparison of percentage suppression (in relation to responder cells with APC, CD3 
and no Treg) of TGM-generated iTreg and TGF-β-generated iTreg. (B-D) Proliferation as 
assessed by thymidine incorporation. (E-G) Percentage suppression (in relation to 
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Figure 5-11  TGM inhibits proliferation of human CD4+ T cells
Human peripheral blood mononuclear cells were separated from red blood cells 
over a Ficoll gradient, CD4+ T cells were then isolated by MACS positive 
selection and then labeled with CellTrace® violet for generational tracing. 
Isolated cells were cultured at 37°C for 96 hours with a 1:1 ratio of CD3/CD28 
Dynabeads® and the additional conditions shown.
(A) Overlay histograms showing generational trace of CD4+ cells with stimulation 
only (red), or stimulation with TGF-β (blue) or TGM (green) at the concentrations 
shown, with or without stimulation with the Type I TGF-β receptor inhibitor, 
SB431542. 
(B) Percentage of CD4+ cells shown in (A) that have proliferated to six 
generations or more, plot against molar concentration of TGM or TGF-β.  
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Figure 5-12  TGM induces Foxp3 expression in human CD4+ T cells
Human peripheral blood mononuclear cells were separated from red blood cells 
over a Ficoll gradient and CD4+ T cells were then isolated by MACS positive 
selection. Isolated cells were cultured at 37°C for 96 hours with a 1:1 ratio of CD3/
CD28 Dynabeads® and variable concentrations of TGF-β or TGM. 
(A) Treg induction (expressed as a percentage of total CD4+ cells against molar 
concentration of TGM or TGF-β)
(B) Mean fluorescence intensity of Foxp3 expression (of Foxp3+ cells) against 
molar concentration of TGM or TGF-β.
(C) Representative flow cytometry plots (CD4 population shown).
IL-2 only
Figure 5-13  TGM suppresses human CD8+ T cell proliferation
CD8+ T cells isolated from human peripheral blood by ficoll gradient separation 
followed by positive MACS selection. Cells were cultured for 96 hours with variable 
concentrations of CD3/CD8 Dynabeads® with or without 10 ng/ml TGM or TGF-β 
(as shown). Histograms of cell division, as assessed by generational tracing with 
CellTrace® violet.
Human CD8+ T cell Proliferation 
1:64 1:32 1:16 1:8CD3/CD28 !bead : cell ratio
CD3/CD28 only 
CD3/CD28 + 10 ng/ml TGF-β 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5-16  TGM prolongs survival of fully-allogeneic skin grafts
Kaplan-Meier curve of full-thickness skin graft survival: allograft only (BALB/c to 
C57BL/6 skin graft, n = 6), allograft + TGM (BALB/c to C57BL/6 skin graft immediately 
preceded by implantation of an intraperitoneal osmotic minipump eluting 79.2 ng/day 
of TGM, n = 6) and syngeneic grafts (C57BL/6 to C57BL/6 skin graft controls, n = 3). 
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Figure 5-17 TGM induces Foxp3 expression by CD4+ T cells in vivo
Full-thickness allogeneic (BALB/c to C57BL/6) and syngeneic control (C57BL/6 to 
C57BL/6) skin grafts were performed with the following experimental conditions: 
allograft only or allograft + TGM (allograft immediately preceded by implantation of an 
intraperitoneal osmotic minipump eluting 79.2 ng/day of TGM). Two independent 
experiments were performed to allow for analysis of splenic and allograft draining 
lymph node CD4+ T cell populations at 7 and 21 days after transplantation. (A) 
Percentage of CD4+ T cells within the allograft draining lymph node expressing Foxp3 
7 days after transplantation. (B) Percentage of CD4+ T cells within the allograft draining 
lymph node expressing Foxp3 21 days after transplantation. (C) Percentage of CD4+ T 
cells within the spleen expressing Foxp3 7 days after transplantation. (D) Percentage 
of CD4+ T cells within the spleen expressing Foxp3 21 days after transplantation. (E) 
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Figure 5-18 TGM suppresses expression of Tbet by CD4+ T cells
Full-thickness allogeneic (BALB/c to C57BL/6) and syngeneic control (C57BL/6 to C57BL/6) skin 
grafts were performed with the following experimental conditions: allograft only or allograft + TGM 
(allograft immediately preceded by implantation of an intraperitoneal osmotic minipump eluting 79.2 
ng/day of TGM). Two independent experiments were performed to allow for analysis of splenic and 
allograft draining lymph node CD4+ T cell populations at 7 and 21 days after transplantation. (A) 
CD4+Tbet+ cells as a percentage of all CD4+ cells within the allograft draining lymph node 7 days 
after transplantation. (B) CD4+Tbet+ cells as a percentage of all CD4+ cells within the allograft 
draining lymph node 21 days after transplantation. (C) CD4+Tbet+ cells as a percentage of all 
splenic CD4+ 7 days after transplantation. (D) CD4+Tbet+ cells as a percentage of all  splenic CD4+ 
21 days after transplantation.  (E) Representative flow cytometry plots and histograms from (B), red 
shaded area indicates the Tbet expression of the allograft only group.
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Figure 5-19 TGM suppresses expression of ROR-γt by CD4+ T cells
Full-thickness allogeneic (BALB/c to C57BL/6) and syngeneic control (C57BL/6 to C57BL/6) skin 
grafts were performed with the following experimental conditions: allograft only or allo raft + TGM 
(allograft immediately preceded by implantation of an intraperitoneal osmotic minipump eluting 79.2 
ng/day of TGM). Two independent experiments were performed to allow for analysis of splenic and 
allograft draining lymph node CD4+ T cell populations at 7 and 21 days after transplantation. (A) 
CD4+ROR-γt+ cells as a percentage of all CD4+ cells within the allograft draining lymph node 7 days 
after transplantation. (B) CD4+ROR-γt+ cells as a percentage of all CD4+ cells within the allograft 
draining lymph node 21 days after transplantation. (C) CD4+ROR-γt+ cells as a percentage of all 
splenic CD4+ 7 days after transplantation. (D) CD4+ROR-γt+ cells as a percentage of all splenic CD4+ 
21 days after transplantation.  (E) Representative flow cytometry plots and histograms from (B), red 
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Figure 5-20 TGM suppresses expression of GATA3 by CD4+ T cells
(A)  CD4+ T cells from the allograft draining (inguinal) lymph node of C57BL/6 
mice 21 days after transplantation of a full-thickness BALB/c skin graft or 
syngeneic C57BL/6 skin graft control. Experimental groups: allograft only (BALB/
c to C57BL/6 skin graft, n = 6), allograft + TGM (BALB/c to C57BL/6 allograft 
immediately preceded by implantation of an intraperitoneal osmotic minipump 
eluting 79.2 ng/day of TGM, n = 6). CD4+GATA3+ cells as a percentage of total 
CD4+ cells shown.
(B) CD4+ T cells from the spleen of the animals described in (A). CD4+GATA3+ 
cells as a percentage of total CD4+ cells shown.
(C) Representative flow cytometry plots (GATA3+ gating of CD4+ cells shown, 
from splenic populations in (B)).
Statistical significance assessed by two-tailed t tests. FMO - fluorescence minus 
one.















Figure 5-21  TGM suppresses IFNγ and IL-4 production upon restimulation
Splenocytes were harvested from C57BL/6 mice 21 days after transplantation of a full-
thickness BALB/c skin graft or syngeneic control graft. Experimental groups were: allograft 
only and allograft + TGM (allograft immediately preceded by implantation of an 
intraperitoneal osmotic minipump eluting 79.2 ng/day of TGM). Isolated splenocytes (106) 
were restimulated ex-vivo for 72 hours at 37°C in duplicate with the following conditions 
(from left): soluble CD3 (1 µg/ml), 106 irradiated BALB/c (donor strain alloantigen) 
splenocytes,  106 irradiated CBA (third party strain alloantigen) splenocytes, 106 irradiated 
C57BL/6 (recipient strain syngeneic antigen) splenocytes, or complete RPMI media. (A) 
Restimulation supernatant IFNγ concentration measured by ELISA. (B) Restimulation 
supernatant IL-4 concentration measured by ELISA. Statistical significance assessed by 
two-tailed, unpaired t tests.
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5.3 Discussion 
The experimental results described in this chapter reveal that TGM not only mimics 
the action of TGF-β, but also exhibits a number of properties that promote it as a 
more therapeutically tractable mediator than TGF-β itself. 
Despite ligating the TGF-β receptor complex, TGM is structurally distinct from the 
TGF-β molecule - it shares no sequence homology with TGF-β, is almost four times 
greater in size and is not recognised by pan-vertebrate anti-TGF-β antibodies. This in 
itself could be of significant therapeutic relevance – in vitro, TGM has been shown to 
stimulate enhanced downstream signalling compared to TGF-β (as evidenced by 
elevated MFB-F11 signal, Smad2 phosphorylation and Foxp3 expression). The 
mechanism behind this effect is currently unknown, but may be as a result of 
differing receptor binding kinetics or of TGM failing to ligate pseudoreceptors such 
as BAMBI327 on the cell surface. In vivo, TGM is constitutively active – unlike TGF-
β, it has no requirement for enzymatic cleavage and may evade further regulatory 
mechanisms such as the binding of ‘ligand trap’ proteins, which would allow for 
therapeutic dose-response titration that is not possible with exogenous TGF-β. 
Grainger et al previously demonstrated that blockade of TGF-β signalling boosts 
immunity to H. polygyrus infection (as demonstrated by reductions in worm burden), 
whilst antibody-mediated neutralisation of circulating host TGF-β has no effect233. 
Thus, it seems that parasite-derived TGF-β activity plays a vital role in the 
immunomodulation required for successfully establishing chronic infection and it is 
possible that TGM is the key mediator involved in this process. Figure 5-9 shows 
that a polyclonal antibody to recombinant TGM neutralises the MFB-F11 signal of 
TGM but not HES. If TGF-β activity is evolutionarily crucial, TGM may belong to a 
family of products, each of which are individually redundant - the other homologues 
of TGM that have been identified within HES may exhibit as much, or greater, TGF-
β-like activity. Failure to neutralise HES by anti-TGM antibody may instead be due 
to antibody binding of extraneous epitopes in recombinant TGM arising from the 
pSecTag expression vectors (e.g. His-tag or Myc-tag) that are not present in naturally 
produced TGM within HES. Western blots of HES probed with anti-TGM antibody 
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failed to answer this question due to extensive non-specific binding of control IgG to 
HES proteins (data not shown). However, selective blockade of the TβRII subtype of 
the type II TGF-β receptor family (with the inhibitor ITD-1) completely blocked the 
MFB-F11 signal arising from TGM and TGF-β, but not HES (Figure 5-10). This 
strongly suggests that additional TGF-β-like homologues are present within HES and 
signal via a different heteromeric combination of type I and type II TGF-β receptors. 
Expression of the additional known TGM homologues is currently underway. 
The novel finding that TGM induces elevated expression of Foxp3 compared to the 
maximum achieved with TGF-β in both murine (Figure 5-5) and human (Figure 5-
12) CD4+ T cells may have a number of implications. In terms of human Treg 
induction, further optimisation of in vitro assays is required to definitively assess the 
potential of TGM – the assay described in Figure 5-12 assessed Treg composition of 
a whole CD4+ population in culture and therefore the Treg expansion seen with TGM 
(and TGF-β) is likely a combination of both de novo Foxp3 expression in induced 
pTreg and proliferation of tTreg. Further experiments are needed with naïve CD4+ 
cells (CD4+CD25-CD62Lhi isolated by FACS), lower levels of CD3/CD28 
stimulation and addition of exogenous IL-2 to culture media. 
Intensity of Foxp3 expression by Treg has previously been shown to directly 
correlate with suppressive ability333. The suppression assay described in Figure 5-8 
showed TGM-induced Treg to be equal to TGF-β-induced Treg in terms of 
suppressive ability, but this in vitro assay may be insufficiently sensitive to detect 
subtle differences – further investigation with in vivo models is required. High 
concentrations of TGF-β are known to promote Treg over Th17 differentiation342. 
TGM appears to be a more potent ligand than TGF-β and may therefore tip the 
balance away from Th17 differentiation; suppression of ROR-γt expression by TGM 
in allogeneic skin graft recipients supports this (figure xx). Finally, further 
investigation is required to determine whether enhanced intensity of Foxp3 
expression promotes stability of the Treg phenotype, particularly in the presence of 
inflammatory cytokines such as IL-6. 
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In the context of wound healing, enhanced collagen deposition could be potentially 
beneficial during the course of H. polygyrus infection. It is possible that TGM plays 
a role in repairing the intestinal damage caused by H. polygyrus migrating through to 
the subserosal layer, but this is unlikely because TGM suppresses Th2 cytokines 
(which are fundamentally required for effective wound healing in helminth 
infection370) and, in direct contrast to induction of Foxp3, TGM is less efficacious 
than TGF-β in inducing myofibroblast differentiation as demonstrated by alpha 
smooth muscle actin expression and collagen deposition (Figures 5-14 and 5-15). 
Whilst HES contains numerous immunomodulatory mediators in addition to TGM 
that likely act to some degree synergistically, recombinant TGM offers several 
advantages including scalable production, a definable mechanism of action and the 
opportunity for modification to reduce immunogenicity and optimise 
pharmacokinetic characteristics for pharmacological use.  
Furthermore, combination of TGM with currently available immunomodulatory 
agents may be a viable future therapeutic strategy. In particular, combining 
rapamycin or retinoic acid with the potent and predictable TGF-β activity of TGM 
could help to promote Treg over Th17 differentiation. Compared to TGF-β, TGM 
has been shown to be more efficacious in inducing Foxp3 and less so at inducing 
myofibroblast differentiation – this relationship is particularly encouraging for the 
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6 Final Discussion 
 
The development of organ transplantation has revolutionised the treatment of 
numerous diseases, transforming and extending the lives of millions of patients 
worldwide. However, the almost ubiquitous necessity for life-long 
immunosuppression remains problematic. A considerable proportion of the precious 
resource of transplanted organs is lost to rejection every year371. Further, patients are 
exposed to an array of serious adverse effects that are frequently life-limiting141. 
Until recently, the decision to accept this therapeutic risk profile has been 
straightforward, given the alternative of imminently life-threatening organ failure or 
the significant risk of mortality with dialysis15. However, the advent of hand, face 
and other non-life-extending transplants has posed a conspicuous challenge to the 
principle of nonmalificence in this regard and highlighted the need for novel 
alternatives to currently employed immunosuppression regimens372. 
This thesis has explored the potential of Heligmosomoides polygyrus and its secreted 
products to counteract allo- and autoimmune responses. Whilst the overarching focus 
has been on transplantation, study of the autoimmune model, EAE, has provided 
some key additional insights. Many of the currently available immunosuppressant 
agents are utilised in combating both allograft rejection and autoimmune conditions, 
and it is anticipated that emerging novel therapeutic agents could be of benefit in 
both clinical settings also. 
Chapter 3 began by demonstrating for the first time that infection with H. polygyrus 
is capable of prolonging the viability of a transplanted allograft. This effect was then 
recapitulated by administration of HES, confirming that allograft protection is 
resulting from the action of a soluble mediator (or mediators) secreted by the 
helminth; its physical presence (i.e. live infection) is not necessary. Further 
experiments demonstrated that infection with H. polygyrus polarised alloimmune 
Th1 and Th17 responses towards a Th2 phenotype. HES suppressed Th1 and Th17 
differentiation but did not induce allograft-specific Th2 responses. Contrary to the 
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proposed mechanism of allograft protection afforded by other helminth 
species267,269,270, Th2 polarisation was shown to be unnecessary, as demonstrated by 
protection of skin grafts in allogeneic transplant combinations of IL-4Rα-deficient 
mice by administration of HES. 
Chapter 4 explored the ability of H. polygyrus and HES to ameliorate disease in the 
experimental model of multiple sclerosis, EAE. Whilst treatment with HES led to a 
delayed onset of disease, H. polygyrus was dramatically more effective, reducing the 
incidence, duration and maximal severity of disease. In contrast to the situation with 
alloimmunity, a considerable degree of the protection from EAE afforded by H. 
polygyrus infection was found to be Th2-dependent. IL-4Rα-/- mice treated with H. 
polygyrus infection experienced a delayed onset of EAE, but no reduction in the 
maximal severity of disease. This effect was very similar to that of wild-type animals 
treated with HES. Analysis of CD4+ T cell populations revealed that both H. 
polygyrus and HES promote expression of PD-1 and ST2 on the surface of Foxp3- 
effector T cells. Further assessment of the effects of H. polygyrus and HES by 
adoptive transfer of antigen-specific DO11.10 CD4+ T cells and immunisation with 
cognate antigen demonstrated that both treatments could effectively promote 
expansion of Foxp3+ Treg and suppress proliferation of the Foxp3- effector T cell 
population. 
Chapter 5 adopted a more reductionist approach to examine the cellular mechanism 
of action and functional significance of the newly identified immunomodulatory 
molecule within HES, TGM. Despite sharing no sequence homology with TGF-β, 
TGM was found to act via the TGF-β receptor complex to induce Foxp3 expression 
and suppress proliferation in both murine and human T cells. The unique structure of 
TGM compared to TGF-β was confirmed by demonstration of mutually exclusive 
neutralisation by respective specific antibodies. Important functional differences 
were also identified: TGM achieves a greater intensity of downstream signalling 
from the TGF-β receptor complex than TGF-β itself, and this relationship strongly 
correlates with the corresponding efficacy of TGM compared to TGF-β in induction 
of Foxp3 expression by CD4+ T cells. When TGM was assessed for its pro-fibrotic 
potential by culture with human lung fibroblasts, the opposite relationship was 
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observed: TGM can induce fibrosis, but is less potent is this respect than equivalent 
concentrations of TGF-β. Finally, the functional capability of TGM to ameliorate 
allograft rejection was assessed in vivo. TGM was found to significantly prolong the 
survival of fully-allogeneic skin grafts and analysis of the CD4+ T cell populations of 
allograft recipients revealed significant induction of Foxp3+ Treg in addition to 
significant suppression of Th1, Th2 and Th17 effector phenotypes. 
The data outlined above provide some novel insights into previous observations 
made in other experimental models. The vigorous Th2 immune response generated 
by H. polygyrus infection has been long recognised373 and, more recently, it has been 
shown that HES might contribute to this effect (Th2 responses can be generated by 
adoptive transfer of DCs that have been exposed to HES)374. However, the relative 
contribution of the dual stimuli of HES and intestinal trauma that are present in H. 
polygyrus infection has not been previously established.  
The observation presented here that infection with H. polygyrus larvae induces a 
strong Th2 response, but treatment with a continuous infusion of HES over the same 
timeframe does not, indicates that the dominant stimulus for Th2 immunity in vivo is 
related to the physical presence of the parasite (likely as a result of larval migration 
to the intestinal submucosa). Indeed, whereas H. polygyrus infection was found to 
significantly increase expression of GATA3 in the splenic CD4+ T cell populations 
of allograft recipients, both HES and TGM were shown to significantly suppress 
expression even compared to untreated allograft recipients. This finding reflects the 
impact of HES during a rapidly evolving alloimmune response in vivo, within a short 
timeframe and with no period of pre-treatment. It is not incongruous with the 
previously published ability of HES-treated DCs to drive Th2 immune responses374. 
In fact, this possibly explains the reported necessity of a period of pretreatment to 
successfully ameliorate EAE with soluble products from other parasite species (such 
as S. mansoni375 and T. spiralis226,227), in contrast to treatment with H. polygyrus 
infection, which can considerably ameliorate disease without any pretreatment, or 
even precipitate improvement in the clinical condition of animals with established 
disease218: generation of a Th2 response by soluble mediators indirectly via DCs 
takes time and can only influence the disease course if the DC phenotype has been 
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successfully altered prior to antigen presentation and generation of the T cell 
response. By contrast, live infection generates a powerful Th2 response directly as a 
result of intestinal trauma and can therefore suppress (through cross regulation) the 
established Th1/Th17 CD4+ T cells mediating EAE. Further investigation with 
passive models of EAE (adoptive transfer of antigen-specific T cells that have been 
polarised to a Th1 phenotype in vitro) could test this hypothesis by bypassing the 
influence of dendritic cells during antigen presentation. 
It is also clear that HES can induce a number of regulatory mechanisms in the 
absence of a Th2 response including enhanced PD-1 expression, expansion of 
Foxp3+ Treg and suppression of Th1 and Th17 differentiation. The functional 
significance of these effects appears to vary considerably with the specific disease 
model under investigation: HES appears to be similarly effective to H. polygyrus in 
protecting transplanted allografts from rejection, but much less so in ameliorating 
EAE. 
Further work to characterise the mechanism behind HES and TGM-mediated 
suppression of Th1, Th2 and Th17 effector cell phenotypes is required – this effect 
could be simply as a result of the ongoing presence of the expanded Treg population, 
or alternatively because of changes to the alloreactive CD4+Foxp3- T cell population 
itself (similar to that which is evident by the donor alloantigen-specific ‘Th2 switch’ 
in the cytokine profile of splenocytes from allograft recipients infected with H. 
polygyrus). This could be investigated by isolating the CD4+Foxp3- splenic T cell 
populations of allograft recipients prior to allogeneic restimulation for cytokine 
profile analysis, and by assessing the impact of HES and TGM in vivo following 
Treg depletion. 
When considering the translational potential of TGM and other parasite products, 
non-Th2 dependent mechanisms are likely have the greatest translational potential, 
even if the magnitude of the effect observed in experimental murine models is less 
than that of infection with H. polygyrus larvae. The current pharmacopoeia of 
immunosuppressive agents for transplantation is effective in suppressing acute 
episodes of rejection and enhancing allograft survival in the short term, but relatively 
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deficient in the ability to suppress Th17 responses and to prevent long-term graft 
dysfunction. Whilst induction of a Th2 response might enable additional suppression 
of pathological immune responses through cross-regulation (manifest as more 
effective amelioration of acute disease in animal models such as EAE), in the long 
term, alloantigen-specific Th2 responses may be detrimental to allograft function71 
(due to promotion of interstitial fibrosis) and thereby exacerbate the current clinical 
problem rather than improve it. By contrast, TGM effectively suppresses both Th17 
and Th2 differentiation and may therefore represent exactly the type of agent that is 
needed to improve long-term graft function, even if it initially needs to be co-
administered with additional synergistic immunosuppressive agents in the immediate 
post-transplantation period. 
The striking manipulation of alloantigen-specific T cell responses achieved by HES 
and TGM (as demonstrated by restimulation assays) also presents another interesting 
angle for potential therapeutic translation. In the context of living donor 
transplantation, the donor alloantigen is known (and potentially available) for some 
time before the transplant is performed. In this setting, it may be possible to 
introduce the prospective transplant recipient to the donor alloantigen in advance of 
the transplant being performed and, through simultaneous administration of TGM (or 
a derivative), to ‘reprogramme’ the alloimmune response towards a less harmful one 
than would otherwise occur. Enhanced survival of experimental rat kidney allografts 
has been previously demonstrated when the transplants are performed after repeated 
administration of donor allogeneic splenocytes by oral gavage or injection into the 
prospective transplant recipient’s portal vein376. Combination of this technique with 
TGM to further manipulate the alloimmune response might maximise the potential 
benefit for transplant recipients and is worthy of further investigation. 
The data presenting here describing TGM is encouraging with regard to future 
therapeutic potential in a number of respects. First, TGM acts on both murine and 
human T cells to suppress proliferation and induce Foxp3. The level of Foxp3 
expression induced by TGM is greater than that of TGF-β; a feature that has 
previously been shown to correlate with enhanced functional suppressive capacity of 
Treg333. Secondly, TGM is structurally completely distinct from TGF-β and is highly 
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unusual in having no shared homology with any other known molecules. This will 
likely enable evasion of the complex biological processes that regulate TGF-β 
signalling and may underlie the enhanced signalling downstream of the TGF-β 
receptor complex that has been observed. Thirdly, the main predicted adverse effect 
of TGF-β as a therapeutic agent is pathogenic fibrosis; whilst TGM is more potent in 
inducing Foxp3 expression that TGF-β, it is less potent in inducing fibrosis and 
therefore has the potential for a wider safe therapeutic dose range. Finally, TGM has 
been shown to be non-toxic at therapeutic dosages and to be functionally effective in 
prolonging allograft survival in vivo. 
This project began with the hypothesis that H. polygyrus infection can protect 
transplanted allografts from immunological rejection. It is now clear infection can 
achieve this effect, but also that live infection is not required and at least one of the 
secreted products from H. polygyrus shows significant potential as a novel 
therapeutic candidate for further investigation. 
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Helminths and Immunological Tolerance
Chris J.C. Johnston,1,2 Henry J. McSorley,1 Stephen M. Anderton,2 Stephen J. Wigmore,2
and Rick M. Maizels1,3
Current immunosuppression regimens for solid-organ transplantation have shown disappointing efficacy in the
prevention of chronic allograft rejection and carry unacceptable risks including toxicity, neoplasia, and life-
threatening infection. Achievement of immunological tolerance (long-term antigen unresponsiveness in an immu-
nocompetent host) presents the exciting prospect of freedom from immunosuppression for transplant recipients. It is
now 60 years since the first demonstration of immunological tolerance in animal models of transplantation, but
translation into routine clinical practice remains elusive. Helminth parasites may provide novel strategies toward
achieving this goal. Helminths are remarkably successful parasites: they currently infect more than one quarter of
the world’s population. It is now well established that the parasites’ success is the result of active immunomodulation
of their hosts’ immune response. Although this primarily secures ongoing survival of the parasites, helminth-induced
immunomodulation can also have a number of benefits for the host. Significant reductions in the prevalence of al-
lergy and autoimmune conditions among helminth-infected populations are well recognized and there is now a
significant body of evidence to suggest that harmful immune responses to alloantigens may be abrogated as well.
Here, we review all existing studies of helminth infection and transplantation, explore the mechanisms involved, and
discuss possible avenues for future translation to clinical practice.
Keywords: Allograft tolerance, Allograft rejection, Helminth.
(Transplantation 2014;97: 127Y132)
Successful organ transplantation requires negotiation of anumber of complex immunologic barriers. In addition
to cell-mediated rejection resulting from mismatching of
major and minor histocompatibility complexes (1), innate
immune responses are invariably stimulated by a combi-
nation of surgery itself and organ damage resulting from
ischemia and reperfusion (2). Ever-increasing demand for
organ transplantation has unfortunately coincided with a
steady decline in the availability of donor organs in recent
decades (3). This has necessitated amended strategies to ex-
pand the donor pool that can result in donor organs of a lesser
quality and/or greater degrees of immunologic mismatch (3).
Despite this, solid-organ transplantation has become
the standard of care for numerous disease processes that
result in organ failure. Advances in surgical techniques and
immunosuppressive regimens mean that excellent short-
term to medium-term graft survival has now come to be
expected. However, recent scrutiny of long-term allograft
survival data reveals that considerable improvements in the
incidence and management of acute rejection have not been
reflected in improved long-term outcomes (4). For living-
donor kidney transplant recipients in the United States,
organ graft survival half-life is almost unchanged (in 2005,
this was 11.9 years compared with 11.4 years in 1989) (5). A
similar disparity in short-term and long-term survival rates
has also been seen in liver, lung, heart, intestine, and pan-
creas transplantation (6).
Current immunosuppression regimens used in solid-
organ transplantation carry significant risks of toxicity, in-
fection (7), and neoplasia (8). The incidence of neoplastic
disorders such as posttransplantation lymphoprolifera-
tive disease, in particular, relates more to the intensity of
immunosuppression than the specific agent used (1). All
of these factors have fuelled the long-held ambition for
allograft tolerance, defined as durable antigen-specific un-
responsiveness in an immunocompetent host (9).
Despite the achievement of experimental murine al-
lograft tolerance 60 years ago (10), translation to the clinical
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setting has been frustratingly slow. Recent developments in
the understanding of regulatory cell populations have, how-
ever, allowed some ground for optimism (11). In particular, a
recent trial of combining kidney transplantation with a si-
multaneous bone marrow transplant from single human
leukocyte antigen (HLA)Ymismatched donors has allowed for
successful withdrawal of all immunosuppression in four of
five patients (12). With this technique, patients developed
transient mixed chimerism and lasting specific alloantigen
unresponsiveness as a result. With the same technique,
Scandling et al. have independently demonstrated similarly
impressive outcomes with HLA-matched kidney transplan-
tation: from a cohort of 16 patients, 8 have achieved rejection-
free avoidance of immunosuppressive medication for more
than 1 year, and a further 4 patients are in the process of
withdrawal from medication (13). Although many would
consider simultaneous bone marrow transplantation to pres-
ent an unacceptable level of complexity and risk in the
pursuit of solid-organ allograft tolerance (9), this impor-
tant study has shown lasting intragraft regulatory cell pop-
ulations and the successful allograft tolerance this can achieve
in a clinical setting.
The ability of regulatory T cells (Treg) to mediate allo-
graft tolerance in murine models is now well recognized (14).
Expectations of successful translation of Treg therapy into the
clinical setting have been high and preliminary clinical trials
have now been completed in graft-versus-host disease (15)
and hematopoietic stem cell transplantation (16) with modest
but encouraging results. However, a number of obstacles
and concerns persist. First, Good Manufacturing Practice-
compliant ex vivo expansion of Tregs for subsequent reinfu-
sion is a highly specialized process at a cost of approximately
$40,000 per patient (17). Second, difficulty in identifying
regulatory cell populations for purification and ensuring that
they do not convert away from the regulatory phenotype
presents the possibility of harm caused by inadvertent infu-
sion of expanded effector T-cell populations (resulting in en-
hanced rejection or autoimmunity) (18). Finally, the specificity
of Treg-induced immunosuppression is uncertain and may
therefore present a risk of infection or neoplasia similar to that
of current global immunosuppression regimens. Although
results from early studies provide some degree of reassurance
in this regard (19), analysis of long-term clinical safety data is
still awaited.
Helminth Infections and Host Immunity
Helminth worms are particularly successful parasites; as
recently as 1940, the prevalence of infection in children in
some rural areas of the United States was as high as 70% (20)
and the current rate of chronic infection stands at more than
one quarter of the world’s population (21). Helminths’ success
is now recognized to be the result of active modulation of their
hosts’ immune response (21). In addition to facilitating
chronic infection, parasite-derived dampening of the host
systemic immune response also results in reduced reactivity to
unrelated ‘‘bystander’’ allergens and autoantigens or alloanti-
gens. In many cases, this effect is of some considerable benefit
to the host. Recent studies have shown abrogation of multiple
disease processes in the presence of helminth infection, in-
cluding allergic airway inflammation, encephalitis, inflam-
matory bowel disease, rheumatoid arthritis, and type I
diabetes in experimental models (22). Epidemiologically, it is
well established that the prevalence of allergic and autoim-
mune disorders is higher in developed countries compared
with developing nations. Recent cohort studies investigating
allergic responses in children demonstrated reduced skin
responses to antigen testing in helminth-infected subjects
compared with controls and found that this effect was
eliminated after clearance of infections with antihelminthic
therapy (22). Similarly, patients with multiple sclerosis in
Argentina who adventitiously acquired helminth infec-
tions were found to stay in remission but relapsed after
antihelminthic drug treatment (23). A recent phase I trial of
experimental helminth infection with Trichuris suis as a
therapy for Crohn’s disease revealed no adverse effects (in 29
patients) and showed promising considerable reductions in
disease severity scores (24). Large-scale Good Manufacturing
PracticeYcompliant production of T. suis for clinical use has
TABLE 1. Published studies reporting prolonged allograft survival in humans or laboratory animals in helminth-infected
hosts, or in animals given helminth-derived products.
Authors Parasite Allograft model Graft prolongation P
Aboul-Enein et al. (41) Schistosoma mansoni Human skin 2.21 0.001
Hepiretihan et al. (32) Echinococcus multilocularis Rat heart 2.04 G0.05
Li et al. (31) E. multilocularis Rat liver 1.57 G0.05
Liwski et al. (34) Nippostrongylus brasiliensis Mouse heart 2.80 G0.03
Ledingham et al. (33) N. brasiliensis Rat kidney 3.30 G0.001
Araujo et al. (42) Nippostrongylus NES Rat kidney 2.22 G0.001
S. mansoni Mouse skin 1.5 G0.001
Svet-Moldavsky et al. (43) Trichinella spiralis Mouse skin 2.13
Faubert and Tanner (44) T. spiralis Mouse skin 1.89 G0.001
Chimyshkyan et al. (45) Infected mouse serum Mouse skin 1.67
T. spiralis Mouse skin 2.48 G0.001
Alkarmi et al. (46) Trichinella pseudospiralis Mouse skin 3.57 V
T. pseudospiralis extract Mouse skin 2.0 V
T. spiralis Mouse skin 3.57 V
T. spiralis extract Mouse skin 2.43 V
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been approved by the U.S. Food and Drug Administration
and a number of multicenter randomized controlled trials
have commenced (25). In the absence of a corresponding
analysis of allograft survival in helminth infected hosts, we
performed a publication search (Fig. 1) and report here a
synthesis of the relevant literature.
Echinococcus Tapeworms
The metacestode Echinococcus multilocularis (Em) is
endemic among foxes in many parts of Europe and China
such that humans can be affected as accidental hosts. In-
fection can result in severe disease with a clinical course
resembling that of a malignant primary liver tumor (hepa-
tocellular carcinoma) (26). Radical surgical resection of liver
lesions has been shown to be effective in improving survival
and orthotopic liver transplantation is now largely accepted
as appropriate treatment for advanced disease (27). Disease
progression caused by the parasite has been found to ad-
vance rapidly in the presence of host immunosuppression
either as a result of medication (1, 28) or HIV infection (2, 29).
This finding led to guidelines recommending reduced im-
munosuppression regimens after liver transplantation for
Em (30) and long-term follow-up reported unexpectedly
satisfactory tolerance of the allografts (3, 27). Tao et al. have
subsequently corroborated this finding in an experimental
rat model of liver transplantation with Em infection (3, 31)
(Table 1). In this study, survival after orthotopic liver
transplantation found to be significantly prolonged for
Em-infected rats compared with naBve controls (15.5T3.9 vs.
9.9T2.3 days; PG0.05). The Em-infected group was also found
to have reduced CD4+, CD8+, and CD28+ T-cell populations
in peripheral blood, raised serum interleukin (IL)-10 levels,
and reduced histologic liver allograft rejection scores, all of
which reached statistical significance (PG0.05) (4, 31). More
recently, Hepiretihan et al. have shown a that Em infection
exerts a similar protective effect against rejection of rat heart
allografts (16.2T3.2 vs. 7.9T1.9 days) (5, 32). This was asso-
ciated with a reduction in graft-infiltrating CD8+ lympho-
cytes and a shift toward a Th2 cytokine profile in the serum
of peripheral blood. In the clinical setting, eradication of Em
infection usually proves impossible. It therefore remains as
yet unclear as to whether graft protection is afforded by an
ongoing influence of the parasite or as the result of a Th2
cytokine environment at the time of alloantigen presentation.
Nippostrongylus Roundworms
Beneficial enhancement of allograft tolerance in the
presence of helminth infection has now been demonstrated
with a number of parasite species and does not seem to be
restricted to specific organs or host species (Table 1). In
1996, Ledingham et al. demonstrated marked improvement
in the survival of kidney allografts in rats infected with the
gastrointestinal nematode, Nippostrongylus brasiliensis (Nb),
or inoculated with its secretory products compared with
naBve controls (32T10, 21T4.6, and 9.7T1.2 days, respectively;
PG0.001) (6, 33). Representative histologic examination 5 days
after transplantation showed a dramatic reduction of graft
cellular infiltration in the Nb-infected group and this find-
ing was supported quantitatively with flow cytometric anal-
ysis of digested allograft single-cell suspensions (84% and
FIGURE 1. Search strategy.
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81% reduction of CD8+ and CD4+ lymphocytes, respectively).
Although the graft protection afforded by Nippostrongylus
excretory-secretory products (NES) was less pronounced, the
pharmacokinetic profile of the active mediator(s) in NES
is unknown and this may therefore be a purely dose-
dependent difference.
The same group later showed similar (2.8-fold) graft
protection in a mouse cardiac allograft model (7, 34). Nb
infection is known to induce a strong Th2 response in its
host (8, 35), leading those authors to hypothesize that po-
larization away from Th1-mediated allograft rejection may
afford allograft protection. Nb usually achieves only a lim-
ited infection in rodentsVmost mouse strains can clear the
infection within 10 days of inoculation with third-stage
larvae (1, 35). The finding that mouse heart allografts can
survive for considerably longer than the period of infection
(9, 34), presents the exciting therapeutic prospect that graft
protection is afforded by T-cell ‘‘phenotype switching’’ at
the time of alloantigen presentation rather than a mecha-
nism dependent on persisting parasite infection. Enzyme-
linked immunosorbent assay analysis of mixed lymphocyte
reactions supports this hypothesis in demonstrating a Th2
cytokine profile (IL-4 and IL-6) in alloreactive lympho-
cytes from Nb-infected mice compared with naBve con-
trols (34, 36).
Schistosome Flukes
Schistosoma is a genus of blood-borne trematode with
a current prevalence of infection estimated at more than
200 million people worldwide (10, 37). In light of the very
widespread prevalence of schistosomiasis and the diminishing
supply of suitable cadaveric donor organs for transplantation,
a number of human liver (11, 38, 39) and kidney (12, 40)
transplants in patients with clinical schistosomiasis have been
performed (donor and recipient, donor alone, and recipient
alone). No attempts at reducing immunosuppression or
analyzing differences in rejection rates have as yet been
reported. However, one remarkable study has looked at the
differential rejection of full-thickness skin grafts in Egyptian
patients with established schistosomiasis compared with
healthy volunteers. Aboul-Enein et al. (9, 41) recruited 19
patients with advanced Schistosoma mansoni infection and
16 parasite-free volunteer controls. Then, 2.5-cm-diameter
full-thickness skin grafts were applied to the volar forearm.
Two grafts were performed for each patient: one ABO-
matched allograft from a noninfected donor and one auto-
graft control. Grafts were assessed daily for signs for rejection
and rejection was then confirmed histologically. The control
group rejected their allografts after a mean of 10.06T3.21 days.
Of the Schistosoma-infected patients, in 16 cases, rejection
occurred after a mean of 22.25T6.46 days. The remaining
three infected patients showed no signs of rejection 60 days
after the grafting procedure. Notably, the HLA status of do-
nors and recipients was unknown in this study; therefore, the
three cases of long-term graft tolerance may well be the result
of coincidental HLA matching. In spite of this significant ca-
veat, the difference in rejection times between the two groups
was highly significant (PG0.001) and therefore unlikely to be
the result of differences in HLA matching alone.
Allograft protection with Schistosoma infection has
previously been shown in a murine experimental model. In
1977, Araujo et al. found a highly significant difference in the
rejection of fully allogeneic skin grafts in S. mansoniYinfected
versus naBve recipient mice (14, 42). No difference was found
after 30 days of infection, but for grafts performed after 60 days
of infection, infected recipients tolerated their grafts for an
average of 50% longer than naBve controls. A strongly positive
correlation between graft survival and the number of live
parasites remaining in the recipient was also seen (r=0.096).
Trichinella
Finally, murine experimental models of other helminth
species have also demonstrated enhanced tolerance of skin
allografts. Trichinella spiralis is a small nematode that encysts
in mammalian muscle and can affect humans who consume
infected meat. Suppression of skin allograft rejection in mice
infested with Trichinella was first described by Svet-Moldavsky
et al. in 1969 (15, 43) and subsequently confirmed by Faubert
and Tanner (16, 44) and Chimyshkyan et al. (18, 45). In 1995,
Alkarmi et al. performed fully allogeneic skin grafts (C57BL/6
to BALB/c recipients and vice versa) on multiple groups of
mice at varying time points after infection (17, 46). Graft
protection was found to be critically dependent on the timing
of skin transplantation in relation to initial infection and a
maximum effect of 3.5-fold prolongation of graft survival was
found when the transplants were performed 3 days after initial
infection. Repeated intraperitoneal injection of parasite se-
cretions (culture supernatants) replicated the effect of active
infection in a dose-dependent fashion with an observed
maximum twofold prolongation in graft survival (18, 46).
Evolution of Regulation
Coevolution of helminths and humans over millions of
years (19, 47) has resulted in multiple effective mechanisms
of immunomodulation, which may individually or in com-
bination be responsible for the prolongation of allograft
survival. Certainly, it is now clear that helminths act via
multiple distinct and synergistic pathways to down-regulate
host immunity. Expansion of Treg populations in response
to helminth infections such as Heligmosomoides polygyrus
(20, 48) and S. mansoni (21, 49) is one well-recognized mech-
anism, but the same parasites can also engender immuno-
suppressive activity in B-cell populations as well as modified
dendritic cell and macrophage populations (21, 22).
In this context, it is possible that therapeutic extension
of graft survival would also require more than one particular
immunomodulatory pathway. With respect to Treg expan-
sion, exogenous IL-2:anti-IL-2 antibody complex is a potent
short-term stimulant of Treg populations, which can effect
long-term tolerance of allogeneic islet grafts in the absence
of immunosuppression (22, 50). However, multiple at-
tempts to achieve similar tolerance of allogeneic skin grafts
(BALB/c to C57BL/6) have failed (23, 51). It is well known
in the experimental and clinical setting that tolerance of skin
allografts presents a particular challenge (compared with the
solid-organ transplants of heart, liver, or kidney). Important
factors to overcome are likely to be the large proportion of
resident dendritic cells in skin (24, 51) and more potent
Toll-like receptor stimulation by colonizing microbes (25, 52).
Failure of IL-2:anti-IL-2 complexes to achieve the same level
of protection of fully allogeneic skin grafts against rejection
(26, 51) that is seen in Schistosoma infection (27, 41) strongly
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suggests that Treg-independent mechanisms also play a criti-
cal role in helminth-derived allograft protection.
CONCLUSIONS
Enhanced allograft tolerance with helminth infection
has now been demonstrated in multiple species across mul-
tiple organ allograft models (mouse heart and skin; rat heart,
liver, and kidney). These experimental data are consistent with
historical results of skin grafting in established human schis-
tosomiasis and supported by more recent anecdotal sugges-
tions of reduced immunosuppression requirement after liver
transplantation for human Echinococcus infection (27). Thus,
the possibility can now be entertained of including specific
live (nonpathogenic) helminth infection, or defined products
from immunoregulatory helminths, in future transplantation
protocols. Ongoing trials of live T. suis therapy in inflamma-
tory bowel disease (25) are keenly awaited as potential path-
finding studies for translation of this concept to the clinic.
There are indeed multiple potential opportunities for
helminthic and helminth product therapy in transplanta-
tion. The most promising is with living-donor transplanta-
tion, whereupon a course of helminthic therapy may be
commenced before the time of transplantation, allowing
alloantigen presentation to occur in a tolerogenic environ-
ment (either at the time of the transplantation itself or with
known defined alloantigens beforehand). Although treat-
ment with active helminth infection has been shown to be a
safe therapeutic approach (25), reports of mild gastrointes-
tinal side effects do exist and might limit patient accept-
ability (53). Identification and synthetic production of the
active compounds within helminthic secretions for novel
pharmaceutical intervention is a definitive goal and the fo-
cus of much attention (54). Measured against current trans-
plant immunosuppression regimens with multiple serious
adverse effects and inadequate long-term organ protection
against rejection, therapy with helminths or their products
presents the exciting opportunity of a safe, effective, and long-
overdue alternative.
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a b s t r a c t
The TGF-b superfamily is an ancient metazoan protein class which cuts across cell and tissue differenti-
ation, developmental biology and immunology. Its many members are regulated at multiple levels from
intricate control of gene transcription, post-translational processing and activation, and signaling through
overlapping receptor structures and downstream intracellular messengers. We have been interested in
TGF-b homologues firstly as key players in the induction of immunological tolerance, the topic so closely
associated with Ray Owen. Secondly, our interests in how parasites may manipulate the immune system
of their host has also brought us to study the TGF-b pathway in infections with longlived, essentially
tolerogenic, helminth parasites. Finally, within the spectrum of mammalian TGF-b proteins is an exqui-
sitely tightly-regulated gene, anti-Müllerian hormone (AMH), whose role in sex determination underpins
the phenotype of freemartin calves that formed the focus of Ray’s seminal work on immunological
tolerance.
! 2015 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
The TGF-b superfamily is an ancient metazoan protein class
which cuts across cell and tissue differentiation, developmental
biology and immunology. Its many members are regulated at mul-
tiple levels from intricate control of gene transcription, post-
translational processing and activation, and signaling through
overlapping receptor structures and downstream intracellular
messengers. We have been interested in TGF-b homologues firstly
as key players in the induction of immunological tolerance, the
topic so closely associated with Ray Owen. Secondly, our interests
in how parasites may manipulate the immune system of their host
has also brought us to study the TGF-b pathway in infections with
long-lived, essentially tolerogenic, helminth parasites. Finally,
within the spectrum of mammalian TGF-b proteins is an exqui-
sitely tightly-regulated gene, anti-Müllerian hormone (AMH),
whose role in sex determination underpins the phenotype of free-
martin calves that formed the focus of Ray’s seminal work on
immunological tolerance.
2. The TGF-b superfamily
TGF-b was named for its ability to drive fibroblast proliferation
before its broader role in development and immunity had been
established; in the meantime related proteins, such as the Bone
Morphogenetic Proteins (BMPs) were first characterized in verte-
brates before becoming discovered in Drosophila flies, Caenorhabdi-
tis elegans nematodes and other lower animals. Even within the
vertebrates, there are more than 30 distinct molecules including
three isoforms of TGF-b, Bone Morphogenetic Proteins (BMPs),
activins, inhibins, nodal and growth differentiation factors, and
anti-Müllerian hormone (AMH) [1–4]. Structurally, these proteins
are synthesized as !400-amino acid inactive pre-proteins, and
are cleaved by furin-like proteases to yield an active !110-amino
acid C-terminal domain; the active domain is tightly cross-linked
with 3–4 disulfide bonds, and generally forms a homodimer
through one additional cysteine residue on each chain.
The ligand family is complemented by a wide-ranging set of
receptors, which canonically are heterodimers composed of two
serine-threonine receptor kinases, termed Type I and Type II [3].
Depending on the TGF-b family member and expression of appro-
priate receptors on the surface of cells, these ligands initiate pleio-
tropic effects in a broad spectrum of biological processes including
embryogenesis, immunity, angiogenesis and wound healing [5].
Reflecting this remarkable multiplicity of events dependent on clo-
sely related TGF-b proteins, a complex and highly-regulated signal-
ing arrangement exists [6,7].
Regulation of TGF-b signaling takes place in three distinct set-
tings: the extracellular space, the cell membrane and the intracel-
lular region. The full-length TGF-b pro-protein is cleaved to
produce not only the C-terminal homology domain, but also a func-
tional N-terminal ‘latency-associated peptide’ (LAP) which remains
http://dx.doi.org/10.1016/j.cellimm.2015.10.006
0008-8749/! 2015 The Authors. Published by Elsevier Inc.
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non-covalently attached to the cytokine polypeptide thereby
retaining it in inactive form. Prior to secretion from a cell, the
LAP-TGF-b complex binds to a further protein, latent TGF-b binding
protein (LTBP). Because TGF-b is secreted in this way, as a compo-
nent of a biologically inactive compound, processes that liberate
the active TGF-b molecule can be as important to immunomodula-
tion as its transcription and synthesis [8]. In the extracellular
space, the active TGF-b molecule is also prone to sequestration
by ‘ligand trap’ proteins (including LAP), which limit the duration
and range of active TGF-b stimulation [9].
In vivo, cell surface receptors including many integrins have the
ability to bind LAP-TGF-b and release active TGF-b [10]. This mech-
anism is of considerable importance for example av integrin null
mice develop similar embryological aberrations to TGF-b!/! ani-
mals [11]. Furthermore, even if integrin-TGF-b interaction is
ablated solely within the dendritic cell compartment, the resultant
immunological dysfunction is sufficient to induce spontaneous col-
itis in normal environmental conditions [12].
Activated TGF-b signals as a homodimer via the union of two
type I TGF-b receptors and two type II TGF-b receptors. In humans,
5 variants of the type I receptor and 7 variants of the type II recep-
tor have been identified, in contrast to 29 potential ligands [13].
The affinity of each ligand for individual receptors varies, but most
ligands are also able to bind multiple heteromeric combinations of
type I and type II receptors, resulting in different downstream
effects [13]. Upon binding of the TGF-b ligand, the constitutively
active type II receptor is brought into close proximity of the type
I receptor, thereby enabling phosphorylation of the TbRI intracellu-
lar ‘GS’ domain and initiating the Smad signaling cascade [14]
(Fig. 1).
Smads are intracellular proteins first identified in C. elegans
worms (as Sma genes in small phenotype organisms [15]) and
Drosophilia flies (as Mad genes [16]) and are the key intermediaries
in signaling from TGF-b receptors to the nucleus. Hence, not only
the ligands but the entire signaling pathway is conserved in the
animal kingdom, including parasites such as Schistosoma mansoni
[17,18].
Eight Smad proteins have been identified in vertebrates and
they are sub-categorized according to their function: receptor-
activated Smads (R-Smads), common Smads (Co-Smads) and inhi-
bitory Smads (i-Smads) [14]. When TGF-b binds and activates the
TGF-b receptor complex, the intracellular GS domain of TbRI phos-
phorylates Smad2 and Smad3 (R-Smads), which then form a com-
plex with Smad4 (Co-Smad) and enter the nucleus to initiate gene
transcription [19]. This process can be regulated intracellularly by
Smad7, an inhibitory Smad that can bind TbRI, prevent further sig-
nal transduction and then stimulate proteolytic degradation of the
receptor [14]. The importance of the i-Smad7 is underlined by obser-
vations that it is upregulated in inflammatory bowel diseases, and
colitis in mice can be attenuated by antisense Smad7 oligonu-
cleotides [20]. IRF3 is a related transcription factor which can bind
and inactivate Smad3; this mechanism may be important in viral
infections to suspend TGF-b-mediated immunoregulation until
the pathogen is cleared [21].
At the level of the cell membrane, another regulatory mecha-
nism comes into play in the form of ‘decoy’ receptors such as
BAMBI (BMP and activin membrane-bound inhibitor), a transmem-
brane protein that is structurally very similar to TbRI, but lacks an
intracellular GS domain [22]. BAMBI can therefore form a dimer
with TbRII and bind TGF-b without initiating any Smad signaling
Fig. 1. TGF-b signaling and regulation. (A) Active TGF-b is prevented from binding to receptors due to incorporation with ‘ligand trap proteins’ such as latency-associated
peptide (LAP). (B) Binding of TGF-b to the Type II TGF-b receptor leads to phosphorylation of the Type I TGF-b receptor intracellular domain and activation of the Smad
signaling pathway, in addition to Smad-independent signaling including MAPK pathways. (C) Decoy receptors such as BAMBI bind TGF-b but prevent downstream signaling.
(D) Smad7, an inhibitory Smad, binds to the phosphorylated Type I TGF-b receptor and prevents downstream signaling.
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and thereby reduce the number of TbRIIs available to bind other
TGF-b molecules.
The Smad cascade is the ‘canonical’ signaling pathway for TGF-b
and is essential for TGF-b-driven immunoregulation and Treg/Th
cellular differentiation [23]. However, TGF-b is also able to activate
a number of Smad-independent signaling pathways including
mitogen-activated protein kinases (MAPKs). Of these, ERK phos-
phorylation is an important event in the process of epithelial to
mesenchymal transition (EMT), which is necessary in embryologi-
cal development, but can contribute to pathological fibrosis, one of
the major drawbacks in current strategies for therapeutic applica-
tions of TGF-b [24].
3. TGF-b in the immune system
TGF-b is a broadly immune suppressive mediator which can, for
example, block allergic inflammation in the lung [25] and autoim-
mune diabetes in the pancreas [26]. Deficiency in either the cyto-
kine or its receptors results in fulminant inflammatory disease
that proves lethal in the first weeks of life [27], a phenotype that
can be reproduced even if only T cells are unable to respond to
TGF-b [28]. The cytokine is instrumental in almost every compart-
ment of the immune system [29], inducing for example B cell class
switching to IgA [30,31] and driving myeloid cells into a more
tumor-promoting phenotype [32]. But its effects on T cells are per-
haps the most prominent, in particular its ability to stimulate naïve
CD4+ T cells to differentiate into Foxp3+ Treg that can suppress
effector T cell activation and proliferation [33,34], and prolong
allograft survival upon adoptive transfer into recipient animals
[35]. The level of Foxp3 expression by Treg correlates with func-
tional suppressive capacity [36] and stability of Foxp3 expression
is essential for maintenance of a regulatory phenotype [37]. Addi-
tionally, TGF-b is capable of promoting a tolerant state through
Foxp3-independent mechanisms, such as upregulation of CD73
[38], an ectoenzyme that acts to increase the local extracellular
concentration of adenosine.
The combination of TGF-b and certain other cytokines, may
induce T cells to differentiate into non-regulatory phenotyopes
such as Th17 effectors in the presence of IL-6 [39] and Th9 when
IL-4 is present [40]. The action of TGF-b on T cells is antagonized
by IFN-c and IL-4, representing an important pathway by which
these cytokines suppress Th17 differentiation [39].
4. TGF-b and regulatory T cells
CD4+ regulatory T cells (Treg), identified by expression of the
transcription factor Foxp3, are arguably the single most important
cell type in mediating peripheral tolerance [41,42]. Regulatory T
cells are subdivided into two types [43]. Thymic Treg (tTreg) con-
stitutively express Foxp3 before leaving the thymus, indepen-
dently of TGF-b, and play the predominant role of maintaining
tolerance to self antigens. In contrast, peripherally-induced Treg
(pTreg) develop from naïve, mature CD4+ cells exposed to antigens
under tolerogenic conditions (for example by immature DCs with
low levels of co-stimulation), and with an essential requirement
for TGF-b signaling [44].
Tregs are crucial for physiological immune homeostasis and
their absence leads to severe autoimmunity, which is universally
fatal in ‘scurfy’ mice that lack Foxp3 expression [45] and manifests
as a life-limiting multisystem disorder in humans – the immune
dysregulation, polyendocrinopathy, enteropathy, X-linked syn-
drome (IPEX) [46,47]. However, Tregs do also have the potential
to cause harm by permitting neoplastic cells to evade anti-tumor
immunity [48] and preventing immunity in infections [49]; the
long term effects of artificially manipulating Treg populations
in vivo are therefore unknown.
Other subsets of T cells exert regulatory effects while not
expressing Foxp3, through the release of other suppressive cytoki-
nes, in particular IL-10 and IL-35 from Tr1 [50] and iTr35 [51] cells.
While these have potent down-modulatory functions, TGF-b is
unique in being central to both the induction and function of Tregs.
5. TGF-b in transplantation
With the potential to synergise with pro-inflammatory cytoki-
nes such as IL-6, TGF-b has the potential to play janiform roles in
the context of transplantation [52]. In many experimental animal
models, TGF-b-induced immunoregulation, and regulatory T cells
in particular, clearly promote tolerogenesis and allograft survival.
However, detrimental effects can also arise through interstitial
fibrosis as a result of increased myofibroblast differentiation; in
addition, the ability of TGF-b to promote Th17 differentiation in
the presence of pro-inflammatory cytokines (IL-1b, IL-6) and TLR
ligands poses a major threat to transplant acceptance [53]. This
clearly cautions against the use of TGF-b activity as a strategy to
improve graft survival. However, in the absence of TGF-b, Th17
cells can still develop and indeed are more pathogenic due to
enhanced IL-23 receptor expression [54]. Furthermore, higher con-
centrations of TGF-b are able to overcome the Th17 pathway and
restore Treg differentiation [55], arguing that, depending on dose
and context, TGF-b may still provide a therapeutic option.
6. TGF-b in infectious diseases
The central immunosuppressive role of TGF-b is also reflected in
many infectious diseases, particularly in chronic infections. Hel-
minth parasites, which typically establish themselves as long-
term residents in the mammalian host are often associated with
both generalized immunosuppression and elevated TGF-b expres-
sion [56,57]. Moreover, patients with onchocerciasis [58] and lym-
phatic filariasis [59] show in vitro parasite antigen-specific T cell
hyporesponsiveness which can be reversed with anti-TGF-b anti-
bodies. In human helminth infections, IL-10 is also a very promi-
nent immunosuppressive factor [60]; whether this is driven by
high levels of TGF-b remains to be ascertained.
Alongside the elevation of TGF-b cytokine, many infectious dis-
ease settings are accompanied by expansion of Foxp3+ Tregs [49].
Specifically in the context of helminth parasitism, in murine infec-
tions with Brugia malayi [61], Heligmosomoides polygyrus [62–64]
and Strongyloides ratti [65] all drive marked increases in Tregs,
which in the latter twomodels can be shown to functionally inhibit
the host Th2 protective response and promote chronic infection;
moreover, blocking TGF-b signaling in H. polygyrus infection results
in greater worm expulsion [66], establishing a mechanistic link to
this key cytokine. The activity of Tregs is also enhanced in many
human helminth infections and, together with other regulatory
pathways, may establish a form of immunological tolerance to par-
asites allowing them to remain in the body for many months or
years [67,68].
Several mechanisms may operate to raise TGF-b levels in para-
site infection, such as (i) host homeostasis to minimize
immunopathology in chronic infection; (ii) pathogen triggering of
TGF-b production or activation; or (iii) parasite mimicry of the host
cytokine to drive the same pathway as host TGF-b. In fact, exam-
ples of all 3 can now be found (Fig. 2).
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7. Host homeostasis or pathogen ploy?
Every immune response must engender a regulatory compo-
nent that will eventually dampen and terminate that response
[69]; hence an increase in TGF-b and Tregs during an infectious
episode may reflect host homeostatic mechanisms rather than a
strategy evolved by pathogens to suppress immunity.
In a number of parasite models, however, interfering with the
TGF-b pathway results in greater resistance to infection; although
inferential, these findings are often taken to argue that pathogens
benefit from (and may therefore have evolved to favor) TGF-b sig-
naling. These include in vivo studies with SB431542, an inhibitor of
the ALK5 receptor kinase, [66], and in vivo antibody neutralization
of host TGF-b [70], each of which lead to greater expulsion of the
chronic gastrointestinal parasite H. polygyrus.
Interestingly, mice in which T cells express a dominant negative
TGF-bRII are not more resistant to helminth infection, but show
marked overexpression of inflammatory cytokines such as IFN-c,
blocking an effective type 2 anti-parasite response [71,72]; in par-
allel, induction of IL-10 is abrogated in infected mice lacking T cell
TGF-b signaling, emphasizing the importance of TGF-b in driving
other pathways of immunosuppression [71]. Deletion of the TGF-
bRII only in myeloid cells, however, results in enhanced immunity
to intestinal helminths, indicating that the cytokine may normally
inhibit a protective effector myeloid phenotype in vivo [73].
Furthermore, while TGF-b levels are elevated in many helminth
infections, clearance of parasites through anthelmintic chemother-
apy reduces cytokine levels, indicating that the helminths may be
actively inducing high expression [74]. Conversely, in the B. malayi
model system, Foxp3+ Treg expansion required live parasite infec-
tion [61]; the inability of dead parasites to induce a regulatory
response indicated that Treg expansion is driven by the activity
and/or products of live helminths. In some cases, this process
may be indirect, as for example in the case of ES of Trichinella spi-
ralis, which stimulates host DCs to induce Tregs [75].
8. Parasite induction or activation of host TGF-b
TGF-b levels increase in many different helminth infections,
although only in some instances has a causal mechanism been
establishedbywhichparasites initiate a pathway to ensure cytokine
production. For example, in infectionwith thehelminth S.mansoni, a
regulatory cascade is generated through soluble egg antigens (SEA)
that induce T cell differentiation into Foxp3+ Tregs [76]; the effect is
sufficient to protect diabetes prone NOD mice from developing
autoimmunity. SEA is also capable of suppressing CD4+ T cell prolif-
eration and inducing Foxp3 expression indirectly.Whist SEA-driven
Foxp3 induction has only been demonstrated in the presence of DCs
(and not culture with CD4+ T cells alone), an increase in the expres-
sion of TGF-b latency associated peptide on the surface of CD4+ cells
suggests that SEA also induces enhanced secretion of TGF-b by acti-
vated T cells, further facilitating Foxp3+ Treg differentiation [77]. In
humans, although the mechanism has yet to be defined, helminth
infections such as Onchocerca volvulus elicit extremely high local
levels of TGF-b from many cell types around the nodules in which
adult parasite establish themselves [78].
Pathogens may also directly promote activation of TGF-b, as
was found in the case of influenza A neuraminidase activating
the latent TGF-b complex in epithelial cells and tissues [79]; fur-
thermore, the consequent upregulation of extracellular matrix pro-
teins facilitated the adhesion and infection with streptococcal
bacteria, thereby promoting secondary infection of the host.
9. Parasite-derived ligands – homology or mimicry?
We postulated that helminths may express TGF-b homologues
that could interfere with host immunity, and characterized several
members of the gene superfamily listed in Table 1 along with those
identified by other laboratories. In particular, we characterized two
ligands in Brugia [80,81] and four in H. polygyrus [82]. One, Bm-
TGH-2 from B. malayi, was found to activate the MFB-F11 reporter
cell line [81], but in unpublished work we found the closest homo-
logue from H. polygyrus did not do so. In Onchocerca, antibody to
mammalian LAP revealed widespread staining of somatic tissues,
indicating a parasite-encoded protein sufficiently similar to LAP/
TGF-b to be recognized by antibodies [83]. In platyhelminths (flat-
worms) activin-like homologues have been identified in both
S. mansoni [84,85] and Echinococcus multilocularis [86]; since mam-
malian Activin A can also stimulate Foxp3 induction and Treg
development [87,88], it will be interesting to learn if these parasite
ligands can act likewise.
Despite the inability of H. polygyrus TGF-b homologues to drive
signaling, the proteins secreted by this parasite (termed HES) did
directly induce Foxp3+ Treg differentiation in isolated CD4+Foxp3
(GFP)! T cells in vitro with stimulation from Concanavalin A or
plate-bound CD3/CD28 [66]. HES also suppressed proliferation of
CD4+Foxp3(GFP)! T cells and promoted IL-17 expression from naïve
CD4+ cellswhenco-culturedwith IL-6. This led to further investigation
Fig. 2. Helminths and the TGF-b pathway. Several mechanisms may operate to raise TGF-b levels in parasite infection, such as (i) host homeostasis to minimize
immunopathology in chronic infection; (ii) pathogen triggering of TGF-b production or activation by host cells such as DCs; or (iii) parasite expression of homologues or
mimics of the host cytokine to drive the same pathway as host TGF-b.
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with a TGF-b reporter cell line (TGF-b!/!fibroblasts transfectedwith
a TGF-b-responsive alkaline phosphatase reporter), which con-
firmed TGF-b activity within HES that could be completely ablated
with a type I TGF-b receptor kinase inhibitor, but was unaffected
by a pan-vertebrate anti-TGF-b blocking antibody. Thus, HES con-
tains a TGF-b mimic that induces Foxp3 through ligation of the
TGF-b receptor complex, but is sufficiently structurally dissimilar
tomammalian TGF-b as to be unaffected by a neutralizing antibody.
Recently, in work to be published elsewhere, we have isolated the
gene encoding a novel protein with no sequence similarity to the
TGF-b family, which is able to ligate the mammalian receptor.
Similar expression of Foxp3 in T cells has been reported to be
induced by secreted proteins from some other helminths, such as
the fox tapeworm E. multilocularis [89], and the ruminant nema-
tode Teladorsagia circumcincta [66]. Most recently, products from
the Litomosoides sigmodontis filarial parasite have been shown to
ligate the host TGF-b receptor [90]. In each case, the active princi-
ples have yet to be determined.
10. TGF-b homologues in helminth arrested development
Originally the TGF-b superfamily gene daf-7 was found to be a
key player in controlling entry into the arrested larval stage of C.
elegans, the Dauer larvae, which follows the loss of daf-7 expression
[91]; in this model, daf-7 null mutants constitutively entered Dauer
arrest. Parasitic helminths enter crucial and often long-lasting
developmental arrest, for example as infective larvae awaiting
the opportunity to enter a new host, it was plausible that TGF-b
family members might similarly regulate arrest in parasites
[80,92]. However, contrary to this prediction, in a number of para-
sitic species in which TGF-b superfamily homologues were discov-
ered (Table 1), expression was found to be maximal in the arrested
third larval instar (L3) stage that is most closely analagous to the C.
elegans Dauer larva [93–97]. This suggests that either that there
has been a functional reversal in the TGF-b signaling pathway
between free-living and parasitic nematodes, or that this cascade
is not critical to the developmental program of the parasites exam-
ined. In a further departure from expectation, the closest daf-7
homologue in B. malayi, TGH-2, is highly expressed in the newborn
L1 stage, the microfilaria, which enters arrest in the bloodstream of
the host until uptake by hematophagous mosquitos [81]. Whether
this reflects an unusual plasticity in the role of TGF-b ligands in
nematode development has yet to be investigated.
In platyhelminths, the developmental role of superfamily mem-
bers is also being analyzed [18,84,98]. However, recent work has
screened genomic DNA sequences in the liver fluke Fasciola hepat-
ica, identifying 3 homologues, one of which (FhTLM) is able to
enhance egg embryogenesis and motility of juvenile parasites
when administered as a recombinant protein [99]. Further homo-
logs of the TGF-b receptor superfamily and Smad signaling proteins
have also been characterized from several major parasitic helminth
species (Table 2).
11. TGF-b homologue in embryonic sexual differentiation
During early development anti-Müllerian hormone (AMH)
ablates the Mullerian duct (the precursor of the oviduct) in the
male mammal; the only cells expressing AMH are the Sertoli cells
which generate high levels of secreted hormone in the developing
organism – at 11.5 to 12.5 days post-conception in the embryonic
mouse. Amh is secreted at lower levels in the male until puberty
and in the female by granulosa cells after puberty. Regulation of
AMH is one of the most rigorous examples of control in the gen-
ome, and is initiated following expression of the Sry sex determin-
ing region on the Y chromosome [100]. The amh locus is highly
conserved on human chromosome 19 and mouse chromosome
10, adjacent to widely expressed housekeeping genes; hence the
amh promoter appears to be tightly constrained within a few hun-
dred nucleotides of the start site [101].
Working with the murine Sertoli cell line SMAT-1, expression of
AMH was also found to require an enhancer immediately down-
stream of the 30 polyadenylation site. At the promoter level it has
been found that expression is extremely finely regulated by
enhancing (eg GATA1) and inhibitory (eg GATA4) transcription
Table 1
TGF-b ligands in helminth parasites.
Species Ligands Properties References
Ancylostoma caninum Dbl-1 like, Daf-7 like (TGH-2) Upregulated in arrested L3 larvae [93,95]
Brugia malayi Bm-TGH-1, TGH-2 TGH-2 ligated TGF-b reporter cell line [80,81]
Echinococcus multilocularis Activin homolog Induces Foxp3 [86]
Fasciola hepatica Fh-TLM and 2 other homologs Fh-TLM promotes development [99]
Haemonchus contortus Hc-TGH-2 Upregulated in L3 larvae [82]
Heligmosomoides polygyrus Hp-TGH-2 Upregulated in adult worms and eggs [82]
Nippostrongylus brasiliensis Nb-TGH-2 Upregulated in L3 larvae [82]
Parastrongyloides trichosuri Daf-7 like Upregulated in L3 larvae [94]
Schistosoma japonicum SjBMP Ovarian and tegumental expression [135]
Schistosoma mansoni SmInAct Functions in embryogenesis [84,85]
Strongyloides ratti Daf-7 like Upregulated in L3 larvae [94]
Strongyloides stercoralis Sst-TGH-1 [96]
Teladorsagia circumcincta Tci-TGH-1; TGH-2 [96,82]
Table 2
TGF-b family receptors and Smad signaling proteins in helminths.
Species Receptors Properties References
Brugia malayi and Brugia pahangi Bm-TGR-1, -2 [136]
Echinococcus multilocularis EnTR1 Interacts with host BMP2 [137]
Schistosoma mansoni RI + RII Interact with host TGFb [138–140]
Species Smad signaling proteins Properties References
Echinococcus multilocularis EmSmadA-D A and C lack MH1 domain [141,142]
Echinococcus multilocularis EmSmadE Phosphorylated by human BMP and TGFbRI [143]
Schistosoma mansoni Smad proteins [144,145]
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factors binding to noncoding regions (elements) of the gene which
are highly conserved between mammalian species [102–104]. In
particular, a high level of expression requires the presence of an
enhancer motif immediately downstream of the 30 polyadenylation
site [105]. Mutation of an element within this motif, or of the
Wilms tumor element which lies upstream of the gene, ablate high
level expression of amh; these sites can be considered as anchor
points for a specific bridging factor. Remarkably, mutation of a site
lying a few nucleotides upstream of the enhancer anchor point
leads to an accentuated amh expression. Looping between motifs
on either side of the coding sequence is necessary for strong acti-
vation of the gene.
Interestingly, if cattle conceive a heterosexual pair of twins, pla-
cental anastomoses expose the female fetus to the inhibitory
effects of AMH in utero, resulting in a masculinized infertile indi-
vidual known as a freemartin [106]. The other consequence of
the anastomosis is hematological chimerism, resulting in estab-
lishment of immunological tolerance between the twins, as
reported in Ray Owen’s landmark study in 1945 [107].
12. New therapeutic strategies?
The potency and breadth of effect of TGF-b ligands suggest
many therapeutic scenarios to treat inflammatory diseases and
facilitate transplantation. While the non-linear signaling and pleio-
tropic activities of TGF-b present significant therapeutic chal-
lenges, a considerable unmet clinical need currently exists across
many severe conditions, and recent advances in understanding
have brought the goal of driving immunological tolerance several
steps closer. The approaches currently being examined include
direct application to dampen inflammation, administration
in vivo to induce tolerance, and use ex vivo to condition patients’
T cells into the regulatory phenotype.
Direct administration is currently the least favored strategy, in
part because of the pro-fibrotic role of TGF-b which efforts to date
have not well dissociated from its immunosuppressive role. There
are also concerns that generalized immune suppression resulting
from administration of TGF-b might present risks of infection or
neoplasia comparable to those of current non-specific immunosup-
pression regimens.
In recent years, attention has been drawn to the possibility of
administering live helminth infections to attenuate or pre-empt
inflammatory disorders [108]. From a safety perspective, treatment
with low doses of helminth infection may not be hazardous, judg-
ing by the millions of people chronically infected with helminths
worldwide, of whom very few experience immunological sequelae
that approach those of current routine immunosuppression ther-
apy [109,110]. However, the balance between therapeutic efficacy
and parasite pathogenicity is not well understood, and is likely to
depend not only upon the parasite species in question, but also
the genetic predisposition of the host [111], so that adverse effects
in a minority of recipients cannot be excluded. Nevertheless, a total
of 28 clinical trials of therapeutic helminth infection are now
underway or have been completed [112]. While adverse effects
do appear to be reassuringly limited, the proposal of experimen-
tally infecting patients with live helminths still engenders a wide
range of regulatory, logistical and scientific challenges, such that
its unequivocal validation as a beneficial and viable therapy
remains elusive [113].
Identification and reproduction of individual helminth-secreted
immunomodulatory molecules as potential novel therapeutic
agents presents several advantages over live larval therapy [114].
These include consistent pharmacokinetics, scope for pharmaco-
logical modification and optimization (reducing immunogenicity
of large molecules, for example), improved public acceptability
and a lower cost barrier to large-scale production as a routine clin-
ical therapy. Compared with recombinant human TGF-b, it is also
likely that helminth-derived homologues have evolved to evade
some mechanisms of endogenous TGF-b regulation and may there-
fore provide the opportunity for greater precision in dosing and
specificity of action.
Combination therapies are another approach in development,
whereby TGF-b is administered with synergistic ‘Treg permissive’
agents which may allow some control over downstream cellular
differentiation. Of these, rapamycin (sirolimus) can act synergisti-
cally with TGF-b to favor Foxp3 expression and Treg differentiation
over Th17 effector cells [115], while retinoic acid (RA) is thought to
minimize the impact of inflammatory cytokines and co-stimulation
on impairing TGF-b-induced Foxp3 expression [116,117].
TGF-b-dependent induction of Treg also occurs in vivo and tech-
niques that exploit this mechanism to induce tolerance (such as
low dose antigen therapy [118]) appear to generate Treg with more
stable expression of Foxp3 than those generated in vitro [119]. This
suggests that additional stabilizing factors or conditions are pre-
sent in the in vivo setting and might provide encouragement for
in vivo Treg induction techniques over ex vivo expansion and rein-
fusion of isogeneic cells.
Nevertheless, prevailing concerns about in vivo administration
of TGF-b are encouraging emphasis on in vitro use to generate
Tregs which are then administered to patients. In mouse models,
adoptively transferred Treg mediate indefinite tolerance of murine
allografts including pancreatic islet [120], skin [121] and heart
[122]. Expectations of successful translation of Treg therapy into
the clinical setting have been high and preliminary clinical trials
have now been completed in graft-versus-host disease [123] and
hematopoietic stem cell transplantation [124] with modest but
encouraging results. To ensure that transfused Tregs are specific
for the pathogenic epitope (such as an auto- or allo-antigen), it is
also possible to transduce patient T cells in vitro with an engi-
neered T cell receptor, creating a highly-targeted and effective reg-
ulatory T cell population [125].
However, a number of obstacles and concerns persist. First,
Good Manufacturing Practice (GMP)-compliant ex vivo expansion
of Tregs for subsequent reinfusion is a highly specialized process
at a cost of approximately $45,000 per patient [126]. Even if this
level of funding could be justified, the infrastructure and highly
qualified personnel required are likely to limit translation into rou-
tine clinical practice.
Secondly, due to the lack of a unique human regulatory T cell
surface marker, accurate identification of Treg populations remains
imperfect. The optimal approach is with fluorescence-activated cell
sorting (FACS), with selection of, for example, CD4+CD25+CD127lo
cells [124]. However, GMP-compliant FACS isolation of Treg for
clinical therapeutic use is available at very few centers throughout
the world necessitating the use of magnetic cell sorting techniques
for preliminary clinical trials, with Treg populations consequently
of a lower purity [127,128]. Additional steps such as CD8+ T cell
depletion can limit alloreactive effector T cells to a very small per-
centage, but it is likely that any remaining are highly activated, and
the long-term impact of their infusion into a transplant recipient is
unpredictable [128].
Thirdly, concern remains over the question of whether isolated
Treg maintain their regulatory phenotype following re-infusion,
particularly in the context of an inflammatory environment.
Alloantigen-specific pTreg offer the potential advantages of high
functional suppressive ability and a specificity of action that might
lower the risk of side effects such as early viral reactivation
(observed in trial of Treg therapy in hematopoietic stem cell trans-
plantation [129]) and the potential risk of neoplasia with non-
specific Treg therapy. A further caution has been the loss of Foxp3
expression (and therefore regulatory phenotype) once induced
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Tregs are no longer exposed to TGF-b [130]. This poses a risk of infus-
ing a population of cells that effectively revert to allograft-specific
effector T cells, and the ability or otherwise to treat this scenario
with conventional immunosuppression is unknown [131]. Thera-
peutic infusion of tTreg and pTreg comprise two separate arms of
the ONE Study that is currently underway (NCT02129881).
Finally, in the long-term it is unknown whether Treg-mediated
immunosuppression might present risks of infection or neoplasia
comparable to those of current non-specific immunosuppression
regimens. To date, four clinical trials of Treg therapy have been
published: three investigating prevention or treatment of graft vs
host disease (GvHD) [123,132,133] and one for treatment of type
I diabetes [134]. Early follow-up has provided some degree of reas-
surance, with no adverse events reported other than a slightly
increased incidence of viral reactivation in the context of GvHD
[129]. However the longest follow-up period that has been
reported is only 12 months [134] and, particularly regarding a
potential long-term risk of malignancy, it may be very difficult to
determine a follow-up period wherein this question can be
answered definitively. In short, Treg cellular therapy is an attrac-
tive potential therapeutic strategy that has advanced rapidly in
recent years, but many questions and logistical barriers still exist,
such that translation to routine clinical practice is by no means
guaranteed.
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